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ABSTRACT 
 
Bovine herpesvirus-1 (BoHV-1) infects bovine species causing respiratory and genital 
syndromes. VP8, encoded by the ul47 gene, is a tegument protein essential for BoHV-1 to infect 
host animals. This protein is abundantly incorporated into the virus and is extensively expressed 
in BoHV-1-infected cells. VP8 is phosphorylated by a viral kinase, unique short protein 3 (US3), 
and a cellular kinase, casein kinase 2 (CK2). With the aim to investigate the function of VP8 in 
the life cycle of BoHV-1, we hypothesized that US3- and CK2-mediated phosphorylation 
changes the functions of VP8, which in turn affects the replication of BoHV-1. 
Using site-directed mutagenesis and liquid chromatography-mass spectrometry we 
identified minimal amino-acid residues of VP8 required for phosphorylation by US3 and CK2, 
respectively. US3 phosphorylated VP8 at two residues, serine 16 (S
16
)
 
and serine 32 (S
32
). 
Phosphorylation at S
16
 was essential for subsequent phosphorylation at S
32
. CK2 phosphorylated 
at least eleven threonines (T) and serines (S) in VP8. Mutating seven of them (T
65
, S
66
, S
79
, S
80
, 
S
82
, S
88
 and T
107
) blocked the whole protein being phosphorylated by CK2. By replacing the 
critical phosphorylation sites for US3 and CK2 in VP8, we generated a mutant VP8 that was not 
phosphorylated by US3 and CK2. This non-phosphorylated VP8 was studied in parallel with 
wild-type VP8. Promyelocytic leukemia (PML) protein was redistributed by wild-type VP8 but 
not by non-phosphorylated VP8 in transfected cells. This implicates that VP8 may be involved in 
counteracting PML-related host antiviral defenses by redistributing PML protein, and is 
dependent upon its phosphorylation. VP8-transfected cells developed nuclear lipid droplets 
(LDs), suggesting that VP8 causes lipid accumulation in host cells. Wild-type VP8 was more 
abundant around the surface of the droplets compared with the mutant VP8. 
We next investigated the roles of phosphorylated VP8 in the life cycle of BoHV-1. A 
mutant virus (BoHV-1-YmVP8) with non-phosphorylated VP8 was generated by using 
homologous recombination in mammalian cells. The results showed that the DNA encapsidation 
was reduced in mutant virus-infected cells, resulting in a lower virus titer, when compared with 
wild-type virus-infected cells. Capsids without DNA cores were more frequently found in the 
nuclei and perinuclear spaces of mutant virus-infected cells than that of wild-type virus-infected 
cells. However, we did not observe obvious restriction of virus egress during the infection with 
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BoHV-1-YmVP8. Virions lacking DNA core were released into the extracellular medium. 
Therefore, we conclude that phosphorylated VP8 promotes DNA encapsidation of BoHV-1 in 
the nuclei of infected cells. VP8 appeared in the Golgi apparatus of cells infected with wild-type 
virus late during infection. The non-phosphorylated VP8 did not leave the nuclei of BoHV-1-
YmVP8-infected cells, suggesting that phosphorylation is critical for the cytoplasmic transport of 
VP8. By measuring the amount of mature virion-incorporated VP8, we found that mutant BoHV-
1 contained lower amounts of VP8 than wild-type virus. Together with the finding that non-
phosphorylated VP8 was not able to localize in the Golgi, it implies that phosphorylation is 
important to place VP8 into a proper cellular location.  
Based on the finding that cytoplasmic localization of VP8 was inhibited by mutating 
phosphorylation residues, we hypothesized that the cellular localization of VP8 is regulated by 
US3- and/or CK2-dependent phosphorylation. We verified that VP8 was initially localized into 
the nucleus and then transported into the cytoplasm when BoHV-1 infection progressed to late 
stages. The cytoplasmic VP8 subsequently accumulated in the Golgi apparatus. We also found 
that the kinase activity of US3 was critical for VP8 to be exported from the nucleus. Deletion of 
US3 in BoHV-1 or mutating the essential residue for US3-mediated phosphorylation in VP8 
blocked the nuclear-cytoplasmic transport of VP8. In the amino-acid sequence of VP8, US3-
phosphorylated residues are closely adjacent to nuclear localization signals (NLSs), providing 
the possibility that addition of phosphoryl groups to these residues may affect the binding 
activity of the NLSs, blocking VP8 entering or re-entering the nucleus. The US3-phosphorylated 
VP8 is transported to the cytoplasm through more than two pathways that require different types 
of nuclear export signals (NESs). In the cytoplasm, VP8 might experience virus-induced 
modifications or protein interactions, which led the protein to localize in the cis-Golgi cisternae. 
VP8 was less likely to present in the trans-Golgi network (TGN). The cis-Golgi localization of 
VP8 and Golgi accumulation of viral particles suggest that VP8 localizes in the Golgi for 
incorporation into the virions, and that it may not directly contribute to viral egress. 
Altogether, this research described the importance of phosphorylation in regulating the 
functions of VP8 during BoHV-1 infection. Nuclear VP8 phosphorylated through CK2 is 
responsible for DNA encapsidation of BoHV-1 and remodeling the cellular antiviral factor PML. 
When nuclear VP8 is phosphorylated by US3, the cytoplasmic translocation of VP8 is activated 
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possibly by inactivating the NLSs. Subsequently, VP8 aggregates towards the cis-Golgi 
apparatus where VP8 is abundantly incorporated into virions such that the mature virus contains 
enough VP8 to benefit future infection. 
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CHAPTER 1 
1 LITERATURE REVIEW 
Bovine herpesvirus-1 (BoHV-1) is an economically important pathogen in cattle. This 
virus is one of the major causes of infectious bovine rinotracheitis (IBR), which induces over a 
billion dollars losses to the cattle industry of USA (1). In addition, BoHV-1 infection restricts 
international trading (1, 2). This literature review incudes a comprehensive introduction of 
BoHV-1 classification, the disease caused by BoHV-1, and major viral components. BoHV-1 
belongs to the herpesviridae, thus it shares common features with other members of the virus 
family, such as causing lifelong latent infection in host animals, and having a typical herpesvirus 
structure. Researches of several herpesviruses indicate that tegument proteins play important 
roles in promoting virus entry (3, 4), DNA encapsidation (5-8), virus assembly (9-11), and egress 
(12, 13). However, much less is known about the molecular details and biological functions of 
BoHV-1 tegument proteins. An introduction of tegument proteins of other herpesviruses is 
included, and it provides important directions to study the functions of BoHV-1 tegument 
proteins.  
This research aims to characterize phosphorylation of VP8, the most abundantly 
incorporated tegument protein of BoHV-1 (14), and phosphorylation-regulated functions of the 
protein. A viral kinase, unique short protein 3 (US3), and a cellular kinase, casein kinase 2 (CK2), 
phosphorylate VP8 (15). The functions and enzyme properties of these two kinases are covered 
in this literature review. Because specific inhibitors are used to inhibit CK2 activity in this 
research, an introduction of CK2 inhibitors is also included. 
 
1.1 Introduction of bovine herpesvirus-1 (BoHV-1) 
1.1.1 Virus classification of BoHV-1 
According to the International Committee on Taxonomy of Viruses (ICTV) BoHV-1 
belongs to the genus varicellovirus, the alphaherpesvirinae subfamily of the herpesviridae. The 
genus varicellovirus includes an important human pathogen, human herpesvirus-3 (HHV-3), and 
pathogens with veterinary importance, such as bovine herpesvirus-5 (BoHV-5) and equid 
herpesvirus-1 (EHV-1). BoHV-1 has many similarities with other members of the 
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alphaherpesvirinae, for instance human herpesvirus-1 (HHV-1), with respect to the viral 
composition, lytic life cycle, and latency infection. 
BoHV-1 has been classified as three subtypes (1.1, 1.2a, and 1.2b) based on their genetic 
and antigenic characteristics (16). Subtype 1.1 is more associated with respiratory infections; 
subtype 1.2a mostly causes respiratory and genital symptoms; and subtype 1.2b is predominantly 
associated with genital infections (17). Distinctive diagnosis of infection with these subtypes 
requires viral DNA analysis (18, 19). Likewise, HHV-1 commonly causes cold sores around the 
mouth and face in humans (20), whereas HHV-2 is more associated with genital symptoms of 
human patients (21). However, increasing evidences indicate that HHV-1 also is a sexually 
transmitted pathogen (22). Subtype BoHV-1.1 is the most common subtype in feedlot cattle, 
causing respiratory infections (23), thus two BoHV-1.1 isolates were analyzed in this research, a 
Cooper strain (24) from USA and a 108 strain (25) isolated from Alberta, Canada. 
 
1.1.2 BoHV-1 infection and control strategies 
BoHV-1 is responsible for a highly contagious disease in cattle, named infectious bovine 
rhinotracheitis (IBR) (26). BoHV-1 is effectively transmitted through direct contact or airborne 
transmission. Transmission is also frequently conducted by mating and artificial insemination 
within and between breeding groups (27). Animals infected with BoHV-1 may develop 
respiratory symptoms, conjunctivitis, genital disorders, and abortions (28, 29). On top of that, 
BoHV-1 also causes immunosuppression in host animals (30). Together with the increased 
mucous secretion and damaged epithelium it provides a beneficial environment for many other 
pathogens to replicate; BoHV-1 positive animals are frequently co-infected with bovine viral 
diarrhea virus (BVDV), bovine parainfluenza virus-3 (BPIV-3), bovine respiratory syncytial 
virus (BRSV) and several bacterial pathogens, such as Mannheimia haemolytica, Mycoplasma 
bovis, Pastuerella multocida, and Histophilus somni (31), causing bovine respiratory disease 
complex (1, 32). 
 
1.1.2.1 Epidemiology of BoHV-1 
An upper respiratory disease related to BoHV-1 infection was first reported in 1954 on a 
dairy farm in California (33). The virus was firstly isolated in 1958 by a Canadian research group 
 3 
 
and it confirmed that IBR was directly caused by BoHV-1 (26). Infection with BoHV-1 occurs 
all over the world, but the severity of this pathogen differs between countries and regions (34). 
For example, serum-neutralizing antibodies against BoHV-1 are present in 10-67% of free-
ranging elk and domestic cattle in Western Canada (35, 36). The reported prevalence in different 
Turkish regions ranges from 2.32% to 79.74% (37). Infection with BoHV-1 has been reported in 
almost every state in India with a high incidence. For example, the seroprevalence reaches 46.5% 
in domestic cattle in Uttar Pradesh (38) and the predominant circulating subtype in this region is 
BoHV-1.1 (39). The prevalence in the Tibetan region of China has been reported to range from 
27.9% to 44.6% (40). BoHV-1 has been eradicated in several European regions, including 
Bavaria of Germany, Bolzano of Italy, Austria, Denmark, Finland, Switzerland, Sweden and 
Norway (41). With respect to Canada and the United States, eradication would be extremely 
difficult due to the large number of cattle herds and high prevalence of BoHV-1 (23). 
Outbreaks of BoHV-1 in a naive herd are commonly caused by introducing an infected 
animal without diagnostic tests and proper management, leading to quick spread of the disease 
within the herd. After the primary infection, animals become latently infected with BoHV-1. In a 
latently infected herd, disease outbreaks happen in all seasons of the year, with a significant rise 
from December to February in Northern Hemisphere countries (42). During this time, herds have 
increased BoHV-1-related respiratory diseases and abortions (42). Generally, BoHV-1 infection 
occurs in host animals of any age. Calves have a lower rate of seropositivity than the older 
population, which is possibly due to the latent infection over the years (37). Although cattle are 
the major host for BoHV-1, it also infects sheep, red deer, reindeer, mule deer, pronghorn 
antelopes, buffalos, and goats (17, 43). 
Infection with BoHV-1 causes significant losses in animal productivity, although it is 
usually not lethal (44). A study conducted in the UK has reported that the average daily milk 
production is reduced by 2.6 kg in BoHV-1-positive cows compared with negative cows (45). 
BoHV-1 infection also increases the abortion rate in a herd. Abortion induced by BoHV-1 occurs 
between 4 and 8 months after gestation (46). According to a report from India, 21.4% of bovine 
abortions in the state of Punjab are caused by BoHV-1 (46). This rate is over 50% in Western 
Turkey (43). Infections with BoHV-1 and BoHV-4 contribute to 42% of the bovine abortions in 
Morocco of North Africa (47). Moreover, many other important issues are caused by BoHV-1, 
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including reduction of heard health, increase of management costs, and restrictions of 
international trading. 
 
1.1.2.2 Pathogenesis of BoHV-1 
Epithelial cells in the mucosa of upper respiratory and genital tracts of host animals are 
the primary target sites for BoHV-1. The virus starts a lytic replication in host cells, resulting in 
massive virus production. The progeny virus is shed to the extracellular environments or enters 
the blood stream. Blood-stream circulated BoHV-1 passes through the placenta barrier and may 
cause abortion (48). In addition, the virus directly infects neighboring cells by cell-to-cell spread. 
During the primary infection, virus establishes a latent infection in the regional ganglia. It enters 
the axons of local nerve cells, and travels to the neuron bodies along the axons (2). Reactivation 
from latency occurs when a host is under stress or in weak immune condition (48). Once the lytic 
infection is reactivated, the virus enters a new replication cycle and the infected animal starts to 
shed virus. 
 
1.1.2.3 Prevention of BoHV-1 
Vaccination is the major strategy to control BoHV-1 (49-51). In Europe, marker vaccines 
that differentiate infected from vaccinated animals (DIVA) are commonly used. A marker 
vaccine is generated by deleting a gene encoding an immunogenic antigen present in a pathogen, 
thus creating a marker that is negative in vaccinated animals but is positive in infected animals 
(52). For instance, a marker protein, gE, is omitted in an attenuated live vaccine, which avoids an 
immune response against gE in vaccinated animals;, hence an infected animal will be 
distinguished from a vaccinated animal through testing the presence of gE-specific antibodies 
(52). The marker vaccination and test-slaughter strategies have greatly contributed to eradicate 
BoHV-1 in many countries (53). Glycoprotein gE was selected as a marker in the DIVA vaccine 
for the following reasons. Firstly, deletion of gE significantly reduces the virulence of the virus 
(54), and the vaccine virus preserves high immunogenicity (55). Secondly, vaccine virus without 
gE has a reduced chance of reactivation from latency, although it can establish latent infection in 
vaccinated animals (56). Thirdly, deletion of gE allows to distinguish vaccinated animal from 
virus-infected animals by detecting serum gE-specific antibody (57). However, this marker 
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vaccine has several weaknesses. The first weakness is that the diagnostic test is fully dependent 
on detecting serum gE-specific antibody. The limited sensitivity of current gE-specific antibody 
tests, together with the fact that the gE-specific immune response is relatively low, leading to the 
possibility of false negative results. More importantly, there are biosafety concerns about using 
gE-deleted live attenuated vaccine. This vaccine has the potential to cause abortions in pregnant 
animals and to gain virulence by recombination with field strains (18, 19). 
 
1.2 Comparative composition of alphaherpesviruses and BoHV-1 
1.2.1 The genome of alphaherpesviruses and BoHV-1 
The herpesvirus genomes are summarized as five major classes, from A to F (58). This 
classification is based on the structures of the virus genome (59). Class A genome contains a 
unique (U) sequence which is flanked by a direct repeat (R) (Figure 1.1). Class B genome 
consists of a U sequence flanked by variable copies of directly repeated sequences (Rs). Class C 
genome is derived from the class B genome with an internal Rs’, which is not related to the 
terminal Rs. Class D genome is composed of a unique long (UL) region and a unique short (US) 
region, which is flanked by inverted internal and terminal repeats (IRS and TRS). Class E genome 
is similar to the class D, except that the UL sequence is flanked by two inverted repeats (TRL and 
IRL). Class F genome is a simple U sequence lacking inverted and direct repeats (58, 59).  
Alphaherpesviruses HHV-3, EHV-1, SuHV-1, and BoHV-1 represent the class D genome (58). 
HHV-1 and HHV-2 are examples of the class E genome (58).  
 The BoHV-1 genome is a double-stranded linear DNA of about 135 kilo base pairs (kbp) 
(60). It is a class D genome containing a 103-kbp UL region and a 32-kbp US region flanked by 
11-kbp IRS and TRS (Figure 1.1) (61). The UL region is fixed in one orientation, named the 
prototype orientation (62). The US region is flanked by large inverted DNA repeats, namely 
internal repeat (IR) and terminal repeat (TR) (62). Other herpesviruses with class D genomes 
include HHV-3, Suid alphaherpesvirus 1 (SuHV-1), and EHV-1 (61). The BoHV-1 genome 
contains 73 open reading frames (ORFs), of which 33 ORFs are essential for viral replication in 
tissue culture (63). A list of current identified BoHV-1 viral protein components is summarized 
in Table 1.1. The ul47 gene, located in the UL region of the genome, encodes VP8, which is 
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essential for BoHV-1 replication in host animals but not in tissue culture (64). This high-GC-
content gene is flanked by the ORFs of ul48 and ul46 encoding VP16 and VP22, respectively. 
BoHV-1 DNA replicates in the cell nucleus. The mechanism of replication and cleavage 
of the BoHV-1 genome is not well understood. However, the rolling circular replication model of 
the HHV-1 genome (65) may also apply for BoHV-1, because concatemeric DNA is found in 
BoHV-1 infected cells (61), and several viral proteins important for HHV-1 DNA replication is 
conserved in BoHV-1, including single-strand DNA-binding protein (UL29), DNA polymerase 
catalytic subunit (UL30) (66), and alkaline deoxyribonuclease (UL12) (67). Linear BoHV-1 DNA 
is circularized during infection. DNA replication is initiated at one of the origins where one 
strand of the DNA is nicked. The DNA is extended as a long continuous DNA concatemer which 
is subsequently cleaved into individual genomes (Figure 1.2). 
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Figure 1.1 Classification of herpesvirus genome structures. 
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Figure 1.2 Rolling circle model of BoHV-1 DNA replication. 
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Table 1.1 Viral proteins incorporated into BoHV-1 
Protein 
category 
Protein 
name 
BoHV-1 
gene 
Protein Function 
NCBI 
accession 
Reference 
Capsid 
protein 
VP5 ul19 Major capsid protein AFV53400 (64) 
UL6 ul6 Portal protein AFV53413 (68) 
UL26 ul26 
Scaffold protein, serine 
protease 
AFV53392 (69) 
UL26.5 ul26.5 scaffold protein CAB01599 (69) 
UL38 ul38 Capsid typlex subunit 1 AFV53380 (68) 
UL18 ul18 Capsid triplex subunit 2 AFV53401 (68) 
Tegument 
protein 
ICP4 icp4 Transcriptional regulator AFV53424 (68) 
ICP27 ul54 RNA metabolism AFV53364 (63) 
VP8 ul47 
Major tegument protein, 
down-regulates IFN-signaling 
pathway 
AFV53372 (15, 25) 
VP16 ul48 Gene expression regulation AFV53404 (68, 70) 
VP22 ul49 Nuclear-cytoplasmic shuttling AFV53370 (71, 72) 
US3 us3 S/T kinase AFV53428 (15) 
UL3.5 ul3.5 Virus maturation AFV53416 
(68, 73, 
74) 
VP11/12 ul46 Possible gene regulation AFV53373 (68) 
UL17 ul17 DNA encapsidation AFV53403 (68) 
UL25 ul25 DNA encapsidation AFV53394 (68, 75) 
UL31 ul31 Nuclear egress AFV53387 (68) 
UL36 ul36 Capsid transport AFV53382 (68) 
UL37 ul37 Capsid transport AFV53381 (68) 
UL41 ul41 Cellular mRNA degradation AFV53377 (68) 
UL42 ul42 
DNA polymerase prosessivity 
subunit 
AFV53376 (68) 
 UL51 ul51 
Possible viral maturation and 
egress 
APW77332 (76) 
Envelope 
proteins 
gB ul27 Virus entry/ Membrane fusion AFV53391 (77) 
gC ul44 Virus attachment AFV53374 (78) 
gD us6 Virus attachment AFV53430 (78) 
gE us28 Cell-to-cell spread AFV53432 (79, 80) 
gG us4 Cell-to-cell spread AFV53429 (80, 81) 
gH ul22 Virus entry/Cell-to-cell spread AFV53397 (80, 82) 
gI us7 Cell-to-cell spread AFV53431 (79) 
gK ul53 Virus egress AFV53365 (63) 
gL ul1 Virus entry/Cell-to-cell spread AFV53419 (83) 
gM ul10 Membrane fusion AFV53409 (84) 
gN ul49.5 gM binding partner ADE08266 (63) 
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1.2.2 Capsid proteins of alphaherpesviruses and BoHV-1 
A capsid of alphaherpesviruses is an icosahedral protein shell that encloses the viral 
genome. The capsid is assembled and packaged with viral DNA in the host cell nucleus. The 
process of packaging viral DNA into the capsids is called encapsidation (65). In HHV-1, this 
process is initiated through recognizing a unique c (Uc) element and is terminated by recognizing 
a unique b (Ub) element by packaging proteins (85, 86). Modified by nuclease proteins UL12 (87) 
and UL12.5 (88), the viral DNA turns into a suitable configuration for encapsidation. 
Subsequently, the DNA is inserted into a capsid shell through a portal on a unique vertex of the 
capsid (89). The portal is a ring structure formed with 12 copies of portal protein UL6 (90) 
through disulfide bonds in the leucine zipper region of each subunit (90, 91). This leucine zipper 
region is modulated by UL32, a non-capsid protein, to optimize the DNA encapsidation (6). 
When the viral genome is incorporated into a capsid, an additional stabilizing adjustment of the 
capsid by UL25 is required to retain the genome (7). UL25 is exposed on the surface of a capsid 
(92), forming pentamers on each of the capsid vertices (93). On the one hand it associates with 
other capsid proteins, such as VP5 (UL19), to incorporate into the capsids (93). On the other hand, 
it also interacts with a tegument protein, UL17, which stabilize UL25 in the capsids (7). Deletion 
of UL25 from HHV-1 results in aberrant truncation of the genome and reduced DNA-containing 
capsids in infected cells (94). Additionally, many other viral proteins, including capsid protein 
UL15, UL28, and UL33, as well as tegument protein UL16 (8), have been reported to facilitate 
DNA encapsidation (5, 6). 
Capsids egress to the cytoplasm through a unique process, which includes several steps: 
movement of capsids towards the nuclear periphery, disruption of the nuclear lamina, budding 
through the inner nuclear membrane by obtaining a primary envelope, passing the outer nuclear 
membrane by de-envelopment (95).  
The major protein components of BoHV-1capsids is VP5 (64, 68), alike to HHV-1 capsid 
(96). Additionally, it also incorporates UL38 (capsid triplex subunits 1),  UL18 (capsid triplex 
subunits 2), UL26 (scaffolding protein), UL6 (portal protein) (68) and UL25 (75). A mutant 
BoHV-1 omitting UL25 fails to produce virus although it produces viral DNA and late proteins 
(75).  
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1.2.3 Tegument proteins of alphaherpesviruses and BoHV-1 
1.2.3.1 Dissociation of tegument proteins from alphaherpesviruses 
Herpesviruses incorporate large amounts of protein between the envelope and the capsid 
forming the tegument layer which makes up a significant portion of the virus mass (97). When 
herpesviruses enter host cells, tegument proteins are released from the viruses into the host cells 
to modulate the intracellular environment and to initiate viral replication, including suppressing 
cellular protein transcription (98), controlling cell death signaling (99-102), repressing innate 
immune responses (103-105), guiding viral capsids to the nuclear pore (106-110), and promoting 
viral gene transcription (111, 112). 
Tegument dissociation is an energy-consuming reaction that requires enzymes, adenosine 
triphosphate (ATP), and Mg
+
. The dissociation reaction is completely abolished by inactivating 
enzymes at 60 ⁰C or lack of ATP (113). Tegument-protein dissociation is regulated by 
phosphorylation. For example, the dissociation of VP22 from HHV-1 is efficiently promoted by 
phosphorylation through CK2 (113). Thus several tegument proteins of HHV-1 are non-
phosphorylated in the virion but are phosphorylated in infected cells (14, 114, 115). Several 
HHV-1 kinases are incorporated into the tegument, such as UL13 (116) and US3 (113, 117, 118). 
After infection, they are dissociated into infected cells to phosphorylate viral and cellular 
proteins. 
Tegument proteins dissociate from viruses in an order that is related to their locations in 
the virion and their functions in the infection. VP16 of HHV-1 completely dissociates form virus 
particles as soon as they enter the host cell (119). Free VP16 travels into the nucleus to stimulate 
the immediate early gene expression (120). VP13/14 is a minor tegument protein that dissociates 
quickly after HHV-1 entry (113). In HHV-1-infected cells, VP13/14 colocalizes with ICP4, a 
viral transcriptional activator, suggesting a role of VP13/14 in viral RNA translation (121). 
However, VP13/14 does not directly affect the efficacy of reporter RNA translation (122). 
Instead, it maintains the stability of mRNA by interacting with ICP27 (123). In the mature 
virions of HHV-1, VP13/14 is incorporated into the tegument layer. VP22 gradually leaves the 
virus at a slower speed than VP16 (119) and VP13/14 (113). UL36 and UL37, localized in the 
inner tegument layer, are released even more slowly. They are partially dissociated from the 
capsids, and a residual portion remains associated with the capsid during transit toward the 
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nucleus in the neuronal cell body (119). This is in line with their major function of precisely 
guiding the capsids to the nuclear pore complexes (110). A similar dissociation pattern has been 
described for SuHV-1 (124). The dissociation of SuHV-1 UL11, UL47, UL48 and UL49 takes 
place earlier than that of several other tegument proteins, including UL36, UL37 and US3 (124). 
 
1.2.3.2 Tegument proteins that facilitate cellular and nuclear entry of alphaherpesviruses 
In a host cell, herpesviruses cross the cell membrane and nuclear membrane to transport 
their genome into the cell nucleus. Multiple viral glycoproteins and cellular receptor proteins are 
engaged in the viral entry through cell membranes. Two pathways contribute to this stage; one is 
a pH-dependent endocytic pathway and the other is pH-independent fusion between the virion 
envelope and the plasma membrane (124, 125). Glycoproteins are important in the viral 
attachment and entry (124, 126). In the cytoplasm, viruses associate with microtubules for 
intracellular migration (127). 
HHV-1 tegument proteins UL36 (107) and UL37 (106) navigate the incoming virus 
particles towards the nuclear pore complexes. UL36 in HHV-1 particles is essential to lead the 
virus towards the nucleus and to inject the viral DNA into the nucleus. It associates with UL37, 
which directly contacts the capsids. UL36 uses a nuclear localization signal (NLS) to enter the 
nucleus. It takes the capsids towards the nuclear pore complex to inject viral DNA (108). In 
UL36, introducing a single-amino-acid mutation in a region that is responsible for HHV-1 DNA 
entry causes accumulation of viral particles around the nuclear pore area (109). When capsids 
arrive at the nuclear pore complex, UL36 is cleaved to promote viral DNA release (128). This 
cleavage takes place only when the capsids reach the nuclear pore complex (128). UL37 is 
required for the optimal incorporation of UL36 into HHV-1 virions (129). It also transports 
HHV-1 by mimicking host trafficking machinery (130), although it is not an essential factor for 
nuclear docking of viral capsids (129). The N-terminal region of UL37 shares structural 
similarity with the multisubunit tethering complex (MTC), a cellular protein complex controlling 
vesicular trafficking to destination membranes (130). The capsid-transporting functionality of 
UL36 and UL37 is also confirmed in SuHV-1 (106), suggesting a conservative capsid-
transporting machinery in alphaherpesviruses. 
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ICP0, well-studied as an immediate early protein, is incorporated into the tegument layer 
of HHV-1 by interacting with the capsids through its really interesting new gene (RING) finger 
domain (125). ICP0 contributes to the efficient nuclear delivery of HHV-1 capsids through 
degrading related cellular or viral proteins by its E3 ubiquitin ligase activity (125). 
 
1.2.3.3 Tegument proteins are bridging molecules for alphaherpesvirus assembly and egress 
After incorporation with the viral genome, nuclear capsids leave the nucleus to the 
cytoplasm. The process of transporting the nuclear capsids through the two-layer nuclear 
membrane is called nuclear egress, and is mainly accomplished through an envelopment-
deenvelopment-reenvelopment pathway (131). If this pathway is not sufficient or is blocked, the 
nuclear membrane is broken down to allow capsids to be transported to the cytoplasm (9). 
HHV-1 tegument proteins UL31 and UL34 are essential and sufficient for virus to egress 
through the envelopment-deenvelopment-reenvelopment mechanism by forming protein 
complexes docking in the inner nuclear membrane (9). However, UL31 and UL34 are 
independently expressed in the cytoplasm (9) and any interactions between them are inhibited 
before they arrive in the nucleus (10). When the two proteins are transported into the nucleus, 
they firmly interact with each other through multiple regions on the surface of each protein, 
forming a heterocomplex (10, 11). The UL31-UL34 complex causes the membrane to curve 
inwards, forming budding vesicles that enclose nuclear capsids (9). Only when they form a 
protein complex (132), UL31 is able to bridge the connection between the nuclear membrane and 
viral capsids through its C-terminal region, and to activate the virus egress through its N-terminal 
region (10). 
Herpesviruses use several strategies to modify the UL31-UL34 complex to maximize the 
efficiency of UL31-UL34-mediated virus egress. A cellular component P32 is attracted to the 
nuclear egress complex (NEC) and interacts with the UL31-UL34 complex to promote the de-
envelopment of nuclear capsids during HHV-1 infection (133, 134). Moreover, ICP22 associates 
with the NEC to optimize the accumulation of the UL31-UL34 complex to the NEC (135). HHV-
1 US3 is attracted to the NEC. UL31 phosphorylated by US3 has a better capacity to promote 
virus egress than the non-phosphorylated form (12, 13). US3 also phosphorylates lamin A, 
leading to increased permeability of the nuclear membrane (136). During HHV-1 infection a 
 14 
 
cellular kinase, protein kinase C (PKC), is attracted to the nuclear membrane (137) by a viral 
neurovirulent protein, γ134.5 (138). At the nuclear membrane, PKC phosphorylates lamin B and 
thus disrupts the nuclear lamin network (138). 
HHV-1 VP13/14 (133) and ICP34.5 (139) are bridging proteins between P32 protein and 
the UL31-UL34 complex. Deletion of the bridging proteins reduces the amount of primary 
enveloped virus (133, 139). VP13/14 is encoded by the ul47 gene of HHV-1. The expression of 
VP13/14 is activated by ICP8 (140), and a tyrosine kinase-mediated stimulation (141). Cellular 
VP13/14 is phosphorylated, while viral VP13/14 is associated with O-linked oligosaccharides 
(14). Similarly, VP8 of BoHV-1 is phosphorylated and glycosylated (25). However, it is not 
known whether the modification of VP8 is related to virion incorporation. 
VP13/14 is predominantly localized in the nuclei of HHV-1-infected cells. It is associated 
with the nuclear membrane and the nucleoplasm. In the presence of US3, the phosphorylated 
VP13/14 localizes in the nucleoplasm (142). However, without US3-mediated phosphorylation 
VP13/14 is predominantly accumulated on the nuclear membrane (142). The nuclear localization 
of VP13/14 is driven by a NLS contained in the N-terminus of the protein sequence (143). When 
US3 phosphorylates a residue (S
77
)
 
near the NLS, the efficacy of the NLS is increased and 
VP13/14 tends to remain in the nucleoplasm (142). VP13/14 facilitates nuclear egress of HHV-1 
by associating with the UL31-UL34 protein complex (133). VP13/14 is transiently transported 
into the cytoplasm (142-144). The transient cytoplasmic localization of VP13/14 is related to two 
types of NES contained in the sequence (144). One of the NESs localized in the C-terminus acts 
through the CRM1-dependent pathway (144). The other NES is an N-terminal motif which is 
regulated by an unidentified mechanism instead of the CRM1-signalling pathway (144). Inferred 
from the characteristics of VP13/14, the correlation between phosphorylation and cellular 
localization of BoHV-1 VP8 requires further study. 
To egress through the cytoplasmic membrane, HHV-1 virus needs to anchor on the cell 
membrane. Capsid protein VP26 and tegument protein UL37 bind with carboxyl-terminal 
modulator protein 7 (CTMP7), a cytoskeleton cross-linker protein localized in the cell membrane 
(145, 146) to mediate the interaction between the virus and cell membrane. Subsequently, viral 
glycoproteins accumulate on the cell membrane to assist virus egress (147). In neurons, gK is 
essential for virus egress from the cell body (148). 
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1.2.3.4 Tegument proteins of BoHV-1 
Viral proteins incorporated into the tegument layer of BoHV-1 perform various functions 
during the infection. VP22 shuttles between nucleus and cytoplasm (72) and is an essential 
tegument protein for BoHV-1 to infect cattle (149). The nuclear localization and nuclear export 
of VP22 are mediated by NLSs and NESs within the protein sequence (72), which are precisely 
regulated at different stages of virus infection (150). At early stages of BoHV-1 infection, VP22 
mainly localizes in the cytoplasm with accumulation in the perinuclear region (150). When the 
infection enters late stages VP22 massively enters the nucleus, where it regulates the acetylation 
of histone protein (149), and this transport is facilitated by phosphorylation of VP22 (150). 
BoHV-1 incorporates at least two kinase proteins, UL13 and US3, into virus particles (151), 
phosphorylating many viral and cellular proteins. The major tegument protein VP8 is one of the 
substrates of US3 (15). A tegument protein UL3.5 localizes in the Golgi apparatus of BoHV-1-
infected cells, where it interacts with VP16 to promote virus maturation and egress (74). More 
tegument proteins and their functions are listed in Table 1.1.  
VP8 is a major tegument protein of BoHV-1, encoded by the ul47 gene, which is 
conserved among alphaherpesviruses (14, 152, 153). BoHV-1 incorporates VP8 more than other 
viral proteins (152). When VP8 is deleted in BoHV-1, a major part of the tegument layer is 
missing, and the incorporation of several other viral proteins is reduced, causing dramatic 
morphologic changes of mature virions (64). 
In BoHV-1-infected cells, VP8 is initially transported into the nucleus (25, 154). It 
contains two NLSs (NLS1
 
and
 
NLS2) near the N-terminus. NLS1 (P
11
RPRR
15
) is essential but 
not sufficient to mediate nuclear localization of VP8 (155). It requires a minimal nuclear-
transferable peptide (residue 10 to 30) to transport the entire VP8 protein into the nucleus (156). 
NLS2 (R
48
PRVRRPRP
54
) may promote the function of NLS1 (156). In transfected cells VP8 
shuttles from the nucleus to the cytoplasm, and then enters another nucleus within the same fused 
cell. The nuclear export of VP8 is mediated by nuclear export signals (NESs). At least two NESs 
in the sequence of VP8 have been reported. A leucine-rich sequence (NES1, 
L
485
SAYLTLFVAL
495
) is able to transport a reporter gene from the nucleus to the cytoplasm 
(155, 156). The NES1 is a chromosomal maintenance 1 (CRM1)-dependent sequence (144, 156). 
However, the nuclear export activity of NES1 is weak (144, 156) and is not essential for the 
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nuclear-cytoplasmic shuttling of VP8 (155), indicating there are more NESs in VP8. A second 
NES (NES2) is located within residues 95 to 123 (156). This sequence is resistant to the CRM1 
inhibitor and does not contain hydrophobic residues (156). Thus, it uses another nuclear export 
pathway other than the CRM1-dependent pathway. NES2 is more effective than NES1 to 
transport a fusion protein to the cytoplasm (156). However, deletion of NES1 and NES2 does not 
inhibit the cytoplasmic transport of VP8 (156), so mechanisms and biological significances of 
VP8 transport are not fully understood. 
VP8 interacts with many proteins to benefit BoHV-1 infection. Firstly, VP8 binds with 
DNA damage binding protein-1 (DDB1), an element of the Cul4A-DDB1 E3 ubiquitin ligase 
complex, resulting in monoubiquitination of VP8 (157). Secondly, VP8 associates with signal 
transducer and activator of transcription 1 (STAT1), a critical protein in the interferon (IFN)-
signaling pathway. VP8 prevent the entry of STAT1 into the nucleus to interrupt the IFN 
responses (158). Thirdly, VP8 interacts with CK2 and US3 to obtain phosphorylation (15). 
Additionally, in context of BoHV-1-infection VP8 has RNA-binding activity (121, 159).   
 
1.2.4 Glycoproteins of alphaherpesviruses and BoHV-1 
Alphaherpesviruses are enveloped by a lipid bilayer and glycoproteins that facilitate viral 
attachment, penetration, and spread. Glycoprotein D is essential for HHV-1 to attach to host cells 
by binding with cellular receptors (160). A number of cellular receptors for gD have been 
identified, including nectin-1 and -2 (161), herpesvirus entry mediator (HVEM, or HveA) (160), 
and 3-O sulfated heparan sulfate (3-O HS) (162). Glycoprotein D is not conserved among all 
alphaherpesviruses. For example, HHV-3 lacks a gD and its gH-gL complex engages cellular 
receptors (163).  HHV-1 gC also binds to heparan sulphate to facilitate virus attachment (164). 
Entry of HHV-1 is mainly mediated through gB, gH, and gL (165). In the HHV-1 envelope gB 
forms a homotrimer, and gH and gL form a heterodimer (166). After the virus attaches to a host 
cell, the gB complex goes through conformational changes leading to insertion of its fusion loops 
into the host cell lipid bilayer. This triggers merging of the virus envelope and cell membrane 
(166). The conformational change of the gB complex is triggered and regulated by the gH-gL 
complex (165). Other HHV-1 glycoproteins, such as gK (167) and gM (168), show activity of 
mediating membrane fusion, suggesting their roles in virus entry.  
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In addition to facilitating virus attachment and entry, glycoproteins of alphaherpesviruses 
play important roles in virus maturation and cell-to-cell spread. During early stages of HHV-1 
infection, gM localizes in the nuclear membrane and may play a role in the nuclear egress of 
virus capsids by its membrane fusion activity (169). Glycoprotein M directs gN from the 
endoplasmic reticulum (ER) to the Golgi apparatus by interacting with gN, while gN has no 
impact on the localization of gM (169). The interaction of gM and gN is also found during EHV-
1 infection (84). At a late phase of HHV-1 infection, gK interacts with UL20 in the TGN (170) to 
facilitate the egress of virus through promoting virus to transport towards the cell membrane 
(171). This activity of gK to promote virus transport is in line with the fact that gK is essential 
for efficient spread of HHV-1 in corneal epithelium and trigeminal ganglia in a mouse model 
(172). During the egress of HHV-1, gD and the gE-gI heterodimeric complex are important for 
efficient secondary envelopment (173). However, deletion of gD, gE or gI of SuHV-1 does not 
significantly impair the secondary envelopment (173). 
BoHV-1 glycoproteins contributing to attachment are gB, gC, and gD (126). gB forms a 
protein complex  consisting an uncleaved subunit with a mass of 130 kDa, two cleaved subunits 
with masses of 74 kDa and 55 kDa proteins, respectively. These two cleaved polypeptides are 
linked by disulfide bonds (174). Blocking the cleavage site of gB reduces the plaque size of 
BoHV-1, suggesting that gB cleavage contributes to cell-to-cell spread of BoHV-1 (175). The 
74-kDa subunit of gB binds with heparin sulfate on the cell surface to facilitate viral entry (77). 
BoHV-1 additionally uses gC to mediate the initial interaction of BoHV-1 with host cells by 
interacting with a heparin-like moiety on the cell surface (176). The 91-kDa mature product of 
gC forms a homodimer in BoHV-1-infected cells (174). gC is not essential for BoHV-1 to enter 
into host cells, although viral replication is drastically reduced in the absence of gC (126). gD, an 
essential protein for BoHV-1 infection, mediates viral attachment and entry (126, 177). gB and 
gD cause membrane fusion in transiently transfected cells, supporting their activities of 
mediating viral entry (126, 178). Additionally, intramuscular immunization with gB or gD 
induces high levels of neutralizing antibodies and protects cattle from BoHV-1 challenge (179, 
180). 
Two non-essential BoHV-1 glycoproteins, gE and gI, form a complex soon after their 
expression (181) and they remain as heterodimer when they are incorporated in the virion of 
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BoHV-1 (79). gE is essential for the viral incorporation of gI, whilst gI is not required for the 
packaging of gE (79). gI ensures the proper maturation of gE (181). Deleting both proteins 
reduces the size of viral plaques, indicating they are important for the cell-to-cell spread of 
BoHV-1 (79). However, they may not be related to viral attachment and penetration (79). The 
virulence of BoHV-1 with gE-deletion is greatly reduced and the reactivation from latent 
infection is repressed, making the gE-deleted mutant suitable to be a marker vaccine virus (182). 
gG of BoHV-1  is a secreted glycoprotein that binds to a wide range of chemokines, and 
thus blocks chemokine activity by preventing them from binding to receptors (183). gG is 
involved in maintaining the junctional adherence among BoHV-1-infected cells, which is 
important for cell-to-cell spread of virus (81, 184). This protein may also be an anti-apoptotic 
viral factor during BoHV-1 infection (185). Additionally, gG-deleted virus has greatly reduced 
virulence, and gG has the potential to be used as a selective marker in live vaccine (182). 
gH is required for the entry of BoHV-1 into host cells (186). gH needs to form functional 
heterodimers with gL to be properly processed and transported in BoHV-1-infected cells (83). 
The gH-gL complex facilitates the penetration of BoHV-1 (82) through mediating membrane 
fusion between the viral envelope and cell membrane (187, 188).  
 Several other glycoproteins are also identified in BoHV-1, making different contributions 
to virus infection. Glycoprotein K, forming a complex with UL20 in infected cells, plays an 
indispensable role in BoHV-1 infection (189). Glycoprotein M interacts with gN through a 
disulfide bond resulting in a heterodimer in BoHV-1-infected cells (84), suggesting a conserved 
function with the HHV-1 gM-gN complex (169).  
 
1.3 Protein phosphorylation and kinase proteins 
1.3.1 Introduction of protein phosphorylation 
Phosphorylation is a universal protein modification in eukaryotic cells that takes place 
through an acute and reversible reaction (190). The reaction is catalyzed by protein kinases, 
resulting in covalent addition of a phosphoryl group to the side chain of a specific residue in a 
substrate  protein (190). Removing a phosphoryl group is called protein dephosphorylation 
which is catalyzed by protein phosphatases (191). In eukaryotes, most of the phosphorylation 
occurs on serine and threonine, and occasionally on tyrosine. These amino acids have a 
 19 
 
nucleophilic (hydroxyl) group that attacks the gamma phosphate group of ATP, resulting in 
transfer of the phosphoryl group from the donor to the side chain of this amino acid (190). The 
reaction is facilitated by metal ions (192). The addition of one or multiple phosphoryl groups to a 
protein alters the conformation and electric charge of the protein, resulting in changes in protein 
function. 
Protein phosphorylation plays an important regulatory role in protein function (190). It 
transforms extracellular and intracellular signals into metabolic patterns in almost every aspect 
of the cell life cycle because of its specifically controlled mechanisms and flexible combinations. 
It is estimated that 3-4% of the genes in eukaryotes encode protein kinases (193). 
 
1.3.2 Casein kinase 2 (CK2) and CK2-specific inhibitors 
CK2 is a constitutively active kinase. Because it lacks an inactive state, its activity is not 
under regulation of any second messenger (194). Generally, the holoenzyme of CK2 is 
composed of two catalytic subunits (α subunit and α’ subunit) and two regulatory subunits (β 
subunit), forming a tetramer (αα’β2, α2β2, or α’2β2) (195). The CK2 tetramer has a butterfly-like 
shape with a β2 dimer in the center and one α subunit on both sides. The C-terminal tails of the 
β-subunits mediate the β-β and the α-β contacts, making the symmetric holoenzyme a strong 
complex that does not spontaneously dissociate in aqueous solutions (195). Different from most 
of the cellular kinases that require dramatic conformational changes to become activated, the 
catalytic subunits of CK2 have a rigid structure which limits the conformational change and 
underpins its constitutive activity (196). The two catalytic subunits catalyze phosphorylation of 
substrates and their activity is either increases or decreased by the presence of regulatory 
subunits (196, 197). 
CK2 is ubiquitous in mammalian cells. It is expressed in almost all organs of mouse 
embryos (198) and is present in nearly every subcellular compartment (199). CK2 has different 
functions according to its subcellular localization. It shifts between the cytoplasm and the 
nucleus during the different stages of the cell cycle. For example, CK2α subunit is 
predominantly cytoplasmic during the synthesis (S) phase, but more nuclear in the Gap 1 (G1) 
phase, suggesting a regulatory role of CK2 in cell division (200). In the mitochondria, CK2 
activity is primarily in the intermembrane space involving cell death signalling (201, 202). The 
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ER-associated CK2 is responsible for signal transductions, such as ER-stress signaling (203), 
cell-survival signaling (204), and ER-to-Golgi protein transport (205). In microtubules, CK2 
regulates cytoskeletal rearrangement (206). CK2 also associates with centrosomes contributing 
to the growth of microtubules (207). At the stage of embryonic development the plasma 
membrane-associated CK2 might be related to embryonic and postnatal development (208). 
CK2 is a pleiotropic protein kinase. It phosphorylates over 350 substrates, regulating 
almost every aspect of cell metabolism (209, 210). The number of substrates keeps increasing 
every year. CK2 is largely recognized as a S/T protein kinase, but increasing evidence shows 
that it occasionally modifies tyrosine residues (211). CK2 phosphorylation does not 
indiscriminately take place on any hydroxyl amino acid residue, but occurs in certain 
sequence/structural contexts. The amino acid residues flanking the phosphorylated residues are 
important in determining the binding of the kinase to a substrate (210). The recognition motif of 
CK2 has been summarized as (E/D/X)-(S/T/Y)-(D/E/X’)-(E/D/X)-(E/D)-(E/D/X), in which X 
represents any residue except basic residues, and X’ represents any residue but basic residues 
and proline (210). However, the above motif is not strictly necessary for CK2-mediated 
phosphorylation. In some cases it also recognizes a minimizal motif, (S/T/Y)-X-X-(E/D), with 
acidic residues located downstream of the phosphorylation amino acid (209, 212). 
Tethered tetrabromobenzene molecules are cell-permeable inhibits that inhibit CK2 
activity by selectively occupying the hydrophobic area of an ATP-binding pocket (213). A 
compound named 4,5,6,7-tetrabromobenzotriazole (TBB) has remarkable inhibition towards 
CK2, with a half maximal inhibitory concentration (IC50) of 0.50 μM (213, 214). However, TBB 
also displays significant inhibition towards several other kinases, including dual-specificity Tyr 
phosphorylation-regulated kinase 1A (DYRK1α), phosphorylase kinase (PhK), glycogen 
synthase kinase 3β (GSK3β), and cyclin-dependent kinase 2 (CDK2), with IC50 values of 0.19, 
8.70, 11.20 and 15.60 μM, respectively (213-215). Another compound derived from TBB, called 
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), has improved ability to 
inhibit CK2 in comparison with TBB (213). Its IC50 value is 0.14 μM. (213, 215). They share 
the feature of a brominated benzene ring that is important for occupying the ATP-binding 
pocket of CK2, but have different side chains (213). However, an obvious defect of DMAT is 
that it inhibits DYRK1α (IC50 = 0.12 μM) more efficiently than CK2 (213). A further improved 
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inhibitor is tetrabromocinnamic acid (TBCA), which is generated by replacing the five-atom 
triazole ring of TBB with a polar side chain (213). This compound not only causes enhanced 
inhibition, but also has better specificity towards CK2 (IC50 = 0.10 μM). Amongst the common 
cellular kinases, it has no comparable effect on DYRK1α. The inhibitory activity against SKG 
and GSK3β is 12-fold less than that against CK2 (213). 
 
1.3.3 BoHV-1 kinase US3 
US3 is a serine/threonine (S/T) protein kinase. The catalytic loop and ATP binding 
regions of US3 are conserved among the members of the alphaherpesvirinae. In BoHV-1, it is 
encoded by the us3 gene in the US region of the viral genome (216). SuHV-1 expresses two 
isoforms of US3, a short isoform US3a and a long isoform US3b (217). Although US3 is not 
essential for virus infection, it plays important roles through its kinase activity in several 
important events during infection (218). 
A common function of US3 is that it rearranges cytoskeleton proteins through its kinase 
activity, causing cells to round up and to form filamentous protrusions (219-222). The pathway 
has been described in SuHV-1-infected cells. US3 phosphorylates p21-activated kinase 2 (PAK2) 
(223), which subsequently phosphorylates Ras homolog protein family member A (RhoA) (4). 
Phosphorylated RhoA mediates the dephosphorylation of cofilin. Without phosphorylation, 
cofilin is unable to maintain actin stress fibers (221, 224), causing damage to the integrity of the 
plasma membrane (4, 223). The damaged membrane facilitates virus entry (221) and cell-to-cell 
spreading (3, 4). 
By sensing the early events of virus infection, host cells trigger the apoptosis signaling 
pathway to restrict the viral replication (225). Herpesviruses express many proteins to counteract 
apoptosis of host cells. Anti-apoptotic activity of US3 has been observed in HHV-1 (226), 
SuHV-1 (217, 227) and BoHV-5 (220), but is less obvious in BoHV-1 (216). US3 of HHV-1 has 
significant importance in the survival of neurons (99). The expression of US3 in trigeminal 
ganglion (TG) neurons causes the cells to be more resistant towards apoptotic stimulation than 
other primary cell types (100, 101). The anti-apoptotic signaling pathway is activated by US3 in 
the TG cells of SuHV-1-infected pigs even before the onset of symptoms of infection (100). 
Similarly, during HHV-1 infection, US3 restrains the neuronal apoptosis in a mouse model (102). 
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US3 is associated with controlling neurovirulence and maintaining latency infection (99, 102) 
rather than directly contributing to viral lytic infection. This is confirmed by a finding that 
inhibition of apoptosis does not restore the titer of US3-deleted HHV-1 during lytic infection 
(228). 
In addition to phosphorylating cellular proteins, US3 also has a broad range of viral 
protein substrates. In HHV-1, US3 phosphorylates gB (229), VP13/14 (142) and VP11/12 (230) 
to regulate their expression levels and/or incorporation efficiency. US3 of BoHV-1 
phosphorylates VP22 (118) and VP8 (15). This activity of BoHV-1 US3 is abolished by 
mutating two conserved residues K
195
 and K
282
, in the catalytic loop and ATP-binding pocket 
regions, which are critical for the kinase activity of BoHV-1 US3 (15). 
Over all, it was determined in the previous studies that BoHV-1 replication is severely 
impaired when VP8 is depleted (64), and that VP8 is phosphorylated by US3 and CK2 (15). Of 
particular interest is whether phosphorylation contributes to the function of VP8 in BoHV-1 
replication. Previous analysis proposed several potential consensus sequences in VP8 for US3 
and CK2 (15). However, because of the sophistication of protein phosphorylation, identification 
of functional motifs in VP8 relies on experimental confirmation. The first objective of this 
research is to identify US3- and CK2-dependent phosphorylation residues in VP8. Moreover, 
US3 is a viral kinase, whereas CK2 is a cellular kinase; and they are localized differently in 
BoHV-1-infected cells (15), indicating that they may have different effects on the function of 
VP8. Thus the second objective is to identify the impacts of US3- and CK2-mediated VP8 
phosphorylation in the life cycle of BoHV-1. Furthermore, VP8 is mostly localized in the 
nucleus of BoHV-1-infected cells, and it is capable of shuttling between the nucleus and 
cytoplasm (25, 154, 155). The third objective is to understand the impact of phosphorylation in 
the cellular translocation of VP8 during BoHV-1 infection. Over all, this research characterizes 
the phosphorylation-regulated functions and cellular translocation of VP8 in the life cycle of 
BoHV-1.  
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CHAPTER 2 
 
2 LINKER BETWEEN CHAPTER 1 AND CHAPTER 3 
Nuclear domain 10 (ND10) is a cell nuclear structure containing many anti-viral proteins, 
including promyelocytic leukaemia (PML), speckled protein 100 (SP100), alpha thalassemia/ 
mental retardation syndrome X-linked protein (ATRX), and death domain-associated protein 6 
(DAXX) (104, 231-233). Herpesvirus infection significantly changes and disperses the cellular 
foci (234). An increasing amount of research demonstrates that the structure and the dynamics of 
ND10s are gradually changed during herpesvirus infection, and that tegument proteins as well as 
immediate early proteins play important roles in redistributing and degrading ND10 components. 
The current knowledge on how herpesvirus proteins counteracting ND10 is reviewed in the next 
chapter. VP8 is abundantly released from the incoming BoHV-1 virus into host cells, and thus it 
has the potential to target ND10, like other herpesvirus tegument proteins, such as UL35 and 
pp71 of HHV-5 (104, 235-237). This review provides background knowledge for studying the 
interplay between VP8 and ND10 proteins. 
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3.1 Abstract 
The sophisticated anti-viral functions of nuclear domain 10 (ND10) are revealed by 
identifying the role of each component and the countermeasures applied by viruses. Several 
ND10 proteins suppress herpesviruses at initial and early phases of infection. Herpesviruses need 
to antagonize these anti-viral proteins to start a productive infection. In this review the recently 
identified similarities and differences among the strategies adopted by the three subfamilies of 
herpesviruses are discussed, highlighting that one of the significant purposes of incorporating 
tegument proteins into the viral particles might be to counteract ND10 proteins immediately after 
the viral genome enters the host nucleus. Once the infection progresses, a sufficient amount of 
immediate early proteins is expressed to disperse and hydrolyze ND10 proteins, accelerating the 
development of infection. 
 
3.2 Highlights 
 The three herpesvirus subfamilies have tegument proteins that counteract the nuclear 
domain 10-related repression of the viral genome. 
 Each type of herpesvirus discussed in this review contains at least one immediate early 
protein to disrupt ND10, and their mechanisms of action are not exactly the same. 
 Nuclear domain 10 targets pre-replication sites of herpesviruses by recognizing specific 
factors required for viral DNA replication, but not the incoming viral genome. 
 
3.3 Introduction 
Nuclear domain 10 (ND10) contains intrinsic and innate immune factors that respond to 
herpesvirus infections. The composition and existence of ND10 frequently change in response to 
several important events during herpesvirus infection. To overcome the ND10-mediated antiviral 
defences, the three major herpesvirus subfamilies use similar, yet distinct, strategies to reform 
and disrupt ND10 at very early stages of infection. The goal of this review is to discuss recent 
research on the strategies used by each subfamily of herpesviruses. Overall, they share some 
similarities, as is summarized in Figure 3.2. First, the incoming tegument proteins interrupt 
intrinsic antiviral responses before the onset of viral gene expression. To break the cellular 
suppression of the viral input genome, tegument proteins are released into the cells together with 
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viral DNA, so that they can produce a favorable condition for the viral genome as soon as they 
enter host cells. A common target for tegument proteins is the cellular protein complex formed 
by alpha thalassemia/mental retardation syndrome X-linked protein (ATRX) with death domain-
associated protein 6 (DAXX) (236, 238, 239). Meanwhile, other ND10 components may also be 
targeted (240). ATRX primarily is a physical mediator for the association of tegument proteins 
with DAXX, while DAXX is the target to be degraded (104, 241). The ultimate purpose of 
disrupting the ATRX-DAXX complex might be activation of immediate early gene expression 
(103, 104, 241, 242). Secondly, the immediate early proteins target ND10 to manipulate 
interferon (IFN)-stimulated proteins, such as promyelocytic leukemia protein (PML) and 
speckled protein of 100 kDa (SP100). The expression of these viral proteins is increased by 
tegument protein-meditated DAXX degradation (103, 104, 242). The specific approaches used 
by immediate early proteins vary between different herpesviruses. ICP0 of  human herpesvirus 1 
(HHV-1) degrades all isoforms of PML through its E3-ligase activity (243). IE1 of human 
herpesvirus 5 (HHV-5) (244), BZLF1 of human herpesvirus 4 (HHV-4) (245), and ICP0 
homologues in bovine herpesvirus type 1 (BoHV-1) (246) and equine herpesvirus type 1 (EHV-1) 
(246) tend to reduce SUMOylated PML. ICP27 of human herpesvirus 2 (HHV-2) alters the 
splicing of PML pre-mRNA to switch the PML isoforms so that cells predominantly produce 
virus-friendly PML isoforms instead of antiviral isoforms (247). Eventually, in the presence of 
immediate early proteins herpesviruses are less vulnerable to IFN-stimulated repression (105). 
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Figure 3.2 Model of herpesviruses counteracting nuclear domain 10 (ND10).  
1. The viral genome and tegument proteins are released into the cell nucleus. 2. Viral DNA is 
circularized and recruited to the pre-replication foci. 3. ND10 is recruited towards pre-replication 
foci. The ATRX-DAXX complex mediates deposition of histone proteins on the viral genome. 4. 
Viral tegument proteins degrade PML and/or dissociate the ATRX-DAXX complex from ND10 
to allow the transcription of viral mRNA. Tegument proteins that have such functions are listed. 
5. Viral mRNA is transported to the cell cytoplasm. 6. Immediate early proteins are expressed. 7. 
Immediate early proteins are translocated into the nucleus to target PML and/or SP100. 
Immediate early proteins that have such functions are listed. 8. When ND10 is disrupted viral 
DNA replication is facilitated forming a replication compartment. 9. Viral capsid with the 
genome is ready to egress from the nucleus. 
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3.4 Introduction of nuclear domain 10 (ND10) 
ND10s, also called promyelocytic leukemia nuclear bodies (PML-NBs), are nuclear 
matrix–associated domains with a punctate structure. They were originally described in acute 
promyelocytic leukemia (APL) patients. In the APL patients the retinoic acid receptor-α (RARα) 
gene and the pml gene are fused by chromosome translocation and express PML/RARα fusion 
protein causing changes in the size and number of ND10s (248, 249). The ND10 structures are 
characterized by the presence of several constitutive and transient protein components. The 
structural proteins are relatively stable in the foci, with constant and rapid self-renewal (250), 
while the transient proteins only appear in the foci under certain conditions depending on the 
protein function (251). PML is one of the major proteins localized in this structure; thus, the 
ND10s appear as multiple nuclear speckles by immunostaining with anti-PML antibody (252). 
They are present in almost all mammalian cells, and the number varies from 1 to over 30, 
depending on the cell type and condition (252). The dynamic changes in ND10 protein content 
reflect the active function of these nuclear foci. They have been found to play a pivotal role in a 
wide range of important cellular events, including cell–cycle control (253), programmed cell 
death (254) and genome transcription (255). Based on studies of the regulatory function of PML 
in DNA replication, it appears that ND10 is involved in intrinsic and innate defenses against 
virus infection (105). 
 
3.4.1 Promyelocytic leukemia protein (PML) 
PML, a member of the tripartite motif-containing protein (TRIM) family, is also known 
as TRIM 19, and essential for the formation of ND10 (256). It is an IFN-stimulated protein (105) 
and involved in regulating a broad array of ND10-related cellular events. A single copy of the 
human pml gene generates at least 12 isoforms (UniProtKB-P29590) by alternative splicing post-
translation. They share the same N-terminus, encompassing a zinc-really interesting new gene 
(RING) finger domain, B box-1, B box-2 and coiled-coil region (257). Each isoform contains a 
unique C-terminal sequence, exhibiting different characteristics (257). For example, PML 
isoforms 1-5 are nuclear proteins involved in gene transcription regulation and chromatin 
remodeling (258), and PML-2 specifically promotes the formation of nuclear lipid droplets (259). 
 29 
 
The function of PML protein depends on the consensus motifs and post-translational 
modifications. A nuclear localization signal (NLS) is contained in most PML isoforms to 
perform nuclear functions such as regulation of transcription and innate immune responses (257). 
These activities also require the region for DNA-binding, ubiquitin protein ligase-binding, and 
RING-finger (260). The coiled-coil region contributes to the heterodimerization and 
homodimerization, which are important for assembly of ND10 and protein recruitment (261). 
Several SUMOylation motifs are distributed in the PML sequence, and the association with 
SUMO-1/2 is essential for dimerization, maintaining protein stability, and controlling activity 
(262). 
 
3.4.2 Speckled protein of 100 kDa (SP100) 
SP100 is one of the major constituents of ND10. Many factors contribute to the assembly 
of SP100 in the ND10 foci. First, the association of SP100 with ND10 is stabilized by PML, and 
inversely, PML is protected by SP100 from hydrolysis (263). Secondly, covalent SUMO-1 
modification is essential for SP100 to localize in ND10 (264). Finally, SP100 has self-
aggregation properties that may enhance its accumulation in the ND10 foci (265). SP100 
regulates cellular gene activity and tumorigenesis by recruiting heterochromatin protein 1 (HP1) 
(266). As an IFN-induced protein, SP100 is an important factor in the innate immune response, 
mediating IFN-stimulated repression of immediate early proteins of HHV-1 (232).  
Four major alternatively spliced variants of SP100 have been studied, namely SP100-A, 
SP100-B, SP100-C, and SP100-HMG (267). When they are analyzed independently in the 
mammalian cell nucleus, these four isoforms display distinct localization patterns, suggesting 
that they have common as well as specific functions (232). The protein sequence of SP100-A 
contains a SUMO-1-binding motif, HP1-binding motifs and a half-site reaction (HSR) motif 
essential for dimerization (267). Because of the SUMOylation and acidic sequence, SP100-A 
shows a slower electrophoretic mobility than the calculated mass (54 kDa) would predict (264, 
266). Most of the SP100-A sequence (477 amino acid residues) is present in SP100-B, SP100-C, 
and SP100-HMG, but the last three isoforms also share a SAND (named after Sp100, AIRE-1, 
NucP41/75, DEAF-1) domain (267), which has DNA-binding activity and plays a role in 
regulation of chromatin-dependent transcription (268, 269). SP100-C contains a plant 
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homeodomain (PHD) (267), which has the potential to bind to non-methylated histone protein to 
activate gene expression (270). SP100-HMG contains a unique high-mobility group (HMG) 
domain (267), involved in DNA-binding (271). 
 
3.4.3 Alpha thalassemia/mental retardation syndrome X-linked protein (ATRX) and death 
domain-associated protein 6 (DAXX) 
ATRX is a member of the chromatin remodeling protein family (272), which modulates 
histone deposition (273) and genomic DNA methylation (274). These activities contribute to the 
regulatory role of ATRX in cell cycle control and gene expression. By altering phosphorylation 
status, ATRX shuttles between the nuclear matrix-associated ND10 and the chromatin in a cell-
cycle dependent manner (253). In addition, ATRX plays a protective role by controlling aberrant 
gene transcription and tumorigenesis depending on a PHD motif and an ATPase/helicase domain 
(253). Mutation of ATRX is strongly correlated to the development of several cancers (272, 275-
277). Deletion of ATRX accelerates tumour cell replication (272), which is partially due to 
overexpression of anti-apoptotic factor P53 as a result of loss of ATRX (277). Moreover, ATRX 
restricts the genomes of many viruses in the host cells (104, 238, 239). 
DAXX is a histone chaperone that is essential for histone H3.3 deposition covering the 
whole genome in mice (273). This activity requires association with ATRX. By recognizing 
chromatin modifications, the ATRX-DAXX complex selectively localizes to certain regions of 
the heterochromatin, providing an essential condition for H3.3 deposition (273). In the meantime, 
the ATRX-Dnmt3-Dnmt3L (ADD) domain of ATRX (278) interacts with the histone tail of H3.3 
which is trimethylated at lysine 9 (H3K9me3) to maintain the protein on the heterochromatin 
(273). Reversely, disrupting either component of the ATRX-DAXX complex causes H3K9me3 
to disappear from the heterochromatin (273). Overall, the ATRX-DAXX complex plays an 
important role in regulating cellular gene expression by supressing transcription. Disruption of 
the complex causes aberrant transcription (273) and tumor progression (275). It has been 
suggested that in clinical practice the punctated appearance of DAXX and ATRX in the cell 
nucleus should be incorporated into the pathologic evaluation of neuroendocrine and 
neuroblastoma tumors (279, 280), as the ATRX-DAXX complex is frequently disrupted when 
cells become cancerous (275). 
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3.5 ND10 and herpesvirus 
3.5.1 ND10 and alphaherpesvirus infection 
3.5.1.1 Tegument and immediate early proteins are important for alphaherpesviruses to confront 
ND10 
It has been well recognized that ICP0 of HHV-1 disrupts ND10 by degrading a major 
protein, PML, in the structure (281). Recently ORF61, a homologous protein of ICP0 in human 
herpesvirus 3 (HHV-3), was also found to disperse PML-foci, through SUMO-interacting motifs 
(282). The impact of ICP0 on ND10 appears at very early phases of HHV-1 infection. Since 
ICP0 is incorporated into the viral tegument by associating with HHV-1 capsids (283), the ICP0 
from the incoming virus is released into the host cell immediately after viral entry and has the 
potential to target ND10. According to evidence presented by several groups, the pre-existing 
ND10s are dispersed at the initial stages of infection (284, 285). Since it is difficult to separate 
input and de novo synthesized ICP0 at this stage of infection, further studies are needed to 
determine the contribution of input ICP0 to the disruption of ND10. 
Other tegument proteins might directly or indirectly facilitate the disruption of ND10. 
ICP4 is a minor tegument and immediate early protein in HHV-1 (286). At the early stage of 
infection, ICP4 plays a role in mediating the interaction between ND10 and pre-replication foci 
by associating with DAXX (287), and it is contained in the pre-replication foci (288). The input 
ICP4 protein potentially has a similar activity, being involved in ND10 remodeling at a pre-
immediate early stage of infection, before protein synthesis. In BoHV-1 the ul47 gene product is 
a major tegument protein, named VP8 (289). Transfected VP8 recruits PML to form PML-
aggregates in the nucleus (290). Since PML foci are not completely dispersed in cells solely 
expressing VP8 (290), VP8 may assist in remodeling PML foci at initial stages of infection 
before ND10 is disrupted by ICP0. It is not known whether such an activity of the ul47 gene 
product is conserved in other alphaherpesviruses. 
 
3.5.1.2 ND10 is related to cellular repression of the viral genome 
Soon after the pre-existing ND10s are dispersed, a small group of ND10s re-appears in 
the cell nucleus, in association with HHV-1 pre-replication foci, which are the initiation sites for 
viral DNA replication during the early phase of infection (284). By this time, the de novo 
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synthesis of immediate early proteins has started, and ICP4 foci can be experimentally detected 
(284). The re-appearance of ND10 in the pre-replication foci is very transient and takes place 
before the formation of replication compartments (284), suggesting a regulatory role of ND10 in 
initiation of viral DNA replication. The re-appeared ND10s are formed by recruitment of 
diffused components towards the pre-replication foci, and possibly only include PML-isoforms 
that are resistant to ICP0 (284). Thus, they are different from the pre-existing ND10. 
It is unlikely that pre-replication foci form in ND10, but the ND10 components have the 
potential to migrate towards pre-replication foci. This is confirmed by the observation that, in the 
absence of ICP0, pre-existing PML foci are able to move towards the pre-replication foci and to 
merge with them (284, 285). In the presence of ICP0, PML foci associate with the pre-replication 
foci merely for a very short period of time, and soon disappear. In the meantime, pre-replication 
foci are gradually replaced by larger globular nuclear domains, called replication compartments, 
where HHV-1 DNA replication takes place (284). Several ND10 components, except for a 
subpopulation of PML isoforms, remain in the replication compartments when ICP0 is not 
present (284, 291). Certain isoforms of PML are missing (291) and they have different 
morphologic appearances in comparison to that in the cellular pre-existing ND10s (292). A 
subpopulation of HHV-1-infected cells contain a type of cellular foci that partially share protein 
components with the pre-replication foci, for example UL29 (293). However, these foci do not 
contain PML, but are related to cellular DNA synthesis instead of virus replication (293), so they 
are functionally different from pre-replication sites and need to be considered in a different 
context. 
 
3.5.1.3 Recruitment of ND10 towards pre-replication sites 
The aggregation of ND10 towards pre-replication foci is more likely a cellular behavior 
rather than a viral response, because the ND10 components resist viral infection (294). PML at 
the pre-replication sites represses HHV-1 gene expression at the initial stages of infection (294). 
DAXX might indirectly contribute to the association between the ND10 complex and the pre-
replication foci (287). 
Although PML is recruited to repress the initiation of viral infection, viral gene 
transcription does not necessarily have to take place to attract PML (294). PML is recruited by 
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recognizing certain viral elements within the pre-replication sites (287, 291). The pre-replication 
sites contain the viral genomes and viral proteins that regulate viral gene expression and 
replication, including single-strand binding protein UL29, heterotrimeric helicase-primase 
complex (UL5, UL8, and UL52), origin binding protein UL9, and DNA polymerase UL30 (295). 
The presence of UL30 is essential for recruitment of PML to the pre-replication focus; however, 
UL30 does not need to be active (291). This is also in agreement with the fact that the PML 
recruitment at the pre-replication site is independent from the actual event of viral gene 
transcription (294). Several other factors are related to ND10 deposition to the pre-replication 
focus, such as exposure of a short viral gene replication origin (OriS), and viral gene transcription 
proteins (ICP4 and ICP27) (287).  
 
3.5.1.4 The development of replication compartments is facilitated by disruption of ND10 
DNA replication compartments develop from pre-replication sites, which are often 
marked by ICP4 for study purposes (288). ND10 is found in the vicinity of the pre-replication 
sites, which are composed of factors promoting viral replication, such as DNA polymerase and 
origin binding protein (284, 288). ICP0 disrupts ND10 to ensure optimal DNA replication by 
promoting pre-replication sites to develop into replication compartments. However, the number 
of pre-replication sites is usually higher than that of the replication compartments, because not 
all but only several pre-replication sites are able to enlarge to globular structures, while the rest 
are abolished (288). When ICP0 is present, the pre-replication sites have a significantly higher 
chance to become replication compartments than in the absence of ICP0 (288) as ICP0 
eliminates the restriction factors by disrupting ND10. ICP4 foci without ICP0 are less likely to 
become replication compartments because of the restriction from ND10. ICP0 targets the anti-
viral ND10 as opposed to directly being involved in pre-replication events. The sub-nuclear 
localization of ICP0 is in agreement with it targeting ND10 instead of pre-replication sites as 
ICP0 precisely co-localizes with ND10 and not with pre-replication sites (288).  
ICP0 of HHV-1 damages ND10 by mediating PML dissociation and degradation, thus 
promoting viral gene replication and expression (296). The C-terminal domain of ICP0 
associates with the ND10 structure, and the RING finger is the active domain for redistribution 
of PML (243). The redistributed PML is degraded by the E3 ubiquitin ligase activity of ICP0 
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through a ubiquitin-dependent proteasome pathway (296). In addition, herpesvirus-associated 
ubiquitin-specific protease (HAUSP) (296) and ubiquitin-conjugating enzyme H5a (UbcH5a) 
(297) have been found to contribute to the ICP0-mediated degradation of PML. The methods of 
PML degradation by ICP0 vary between different alphaherpesviruses. In BoHV-1 and EHV-1, 
ICP0 proteins reduce SUMO-modified PML-1/2 without affecting the un-modified PML-1/2 
(246). Therefore, ICP0 of BoHV-1 and EHV-1 have not been found to disperse ND10 foci in the 
cell nucleus (246, 298). 
In addition to being a target for degradation by ICP0, PML might also attract ND10-
degrading proteins to disperse SP100. It is known that IFN treatment enlarges SP100 foci and 
causes reformation of SP100 foci even when PML is knocked down in human epithelial type 2 
(Hep-2) cells (105). However, in the context of IFN treatment, ICP0-induced dispersal of SP100 
foci is delayed in the PML-null cells in comparison with wild-type cells (105), possibly because 
ICP0 has a lower chance to access SP100 foci when PML is not present (105). 
It is a topic of debate whether ICP0 directly contributes to the degradation of SP100. In 
one study focused on individual isoforms of SP100, transient expression of ICP0 was found not 
to degrade SP100-A, SP100-B, SP100-C, or SP100-HMG (232). Similarly, homologues of ICP0 
in BoHV-1 and EHV-1 do not reduce the SP100-A protein levels (246). However, this is not 
consistent with the statements from several other publications that ICP0 degrades SP100 through 
the proteasome pathway (297, 299, 300). A convincing conclusion is that during HHV-1 
infection, the SP100 protein level is drastically reduced, and SP100 foci are dispersed (297, 299). 
It is possible that ICP0 mediates the dispersion of SP100 through degrading PML and that SP100 
is degraded through an ubiquitin-dependent pathway. This contention is based on the following 
evidence. First, PML, the essential factor to maintain SP100 in ND10 (301), is degraded by ICP0 
through the proteasome pathway (243, 302). A proteasome inhibitor, MG132, protects the SP100 
from degradation during infection (299), perhaps because treatment with the proteasome 
inhibitor protects PML from degradation, which subsequently preserves SP100 from 
displacement. Secondly, UbcH5a is involved in the degradation of SP100 (297), suggesting that 
it is an ubiquitin-dependent protein degradation, which is sensitive to MG132. It is possible that 
the dissociation of SP100 in ICP0-expressing cells (300) is the result of ICP0-induced PML 
degradation, and the mechanism of SP100 degradation requires further investigation. 
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3.5.1.5 ND10 restricts viral DNA activity, not only at early stages of infection 
The impact of ND10 on viral infection may last till the time when replication 
compartment develops, because some ND10 protein components appear in replication 
compartments in the absence of ICP0 (303). To avoid ICP0-induced disruption of ND10, 
replication compartments were established by transfecting essential elements of HHV-1 DNA 
synthesis (303). This is based on the theory that DNA synthesis initiates at one of three viral 
origins of the HHV-1 genome, including one copy of OriL (long) and two copies of OriS (short) 
(65). It also requires seven essential replication proteins, namely heterotrimeric helicase primase 
complex (UL5, UL8 and UL52), a DNA polymerase (UL30), a DNA polymerase accessory subunit 
(UL42), origin-binding protein (UL9), and a single-strand DNA-binding protein (UL29) (303). 
Co-transfection of plasmids containing these essential replication proteins and HHV-1 replication 
origin creates replication compartments in the cell nucleus (303). PML-foci are closely 
associated with the edges of these artificially introduced replication compartments (303), 
suggesting that this protein may have an impact throughout the later phases of viral DNA 
replication. 
ND10 proteins associate with HHV-1 replication compartments to restrict DNA 
replication later during HHV-1 infection (304). This was studied in context of deletion of ICP0 
from the HHV-1 genome (304). The punctated appearance of ND10 is not disrupted in ICP0-null 
virus-infected cells and stably remains adjacent to the parental viral genome (304). The 
formation of replication compartments starts from the viral DNA sites and they gradually grow 
into globular structures, accompanied by ND10 foci (304). With the growth of the compartments, 
the major components of ND10 form different patterns within the compartments (292). The 
medium-sized compartments contain PML and SP100 as punctated foci (292). Subsequently, the 
large-sized compartments contain thread-structured PML and SP100 (292). DAXX recruitment is 
less significant in the large compartments than in the medium ones (292). Cellular repression of 
the genome of ICP0-null virus is decreased when PML is depleted, demonstrating that PML 
aggregation to the viral genome is a cellular antiviral response (294, 305). 
Remodeling of ND10 is closely associated with the behavior of the HHV-1 genome in 
trigeminal ganglion neurons during the establishment of latent infection (306, 307). This is 
reflected by the appearance of the viral genome and PML in neurons. During latency, HHV-1 
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genomes are stored within the nucleus of ganglion neurons with punctated appearance (306). 
Each cell contains a single focus or multiple foci of viral genomes because of the heterogeneity 
of the viral genome during latency infection (306). The single genome focus in the neural 
nucleus is more frequently covered with a PML shell and co-localized with ATRX and DAXX, 
whereas the multiple genome foci are less likely to be associated with PML, DAXX, and ATRX 
(306). If the genome is associated with the above ND10 proteins, active transcription of latency-
associated transcript (LAT), which is the only gene highly expressed during latency, is less likely 
to occur; this agrees with the fact that LAT expression occurs more significantly within the 
multiple foci. These reports suggest that ND10 plays a major role in the control of latency (306, 
308).  
 
3.5.1.6 ND10 is a mediator of the interferon-induced antiviral response 
Convincing data have been reported to support the involvement of PML in the IFN-
stimulated antiviral defence. PML has been shown to suppress HHV-1 infection when ICP0 is 
removed (309) or a low level of input virus is applied to the cells (105). IFN-α and -γ reduce the 
production of ΔICP0-HHV-1 in PML-containing wild-type cells more effectively than in PML-/- 
cells (309). PML
-/-
 cells produce more HHV-1 than wild-type cells do when cells are infected 
with low PFU of virus (105). However, HHV-1 replicates equally well in both types of cells 
when given high PFU of virus (105), demonstrating that the restriction by PML can be easily 
eliminated by a high amount of input virus, which contains sufficient viral proteins to counteract 
PML (105). Together with the fact that PML is an IFN-stimulated protein (310-312), it has been 
concluded that PML is a downstream responder of the IFN-stimulated antiviral pathway. 
SP100 is another ND10-resident IFN-stimulated protein. The sensitivity to IFN treatment 
of individual SP100 isoforms varies depending on the cell type. For example, IFN-β more 
favorably stimulates SP100-A in Hep-2 and human embryonic kidney (HEK-293) cells (232), 
while SP100-C is more significantly enhanced by IFN-β than other isoforms in Stemgent BJ 
human fibroblasts (BJ) cells (263). SP100-B, -C, and -HMG effectively suppress immediate 
early protein expression, and IFN-β enhances the repression (232). Furthermore, nuclear DNA 
helicase II (NDHII) is recruited to ND10 and associates with SP100 to regulate IFN-α-stimulated 
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gene transcription (313). This provides evidence that ND10 is a gene-transcription regulating site 
stimulated by IFN. 
 
3.5.2 ND10 and betaherpesvirus infection 
3.5.2.1 ND10 restricts human herpesvirus 5 (HHV-5) infection 
HHV-5, a betaherpesvirus that establishes latent infection in monocytes, is usually 
asymptomatic in healthy humans, but can be life-threatening in immunocompromised individuals 
(314, 315). During initial phases of HHV-5 infection, ND10 associates with pre-replication sites 
to downregulate viral DNA replication and transcription, in a similar manner as during HHV-1 
infection. First, PML- and SP100-containing foci become closely adjacent to pre-replication sites 
(316, 317), which contain six DNA replication core proteins including DNA polymerase UL54, 
processivity factor UL44, primase subunit UL70, primase-associated factor UL102, DNA helicase 
subunit UL105, and single-strand DNA binding protein UL57 (316). Subsequently, some of these 
foci gradually expand to globular replication compartments (316). The purpose of PML/SP100-
foci aggregation near the pre-replication sites is to prevent them from developing into replication 
compartments (318). The antiviral function of ND10 is also supported by the fact that when 
ND10 is dispersed from pre-replication sites by a viral immediate early protein, IE1, the virus 
achieves better infection (234, 316, 317, 319). 
 
3.5.2.2 Immediate early protein of HHV-5 disrupts ND10 
An immediate early protein of HHV-5, IE1, disrupts the structure of ND10 by 
redistributing PML (316, 318), which is a restriction factor for HHV-5 infection (318). Shortly 
afterwards, IE1 diffusely distributes in the nucleus (234, 319). Without IE1, HHV-5 fails to 
disrupt ND10, and consequently shows delayed formation of a replication compartment and slow 
progression of infection (316, 318). Instead of causing significant degradation of the total protein 
level of PML, IE1 tends to attack SUMO-1-modified PML by degrading (244) or de-
SUMOylating (320) PML. Specifically, the residue Leucine
174
 in the globular core domain of 
IE1 (IE1CORE) is essential for this activity (321). Direct interaction between the two proteins 
requires an acidic domain near the C-terminus of IE1 (231, 319), which targets the coiled-coil 
region of PML (322). Moreover, the RING finger domain of PML also contributes to the 
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interaction (231, 322). The structural interaction indicates that IE1 dissociates PML by 
occupying or deforming the critical structure for ND10-binding, which are the RING finger 
domain and the coiled-coil region on the N-terminus (231), leading to blocking of 
oligomerization and protein complex formation of PML (231). This results in the dissociation of 
ND10 from pre-replication sites (231). 
Another immediate early protein, IE2, is involved in activating gene transcription by 
directly interacting with the parental viral genome (323). IE2-containing foci are frequently 
adjacent to ND10 (234, 316, 317, 319). However, a direct association between the viral genome 
and PML has not been reported, indicating that ND10 might be recruited towards pre-replication 
sites by recognizing a related protein instead of viral DNA. 
 
3.5.2.3 Tegument proteins of HHV-5 target antiviral components in ND10 
In addition to PML (233, 318, 324) and SP100 (324, 325), DAXX (233, 325) and ATRX 
(104) suppress initiation of viral gene expression, resulting in delayed or less productive HHV-5 
infection. In eukaryotic cells, newly synthesized histones are rapidly deposited onto the cellular 
DNA immediately behind the replication fork to restrain aberrant replication or transcription 
(326). In this context, the viral DNA would be quickly wrapped by histones. DAXX interacts 
with histone deacetylases (HDAC) which tighten histones on DNA to suppress immediate early 
gene transcription (242). Since there is lack of evidence indicating direct association between 
DAXX and viral DNA, DAXX and HDAC may bind to the immediate early gene promoter 
through some unidentified complex (242). The DAXX-binding protein, ATRX (274), contains a 
zinc-finger domain implicated in DNA binding activity (327); thus, ATRX is a potential 
mediator between DAXX and the viral genome. The ATRX–DAXX complex represses viral 
immediate early gene transcription by modifying the acetylation of histone proteins (104, 242). 
In this scenario, PML and SP100 may play a role in repressing immediate early gene expression 
partially through maintaining the ND10 structure, which contains ATRX and DAXX. 
Before the de novo synthesis of viral proteins, HHV-5 releases tegument proteins to 
counteract the ATRX-DAXX complex within ND10. Pp71(UL82), a tegument protein encoded 
by the ul48 gene, disrupts the ATRX-DAXX complex from ND10 (104) to activate immediate 
early gene expression (103). Immediately after infection, pp71 is released from virions and 
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delivered into the nucleus, appearing as punctated foci that colocalize with ND10s (328), where 
it breaks the interaction between ATRX and DAXX by associating with the coiled-coil domain 
of DAXX (329). This association may compete for the binding area with ATRX or directly 
interfere with the ATRX-binding domain on DAXX, making it an essential factor to disrupt the 
ATRX-DAXX interaction (104). Without the interaction with ATRX, DAXX becomes 
vulnerable to degradation mediated by pp71 through an ubiquitin-independent (239), 
proteasome-dependent pathway (242), leading to increased immediate early gene expression 
(242, 329). During HHV-5 infection, the strategy of removing DAXX is more predominant than 
degradation of PML and SP100 (242). At about 2 hpi the DAXX level is significantly reduced 
(242), while the PML and SP100 levels show a slight reduction (242, 320). 
Several other tegument proteins have been found to collaboratively regulate the function 
of pp71, such as UL35 and UL35a (235, 236), although pp71 is sufficient to induce DAXX 
degradation (104). UL35 is a late protein that is incorporated into mature virus as a minor 
tegument protein, and UL35a is a viral protein expressed from early to late phases of infection 
and does not appear in the mature virus (235). UL35 interacts with pp71 and collaboratively 
activates immediate early gene transcription (237). Together with the observation that UL35 is 
able to independently remodel the ND10, and strongly co-localizes with the remodeled ND10 
structures (235, 236), this indicates that UL35 may facilitate pp71-mediated DAXX-ATRX 
disruption. However, UL35a negatively regulates this process because it prevents UL35 from 
remodeling ND10 and directs pp71 to the cytoplasm (236). 
 
3.5.3 ND10 and gammaherpesvirus infection 
3.5.3.1 ND10 counteracts human herpesvirus 4 (HHV-4) infection 
ND10 plays a significant role in the pathogenesis of HHV-4, which is a 
gammaherpesvirus that establishes latency in B lymphocytes and causes immortalization of B 
cells (330), as well as epithelial cells (331). First, during primary infection ND10 may repress the 
origin of DNA replication (332) and immediate early gene expression (333). In the cell nucleus 
ND10 is juxtaposed to HHV-4 replication compartments that are created by transfection with 
plasmid carrying the viral origin of lytic replication (332). This physical interaction also provides 
access for PML and SP100 of ND10 to supress immediate early gene expression (333, 334). 
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Secondly, the reactivation of HHV-4 from latency is suppressed by ND10 (112, 335). To 
counteract the multiple types of repression caused by ND10, HHV-4 uses tegument proteins (241) 
and immediate early proteins (245) that specifically target the ATRX-DAXX complex, PML and 
SP100. Because these cellular proteins are important cell-death modulators, disturbing their 
function may contribute to the immortalization of infected cells. 
 
3.5.3.2 HHV-4 uses tegument and immediate early proteins to neutralize ND10 
DAXX and ATRX are transcription repressors that form heterodimers and are implicated 
in repressing transcription of viral genomes by reprograming histone proteins (273). BNRF-1, 
the major tegument protein of HHV-4, is delivered to the nucleus to subvert these antiviral 
factors. After dissociating from the virus, BNRF-1 closely associates with ND10 by interacting 
with DAXX (241), forming a stable quaternary complex with DAXX, Histone H3.3, and H4 
(238). In the meantime, BNRF-1 disrupts the bond between DAXX and ATRX by dispersing 
ATRX (241), ending the repression of viral immediate early gene expression (241), and also 
contributing to immortalization of host B cells (238). The high amount of BNRF-1 in the 
infectious virions (336) is consistent with the important role of breaking cellular repression at the 
initial stages of infection. 
With the help of BNRF-1, immediate early proteins of HHV-4 are efficiently expressed 
(241), and some of them, such as BZLF-1, EBNA-1 and EBNA-5 (EBNA-LD), target ND10-
associated proteins through different mechanisms. BZLF-1 disrupts ND10 by reducing SUMO-1 
modified PML (245). This viral protein may competitively inhibit PML SUMOylation by 
consuming limited amounts of SUMO-1(245). EBNA-1 degrades PML through the proteasome 
pathway (337). HAUSP is attracted to ND10 by EBNA-1 and contributes to PML degradation 
(337). In the meantime, CK2 is recruited to ND10 by EBNA-1, thereby enhancing 
phosphorylation of PML, which benefits polyubiquitination and degradation of PML (338). 
EBNA-5 associates with ND10 to target SP100 (333, 339). At early phases of infection, EBNA-5 
is homogenously distributed throughout the nucleus and, soon after, is associated with ND10 
(340) by interacting with SP100 (333), which leads to dispersal of SP100 (339). Tegument 
protein-induced ND10 disruption has also been observed during infection with murine 
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herpesvirus 68 (MHV68). This virus expresses ORF75c, a homologous protein of BNRF-1, to 
degrade PML protein and disrupt ND10 (240). 
 
3.6 Conclusions 
The intrinsic immune responses mediated by ND10 components are likely to constrain 
the initiation of herpesvirus infection. The three herpesvirus subfamilies have adopted unique 
strategies to disrupt the ND10. Tegument proteins released from input viruses could be the 
earliest viral factors disrupting ND10 proteins at a pre-immediate early phase. A betaherpesvirus, 
HHV-5, is so far the best described virus in this context, using its tegument proteins, pp71 and 
UL35, to disrupt the ATRX-DAXX complex, which results in ATRX dispersion and DAXX 
degradation (104, 237, 239, 329). Pp71 plays an essential role, whereas UL35 is a facilitator (236, 
237). A major tegument protein of HHV-4, BNRF-1, has a similar function as pp71. It disperses 
the ATRX-DAXX complex by disrupting the interaction between ATRX and DAXX (241). This 
example indicates that gammaherpesviruses also express tegument proteins to interrupt the 
ATRX-DAXX complex. An example in alphaherpesviruses is a major tegument protein of 
BoHV-1, VP8 (ul47 gene product), which relocates PML foci (290), raising the possibility that 
alphaherpesviruses may also use tegument proteins to target ND10 components. The pattern of 
PML foci redistributed by VP8 (290) is morphologically similar to that induced by UL35 of 
HHV-5 (236, 237), and both do not eliminate ND10; hence, another protein in BoHV-1 may have 
the ability to disrupt the ATRX-DAXX complex. Some tegument components vary between 
BoHV-1 and HHV-1 in several aspects. First, the ul47 gene product is a major tegument protein 
in BoHV-1, but a minor tegument protein in HHV-1 (14, 289). Secondly, ICP0 protein has been 
found in HHV-1 virions (286), but not in BoHV-1 virions (68). Thus, the specific activities of 
viral proteins to counteract ND10 components may not be absolutely conserved in 
alphaherpesviruses. 
When a herpesvirus infection enters the immediate early phase, ND10 foci are 
completely disrupted. This has been confirmed for HHV-1 (341), HHV-3 (282), HHV-5 (318), 
and HHV-4 (112). Immediate early proteins play critical roles at this stage and can be classified 
into three groups by their activities. The first group constitutes the proteins that target PML. 
ICP0 of HHV-1 degrades all identified PML isoforms through the proteasomal pathway (341). 
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Others disrupt SUMOylated PML isoforms, including ICP0 of BoHV-1 (246, 298), ICP0 of 
EHV-1 (246), IE1 of HHV-5 (317-319, 342), and BENA-1 and BZLF-1 of HHV-4 (245, 343). 
The second group targets SP100, for example, EBNA-5 of HHV-4 (333, 339). The third group 
includes immediate early proteins ICP27 of HHV-2, which alters splicing and thereby switches 
PML isoforms (247), and IE2 of HHV-5 (317) and ICP4 of HHV-1 (287), which indirectly 
impact ND10, but do not degrade PML. Overall, the three subfamilies of herpesviruses have 
unique gene products to abolish ND10 proteins that restrict viral infection. 
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CHAPTER 4 
 
4 HYPOTHESIS AND OBJECTIVES 
4.1 Rationale and hypothesis 
VP8 is indispensable for BoHV-1 to infect cattle, and deletion of VP8 causes drastic 
reduction of virus replication in tissue culture (64). The importance of VP8 is also reflected by 
the abundant incorporation into mature virus (14), implicating that VP8 is needed at the initial 
stages of BoHV-1 infection. In addition, VP8 is extensively phosphorylated in BoHV-1 infected 
cells (25). This raised the possibility that phosphorylation might be involved in regulating the 
function of VP8. We propose that CK2 and US3 may contribute differently to modulate the 
phosphorylation status and the biological characteristics of VP8, resulting in distinctive impacts 
on the function of VP8 during BoHV-1 infection. 
Containing NLSs and NESs, VP8 has the potential to localize inside and outside a cell 
nucleus. The cellular localization of VP8 is under strict regulation, possibly through altering 
phosphorylation status. Understanding of the phosphorylation and translocation of VP8 in 
BoHV-1 infected cells might uncover unknown regulatory mechanisms of BoHV-1 infection. 
Thereby, we hypothesize that the nuclear and cytoplasmic localization of VP8 is regulated by 
CK2- and/or US3-mediated phosphorylation and that VP8 has different roles at different 
subcellular location of BoHV-1 infected cells. 
 
4.2 Objectives 
o Characterize the phosphorylation pattern of VP8 mediated by CK2 and US3 and identify 
VP8 residues that are essential for the two kinases. 
o Study the function of phosphorylated VP8 mediated by CK2 and US3 in the life cycle of 
BoHV-1. 
o Examine the impact of CK2- and/or US3-dependent phosphorylation on the cellular 
localization of VP8, and verify the roles of VP8 at different subcellular locations within 
BoHV-1-infected cells. 
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5.1 Abstract 
The major tegument protein of bovine herpesvirus-1 (BoHV-1), VP8, is essential for viral 
replication in cattle. VP8 is phosphorylated in vitro by casein kinase 2 (CK2) and BoHV-1 
unique short protein 3 (US3). In this study VP8 was found to be phosphorylated in both 
transfected and infected cells, but was detected as a non-phosphorylated form in mature virions. 
This suggests that phosphorylation of VP8 is strictly controlled during different stages of the 
viral life cycle. The regulation and function of VP8 phosphorylation by US3 and CK2 were 
further analyzed. An in vitro kinase assay, site-directed mutagenesis, and liquid chromatography-
mass spectrometry were used to identify the active sites for US3 and CK2. The two kinases 
phosphorylate VP8 at different sites, resulting in distinct phosphopeptide patterns. S
16
 is firstly 
phosphorylated by US3 and it subsequently triggers phosphorylation at S
32
. CK2 has multiple 
active sites, among which T
107
 appears to be a preferred residue. Additionally, CK2 consensus 
motifs in the N-terminus of VP8 are essential for the phosphorylation. Based on these results, a 
non-phosphorylated VP8 mutant was constructed, and used for further studies. In transfected 
cells phosphorylation was not required for nuclear localization of VP8. Phosphorylated VP8 
appeared to recruit promyelocytic leukemia (PML) protein, and to remodel the distribution of 
PML in the nucleus; however, PML protein did not show an association with non-
phosphorylated VP8. This suggests that VP8 plays a role in resisting PML-related host antiviral 
defenses by redistributing PML protein, and that this function depends on the phosphorylation of 
VP8.  
 
5.2 Importance 
The progression of VP8 phosphorylation over time and its function in BoHV-1 
replication have not been characterized. This study demonstrates that activation of S
16
 initiates 
further phosphorylation at S
32 
by US3. Additionally, VP8 is phosphorylated by CK2 at several 
residues, with T
107
 having the highest level of phosphorylation. Evidence for a difference in 
phosphorylation status of VP8 in host cells and mature virus is presented for the first time. The 
phosphorylation was found to be a critical modification, which enables VP8 to attract and to 
redistribute PML protein in the nucleus. This might promote viral replication through 
interference with PML-mediated antiviral defense. This study provides new insights into the 
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regulation of VP8 phosphorylation and suggests a novel, phosphorylation-dependent function for 
VP8 in the life cycle of BoHV-1, which is important in view of the fact that VP8 is essential for 
viral replication in vivo. 
 
5.3 Introduction 
Bovine herpesvirus-1 (BoHV-1) is a herpesvirus belonging to the subfamily 
alphaherpesviridae and one of the most common pathogens in cattle. The major clinical 
symptoms caused by BoHV-1 are infectious bovine rhinotracheitis, conjunctivitis, vulvovaginitis 
and balanoposthitis. The virus particle is composed of a capsid containing the double-stranded 
DNA genome, which is surrounded by a tegument layer and an envelope containing viral 
glycoproteins. The tegument layer is a stable macromolecular structure formed by tegument 
proteins, which provide critical functions, such as regulation of transcription (344), kinase 
functions (142) and virus assembly (345). 
Viral protein 8 (VP8), a phosphoprotein encoded by the ul47 gene (289), is the most 
abundant tegument protein in BoHV-1. VP8 plays an indispensable role in BoHV-1 replication 
in host animals. A BoHV-1 mutant defective in expression of VP8 cannot establish a productive 
infection in cattle and poorly replicates in tissue culture (64). Herpesvirus tegument proteins can 
be post-translationally modified in several ways (14, 346), and based on the studies with human 
herpesvirus-1 (HHV-1) (345-347), it is conceivable that phosphorylation regulates the function 
of tegument proteins in BoHV-1. The HHV-1 tegument protein VP22 is phosphorylated in 
infected cells, which promotes expression and packaging of ICP0 (345); the VP22 itself is only 
packaged into mature virus particles after dephosphorylation (348). In BoHV-1, however, 
phosphorylation of VP22 is required prior to its incorporation into virions (71). The 
phosphorylation of HHV-1 VP13/14, a VP8 homologue, initiates dissociation of the structural 
components of the tegument (346). 
Phosphorylation, in addition to potentiating functions, may also play a role in altering the 
cellular localization of target proteins. For example, HHV-1 VP22 has the capacity to perform 
nuclear-cytoplasmic shuttling during infection, and the non-phosphorylated form localizes to the 
cytoplasm while the phosphorylated form localizes to the nucleus (348, 349). BoHV-1 VP8 has 
been found to shuttle between the nucleus and cytoplasm, and this is mediated by two nuclear 
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localization signals (NLS) and one nuclear exportation signal (NES) (154, 155). However, the 
impact of phosphorylation on the cellular localization of VP8 is not known. 
Promyelocytic leukemia (PML) protein is one of the components of PML nuclear bodies, 
also known as nuclear domain 10 (ND10). The PML protein contributes to the cellular defense 
by repressing viral lytic gene expression through modifying the viral genome (350), and thereby 
plays a key role in reducing herpesvirus replication (305). However, herpesviruses have 
developed a defence system against the PML-mediated anti-viral response. This is supported by 
evidence that when ICP0 is mutated, HHV-1 replication is reduced by failing to disrupt PML 
bodies (351). Further studies demonstrated that viral proteins disrupt PML bodies by interfering 
with the SUMOylation of PML protein (352). Some tegument proteins also remodel the PML 
protein. For example, human cytomegalovirus (HCMV) tegument protein UL35 forms nuclear 
bodies that subsequently recruit PML protein (236). 
According to previous in vitro studies, VP8 is phosphorylated by at least two kinases, the 
unique short protein 3 (US3), a BoHV-1 kinase, and casein kinase 2 (CK2), a cellular kinase (15). 
The VP8 open reading frame translates 741 amino acids, and 9.2% of them are serines and 
threonines, most of which are within consensus motifs for CK2 and US3. To better understand 
the role of VP8 phosphorylation during BoHV-1 infection, we investigated the phosphorylation 
events of VP8 at different viral life stages, and identified the active sites for US3 and CK2. We 
also showed that VP8 altered the distribution of PML protein in a phosphorylation-dependent 
manner. 
 
5.4 Materials and methods 
5.4.1 Cells and virus. 
Madin Darby bovine kidney (MDBK) cells, African green monkey fibroblast-like (COS-
7) cells, and primary fetal bovine testis (FBT) cells were cultured in Eagle’s Minimum Essential 
Medium (MEM, Gibco, Life Technologies, Burlington, ON, Canada) supplemented with 10% 
fetal bovine serum (FBS, Gibco). Production of BoHV-1 strain 108 and Cooper were carried out 
in MDBK cells as previously described (25). Briefly, virus infections were accomplished by 
rocking 150 cm
2
 85-90% confluent cell monolayers with BoHV-1 in 10 ml MEM at 37°C, which 
was replaced after 1 h with 10 ml MEM supplemented with 2% FBS, followed by further 
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incubation at 37°C. The virus titer was determined by plaque titration in 24-well plates overlayed 
with 8% low melting agarose (25). 
 
5.4.2 Antibodies and chemical reagents. 
Monoclonal anti-VP8 antibody, polyclonal anti-VP8 antibody (25) and polyclonal anti-
US3 antibody (118) have been generated previously. Polyclonal anti-CK2α (Abcam, Toronto, 
ON, Canada), monoclonal anti-FLAG (Sigma-Aldrich, St. Louis, MO, USA), polyclonal anti-
nucleolin (Abcam) and polyclonal anti-PML (Santa Cruz Biotech, Dallas, TX, USA) antibodies 
are all commercial products. IRDye® 680RD goat anti-rabbit IgG and IRDye® 800CW goat 
anti-mouse IgG were purchased from LI-COR Biosciences (Lincoln, NE, USA).  Alexa® 488-
conjugated goat anti-mouse IgG and Alexa® 633-conjugated goat anti-rabbit IgG were 
purchased from Life Technologies. The inhibitors SNS032 and AT7517 are products from Tocris 
Bioscience (Bristol, BS, USA) and Selleckchem (Houston, TX, USA). Phos-tag™ Acrylamide 
AAL-107 was purchased from Wako Pure Chemical Industries (Richmond, VA, USA). 
 
5.4.3 Plasmid construction. 
The ul47 gene (GenBank accession no. AY530215.1) was cloned into the pFLAG-CMV-
2 expression vector (Sigma-Aldrich), as previously described (15). The YFP ORF was cloned 
into pFLAG-CMV-2 to give pFLAG-YFP. VP8 mutations and deletions were constructed by 
PCR amplification using primers designed to create either mutations or deletions after ligation of 
PCR fragments back into the constructs. All primers were synthesized by Life Technologie 
(Table 5.1). PCR amplifications were carried out with Q5® Hot Start High-Fidelity DNA 
Polymerase (NEB, Ipswich, MA, USA) according to the manufacturer’s instructions. Briefly, a 
50 μl PCR reaction was carried out with 1 ng template, 1 μM primer pair, 200 μM dNTPs and 2 
U DNA polymerase. The PCR-amplification products were purified with a PCR purification kit 
(Qiagen, Germantown, MA, USA) and treated with DpnI (NEB). DH-5α competent cells were 
transformed with the DNA fragments ligated with T4 DNA ligase (NEB) and plated on selective 
LB agar plates. Plasmid purification was carried out following the Qiagen mini prep protocol. 
The selected positive mutants were confirmed by DNA sequencing performed by the NRC-Plant 
Biotechnology Institute (Saskatoon, SK, Canada). 
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Table 5.1 Primer list for plasmid construction using PCR (5’ to 3’end) 
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5.4.4 Immunoprecipitation 
BoHV-1-infected MDBK cells and plasmid-transfected COS-7 cells were pretreated with 
L-methionine-free or phosphate-free DMEM (Life Technologies) for 3 h prior to incubation with 
[
35
S]-methionine or [
32
P]-orthophosphate (Perkin Elmer, Woodbridge, ON, Canada).  Cell lysates 
were pre-cleared with Protein G Sepharose (GE Healthcare, Burnaby, BC, Canada), and then 
incubated with anti-VP8 monoclonal antibody and Protein G Sepharose overnight at 4°C. The 
Protein G Sepharose was washed three times with wash buffer (50 mM Tris/HCl, 150 mM NaCl, 
pH 7.4) and boiled for 5 min with SDS-PAGE sample buffer. The samples were separated by 
SDS-PAGE in 10% gels. The gels were subsequently dried and exposed to Imaging Screen-K for 
visualization on a Molecular Imager FX (Bio-Rad, Mississauga, ON, Canada). 
 
5.4.5 Protein purification and in vitro kinase assay 
COS-7 cells in 6-well plates were transfected with plasmid (1.5 μg/well) using 
Lipofectamine and PLUS reagent (Life Technologies). Cell lysates were collected at 48 h post 
transfection (hpt). Twenty μl of anti-FLAG M2 affinity gel (Sigma-Aldrich) or anti-HA agarose 
(Pierce, Rockford, IL, USA) was washed according to the manufacturer’s instructions and 
incubated with 200 μl of the appropriate lysate overnight at 4°C. The beads were washed five 
times with 1 ml wash buffer (50 mM Tris/HCl, 150 mM NaCl, pH 7.4). FLAG-VP8 (wild type, 
mutations and deletions) was eluted with 3×FLAG® tag peptide (Sigma-Aldrich) according to 
the manufacturer’s instructions. The proteins were stored at -80°C until use.  
Kinase assays were performed following a procedure described previously (15) with a 
few optimized steps. Briefly, a 25 μl reaction consisting of 0.3 mCi of [ɣ-32P] ATP (Perkin 
Elmer), 1 μg of substrate protein, 0.5 ng of CK2 (EMD Millipore, Burlington, ON, Canada) or 5 
μl of US3-HA on anti-HA agarose, and 6.25 μl of 4 × reaction buffer (80 mM HEPES pH 7.6, 
0.6 M NaCl, 0.4 mM EDTA, 20 mM DTT, 0.4% Triton X-100) was incubated at 30°C for 10 
min. The reaction was stopped by boiling with SDS-PAGE sample buffer for 5 min, and then the 
proteins were separated by SDS-PAGE in a 10% gel. The gels were dried and exposed to 
Imaging Screen for visualization on a Molecular Imager FX. 
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5.4.6 Co-immunoprecipitation and Western Blotting 
Whole-cell extracts were prepared by suspension of cell pellets in RIPA buffer (50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1% deoxycholate, 0.1% SDS) supplemented with 
protease inhibitor cocktail (Sigma-Aldrich) or phosphatase inhibitor cocktail (EMD Millipore). 
The cell lysates were clarified by centrifugation at 13,000 × g for 10 min at 4°C. Anti-FLAG M2 
affinity gel or anti-HA agarose was incubated with cell lysate (20 μl resin per 400 μl) overnight 
at 4°C and washed three times with 1 ml wash buffer (150 mM NaCl, 50 mM Tris/HCl, pH 7.4). 
Proteins were eluted by boiling in SDS-PAGE sample buffer for 5 min. In each experiment, 20 
μl of each sample was subjected to SDS-PAGE in a 10% gel, and then the proteins were 
transferred to nitrocellulose membranes and incubated with the appropriate antibodies. After 
washing, the membranes were further incubated with IRDye® 600RD/800CW-conjugated 
secondary antibodies at a 1:20,000 dilution and scanned with an Odyssey® CLx Infrared 
Imaging System (LI-COR Biosciences). 
 
5.4.7 Liquid chromatography–mass spectrometry (LC-MS) 
FLAG-VP8 protein on anti-FLAG M2 affinity gel was treated with λ-protein phosphatase 
(NEB) at 30°C for 30 min, and then eluted with 3 × FLAG peptide. The dephosphorylated VP8 
was rephosphorylated with the appropriate kinases in the in vitro kinase assays, and subsequently 
subjected to SDS-PAGE. The gels were stained with Coomassie Brilliant Blue (CBB) R250 in 
40% methanol, 10% acetic acid. Protein bands of interest were prepared and submitted to the 
University of Victoria Genome British Columbia Proteomics Centre (Victoria, BC, Canada) to 
analyze the tryptic peptide molecular masses by LC-MS. Briefly, gel slices were manually cut 
into 1 mm
3
 pieces and transferred to a Genomics Solutions ProGest perforated digestion tray. 
The gel pieces were de-stained (50/45/5 v/v methanol/water/acetic acid) prior to reduction (10 
mM dithiothreitol, Sigma-Aldrich) and alkylation (100 mM iodoacetamide, Sigma-Aldrich).  
Modified sequencing grade porcine trypsin solution (20 ng/µL, Promega, Madison, WI, USA) 
was added to the gel slices at an enzyme/protein ratio of 1:50. Protein was then digested for 5 h 
at 37°C prior to collection of tryptic digests and acid extraction of the gel slices (50/40/10 v/v 
acetonitrile/water/formic acid). The peptide mixtures were separated by on-line reverse phase 
chromatography using a Thermo Scientific EASY-nLC 1000 system. The chromatography 
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system was coupled on-line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA) equipped with a Nanospray Flex NG source (Thermo Fisher 
Scientific). 
 
5.4.8 Immunofluorescence staining 
COS-7 cells, cultured on Permanox 2-well chamber slides (Thermo Fisher Scientific), 
were transfected with 1.5 μg DNA per well using Lipofectamine and PLUS reagent for 3 h. After 
incubation for 20 h, the cells were washed three times with PBS, fixed with 4% 
paraformaldehyde for 20 min and then washed three times with PBS. Subsequently, the cells 
were permeabilized with 0.1% Triton X-100 in PBS for 20 min, washed with PBS, and then 
incubated with 1% normal goat serum (Gibco) in PBS for 2 h at room temperature. The cells 
were incubated with primary antibodies at the appropriate dilutions for 2 h at room temperature, 
followed by washing with PBS and incubation with Alexa Fluor®-conjugated antibodies (Life 
Technologies) at a 1:500 dilution for 1 h at room temperature. Finally, the cells were incubated 
with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride; 0.5 μg/ml; Life Technologies) at 
37°C for 10 min. Slides were washed with PBS followed by de-ionized water, and then air-dried 
and mounted using ProLong Gold Antifade Reagent (Life Technologies) prior to examination on 
a Zeiss LSM410 confocal microscope equipped with external argon ion 488/633/461 nm laser. 
 
5.4.9 Precision-cut lung slices (PCLS) preparation 
An ovine lung was perfused with 1.5% low gelling temperature agarose (Sigma) in RPMI 
(Roswell Park Memorial Institute) medium prior to sectioning. 220-250 μm sections were 
obtained by a Krumdieck Tissue Slicer (TSE Systems, MO, USA). They were washed in 3 
changes of RPMI medium with antimycotic, baytil, clotriazole and kanamycin, and then 
incubated overnight at 37°C. The sections were infected with 10
6
 PFU of BoHV-1 Cooper strain 
for 24 h. The slides were analyzed by immunofluorescence staining using polyclonal anti-VP8 
antibody and goat anti-rabbit Alexa Fluor®-conjugated antibodies (Life Technologies) as 
described above. 
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5.5 Results 
5.5.1 VP8 is phosphorylated in BoHV- infected cells but not in virions 
VP8 has been identified as a 97 kDa phosphorylated tegument protein expressed during 
the later stage of BoHV-1 infection. By using [
35
S]-methionine or [
32
P]-orthophosphate to label 
the proteins, we confirmed VP8 to be extensively phosphorylated in BoHV-1-infected MDBK 
cells. The phosphate was completely removed by λ-phosphatase treatment (Figure 5.1A). The in 
vitro dephosphorylation was confirmed by LC-MS, as no phosphopeptide was detected in the λ-
phosphatase-treated VP8 (data not shown).  
The VP8 phosphorylation status differed at different stages of infection. By using a Phos-
tag
TM 
acrylamide gel (353) followed by Western Blotting we showed that VP8 from transfected 
COS-7 cells and BoHV-1 infected MDBK cells migrates more slowly than VP8 from purified 
virus or a λ-phosphatase-treated protein sample (Figure 5.1B, upper panel). Phosphorylated 
protein associates with the phos-tag, which specifically binds phosphorylated ions, resulting in a 
greater molecular weight of phosphorylated protein than non-phosphorylated protein (353). As a 
result, the higher bands in the Phos-tag
TM 
acrylamide gel represent phosphorylated VP8, and the 
lower bands are non-phosphorylated VP8. All samples had the same molecular weight in 
standard polyacrylamide gels (Figure 5.1B, lower panel). This suggests that VP8 differs 
phosphoisoforms during the life cycle of BoHV-1. 
 
5.5.2 Identification of US3 phosphorylation sites in VP8 
Previously we identified US3 as one of the kinases responsible for phosphorylation of 
VP8 in in vitro kinase assays (15). Interaction between VP8 and US3 was confirmed by co-
immunoprecipitation. US3-HA was pulled down by FLAG-VP8 in co-transfected COS-7 cells, 
while FLAG-VP8 was pulled down by US3-HA (Figure 5.2A, left panel). There was no 
interaction between US3-HA and the anti-FLAG beads when FLAG-VP8 was not present or 
between the FLAG-VP8 and the anti-HA beads when US3-HA was not present. pFLAG-YFP 
was used as a control plasmid. As shown in Figure 5.2A (right panel), there was no interaction 
between FLAG-YFP and US3-HA in co-transfected COS-7 cells. 
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Figure 5.1 VP8 is phosphorylated in transfected and BoHV-1-infected cells, but is not 
phosphorylated in virions. 
(A) [
32
P]-orthophosphate- or [
35
S]-methionine-labeled MDBK cells were infected with BoHV-1 
at a MOI of 10. Cell lysates were collected at 18 hours post infection (hpi), and subsequently 
used for VP8 purification by incubation with anti-VP8 monoclonal antibody and Protein G 
Sepharose. A duplicate sample was treated with λ-phosphatase for 1 h at 30°C. The samples were 
separated by SDS-PAGE and exposed to Imaging Screen K. (B) BoHV-1 infected MDBK cell 
lysate, purified virus lysate, λ-phosphatase dephosphorylated FLAG-VP8, and pFLAG-VP8 
transfected COS-7 cell lysate were analyzed in both Phos-tag™ and standard polyacrylamide 
gels followed by Western Blotting. MDBK and COS-7 cell lysates were used as controls. A 
polyclonal anti-VP8 antibody and IRDye® 800CW goat anti-mouse IgG were used to detect 
VP8. The upper panel shows migration of VP8 in the gel supplied with Phos-tag acrylamide, and 
the lower panel represents VP8 in a standard gel. 
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The phosphorylation of VP8 by US3 was further studied in vivo in pFLAG-VP8 and 
pUS3-HA co-transfected, [
32
P]-orthophosphate-treated COS-7 cells. Phosphorylated VP8 was 
detected as early as 3 h post labelling, and the phosphorylation increased in a time-dependent 
manner (Figure 5.2B). At each time point, the intensity of phosphorylation was stronger in the 
presence of US3 than without US3 (Figure 5.2B). The in vitro kinase assay confirmed that VP8 
is a substrate of US3 (Figure 5.2C). VP8 was intensely phosphorylated by wild-type US3, but not 
by the four US3 mutants, in which the two critical active sites for US3, K
195 
or K
282
, located in 
the catalytic loop and in the ATP-binding pocket, were mutated (118). These results indicate that 
US3 phosphorylates VP8 in vitro and in vivo. 
To identify the active sites for US3 on VP8, single site mutations were introduced into 
the potential target residues on VP8. Through aligning the VP8 sequence with a published 
minimal consensus sequence for US3 (118) four potential motifs (RRS
16
GTYR, RRS
32
LL, 
RRS
173
LR and RRVT
632
VR) have been identified. The serine and threonine within these motifs 
were replaced with alanine using site-directed mutagenesis. The six VP8 mutants were 
subsequently analyzed in the in vitro kinase assay in the presence of the CK2 inhibitor TBCA, 
which showed that mutating S
16 
with an A (S16A) completely blocked phosphorylation by US3. 
Mutating S
16 
and T
18
 (S16A, T18A) had the same impact. However, other mutations had no 
obvious effect on US3 phosphorylation (Figure 5.2D). As observed previously, US3 performed 
auto-phosphorylation.  
To further identify the US3 phosphorylation sites on VP8, purified VP8 phosphorylated 
by US3 was digested with trypsin and scanned by LC-MS. This method allowed the 
unambiguous assignment of a phosphorylation site on a phosphopeptide, RS
32
LLDALR (Table 
5.2). This phosphopeptide was identified in 2 spectra, presenting the frequency of detection of 
this peptide, with a confidence greater than 95%, indicating a positive match. A non-
phosphorylated peptide with the same sequence was detected in the λ-phosphatase-treated 
sample. Six spectra were identified with the highest confidence of 92%, indicating that the 
phosphoryl group on the S
32
 was removed by the phosphatase. However, due to the frequent 
presence of arginine in the VP8 sequence, especially within the US3 phosphorylation motifs, the 
tryptic LC-MS only covered 61% of VP8, and the S
16
 could not be identified. 
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Figure 5.2 VP8 is a substrate for US3, and S
16
 is a critical residue for the phosphorylation. 
(A) FLAG-VP8 interacts with US3-HA. COS-7 cells were co-transfected with pFLAG-VP8 and 
pUS3-HA. Cell lysates were collected at 48 hpt. Protein was purified by incubating cell lysate 
with anti-FLAG beads or anti-HA beads for 12 h at 4°C, and was analyzed by Western Blotting. 
pFLAG-YFP was used as a negative control for co-immunoprecipitation. FLAG-VP8, US3-HA, 
and FLAG-YFP were detected by monoclonal anti-VP8 antibody, polyclonal anti-US3 antibody 
and monoclonal anti-FLAG antibody, followed by IRDye® 680RD goat anti-rabbit IgG 
or IRDye® 800CW goat anti-mouse IgG, respectively. (B) The presence of US3 increases 
phosphorylation of VP8 in vivo. COS-7 cells co-transfected with pFLAG-VP8 and pUS3-HA or 
transfected with pFLAG-VP8 were labeled with [
32
P]-orthophosphate at 12 hpt. After a 
subsequent 3, 6 and 9 h incubation, FLAG-VP8 was purified from the cell lysate by anti-FLAG 
beads. The samples were separated by SDS-PAGE, exposed to Imaging Screen K and stained 
with CBB. Band densities were scanned by the Quantity One program (CBB/
32
P labeled band). 
(C) VP8 is phosphorylated by wild-type US3 but not by US3 mutants. VP8 and US3 (wild type 
or mutants) were analyzed by in vitro kinase assays with [λ-32P] ATP. TBCA was used to inhibit 
cellular kinases carried over by anti-FLAG beads and anti-HA beads during the protein 
purification process. Proteins were separated by SDS-PAGE and exposed to Imaging Screen K. 
(D) VP8 mutants were generated by substituting the serine/threonines with alanines. The VP8 
mutants were analyzed by the in vitro kinase assay. Protein expression was confirmed by Western 
Blotting with monoclonal anti-VP8 antibody and IRDye® 800CW goat anti-mouse IgG. 
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5.5.3 VP8 is phosphorylated by CK2 
Previously, we identified CK2 as a kinase phosphorylating VP8 in vitro (15). To confirm 
this and explore a potential role of other kinases, different kinase inhibitors were used to block 
VP8 phosphorylation. The phosphorylation was reduced by TBCA in a concentration-dependent 
manner, but not by other two kinase inhibitors, SNS032 and AT7519 (Figure 5.3A). TBCA, 
SNS032 and AT7519 specifically inhibit the activity of CK2, cyclin-dependent kinases (CDK) 
and glycogen synthase kinase-3 beta (GSK-3β), respectively. To test the impact of TBCA on the 
phosphorylation of VP8 in vivo, pFLAG-VP8 transfected COS-7 cells were pre-treated with 
TBCA at 80 μM for 3 h and then labeled with [32P]-orthophosphate for 3, 6 or 9 h in the presence 
of TBCA. The phosphorylation was reduced in the TBCA-treated samples compared with the 
ones not treated with TBCA (Figure 5.3B). The phosphorylation of VP8 by CK2 was confirmed 
by subjecting CK2 and VP8 to the in vitro kinase assay (Figure 5.3C). The result showed that 
VP8 was phosphorylated in the presence of CK2 and that CK2 performed auto-phosphorylation. 
The interaction between CK2 and VP8 was confirmed by co-immunoprecipitation. The 
45 kDa CK2α subunit was pulled down by FLAG-VP8 in pFLAG-VP8 transfected COS-7 cell 
lysate, while the CK2α subunit was not pulled down by anti-FLAG beads in non-transfected or 
pFLAG-YFP-transfected cell lysate (Figure 5.3D). 
 
5.5.4 CK2 phosphorylates VP8 at multiple residues 
To identify the phosphorylation sites for CK2, a series of truncated VP8 proteins was 
constructed and analyzed in the in vitro kinase assay. The constructs without residues 1-120 
(VP8 121-741, VP8 219-741, VP8 343-741 and VP8 538-741) were not phosphorylated by CK2, 
while the truncations containing the residues 1-120 (VP8 1-120, VP8 1-125 and VP8 1-258) 
were phosphorylated by CK2 (Figure 5.4A). These results imply a critical role of residues 1-120 
in phosphorylation. There are five consensus sequences matching a published CK2 motif within 
residues 1-120, which were named CK2 motif 1 (CM1) to CK2 motif 5 (CM5) (Figure 5.4B). 
Single site mutations of the S/T within these motifs reduced the phosphorylation to different 
degrees, but did not achieve complete inhibition (Figure 5.4C). Shorter deletions in VP8 were 
constructed to determine the involvement of these CMs (Figure 5.4D). Deleting CM1 did not 
have an obvious impact; however, deleting CM2 to CM5 completely blocked phosphorylation, 
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and deleting CM2 and CM3, or CM3 and CM4 almost eliminated the phosphorylation. These 
results suggest that CM2, CM3, and CM4 play an important role in CK2-dependent 
phosphorylation. Indeed, deleting CM2, CM3 and CM4 (residues 65-92) eliminated the 
phosphorylation and mutating the S/T within these areas dramatically attenuated the 
phosphorylation, demonstrating that they all contribute to VP8 phosphorylation. Mutating the 
S/T in the CM2, CM3, CM4 and CM5 all at once achieved complete inhibition (Figure 5.4D). 
The above results reveal that CM2 to CM5 are critical for the phosphorylation of VP8 by CK2. 
To determine whether deleting CM2, CM3 and CM4 affects the interaction between the kinase 
and substrate, co-immunoprecipitation of VP8 D65-92 and CK2 was performed. This showed 
that CK2α was pulled down with VP8 D65-92 (Figure 5.4E), indicating that VP8 with CM2, 
CM3 and CM4 deleted still associated with CK2, but was not phosphorylated. Thus, removal of 
any of these motifs had no effect in preventing formation of the kinase-substrate complex.  
CK2-treated VP8 was analyzed by tryptic LC-MS, which detects any modification of a 
peptide by calculating the mass of the modification. A list of phosphopeptides was identified in 
the CK2 (3.3 ng/μl) treated sample; specifically, peptide GPNGHAGDT107DAPPER was 
detected in 20 spectra with a confidence higher than 95% (Table 5.3). These results indicated 
that five residues (T
107
, S
137
, S
221
, S
240
 and S
679
) were phosphoreceptors, among which the T
107
 
had the highest level of phosphorylation. However, in the sample treated with lower 
concentration of CK2 (≤ 3.3 pg/μl) two phosphopeptides containing residues T107 and S137 were 
detected, while the peptides containing S
221
, S
240
 and S
679
 were non-phosphorylated. 
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Table 5.2 Peptides identified by liquid chromatography–mass spectrometry (LC-MS) in the US3-
phosphorylated VP8. 
Identified Peptide Sample Treatment Phosphorylated Non-phosphorylated 
Prob. (%) Ident. Prob. (%) Ident. 
RS
32
LLDALR VP8 with US3 98 2 98 12 
VP8 without US3 0 0 92 6 
Note: “Prob.” indicates the highest probability score; and “Ident.” indicates the identification of 
events. 
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Figure 5.3 VP8 is a substrate for CK2, and interacts with CK2. 
(A) A series of VP8 truncations was constructed as listed. The solid bar indicates the VP8 
portion and the broken line indicates the deleted portion. The truncated proteins were purified 
from transfected COS-7 cell lysate and applied to in vitro kinase assays with CK2. Truncated 
proteins deleted in residues 1-120 and greater (VP8 121-741, VP8 219-741 and VP8 343-741) 
were not phosphorylated, while those truncated at the carboxyl end beyond residue 120 (VP8 1-
120, VP8 1-125 and VP8 1-258) were phosphorylated by CK2 (upper panel). Protein expression 
is demonstrated by Western Blotting using anti-FLAG antibody (lower panel). (B) Five CK2 
consensus motifs (CM1-CM5) found within residues 1-127 by aligning the VP8 sequence with a 
published CK2 motif, T/S-Xn-E/D (n≥0). The bar symbolizes the VP8 sequence with 741 amino 
acids, and residues 1-127 are highlighted. (C) Single-site mutations of VP8 by substituting S/T 
with an A within the identified CMs were analyzed by the in vitro kinase assays with CK2. 
Replacing S
66
, S
88
 or T
107 
greatly reduced VP8 phosphorylation. The protein loading is shown by 
Western Blotting. The band density was scanned and analyzed by Quantity One. (D) Analyses of 
the truncations and mutants of VP8 in in vitro kinase assays. VP8 deletions, D, and multiple site 
mutations, M, were constructed according to Figure 5.4B. Purified proteins were applied to the in 
vitro kinase assays with CK2. The protein loading is shown by Western Blotting using 
monoclonal anti-FLAG antibody and IRDye® 800CW goat anti-mouse IgG. (E) Interaction of 
FLAG-VP8 D65-92, which has CM2, 3, 4 deleted, with CK2 in the transfected COS-7 cells. 
pFLAG-VP8 and pFLAG-CMV2 were used as positive and negative controls, respectively. The 
transfected COS-7 cell lysate was collected at 48 hpt, and analyzed by co-immunoprecipitation. 
VP8 and CK2 were detected by polyclonal anti-VP8 antibody and polyclonal anti-CK2α 
antibody followed by IRDye® 680RD goat anti-rabbit IgG. 
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Figure 5.4 Identification of the critical residues on VP8 for phosphorylation by CK2. 
(A) A series of VP8 truncations was constructed as listed. The solid bar indicates the VP8 
portion and the broken line indicates the deleted portion. The truncated proteins were purified 
from transfected COS-7 cell lysate and applied to in vitro kinase assays with CK2. Truncated 
proteins deleted in residues 1-120 and greater (VP8 121-741, VP8 219-741 and VP8 343-741) 
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were not phosphorylated, while those truncated at the carboxyl end beyond residue 120 (VP8 1-
120, VP8 1-125 and VP8 1-258) were phosphorylated by CK2 (upper panel). Protein expression 
is demonstrated by Western Blotting using anti-FLAG antibody (lower panel). (B) Five CK2 
consensus motifs (CM1-CM5) found within residues 1-127 by aligning the VP8 sequence with a 
published CK2 motif, T/S-Xn-E/D (n≥0). The bar symbolizes the VP8 sequence with 741 amino 
acids, and residues 1-127 are highlighted. (C) Single-site mutations of VP8 by substituting S/T 
with an A within the identified CMs were analyzed by the in vitro kinase assays with CK2. 
Replacing S
66
, S
88
 or T
107
 greatly reduced VP8 phosphorylation. The protein loading is shown by 
Western Blotting. The band density was scanned and analyzed by Quantity One. (D) Analyses of 
the truncations and mutants of VP8 in in vitro kinase assays. VP8 deletions, D, and multiple site 
mutations, M, were constructed according to Figure 5.4B. Purified proteins were applied to the in 
vitro kinase assays with CK2. The protein loading is shown by Western Blotting using 
monoclonal anti-FLAG antibody and IRDye® 800CW goat anti-mouse IgG. (E) Interaction of 
FLAG-VP8 D65-92, which has CM2, 3, 4 deleted, with CK2 in the transfected COS-7 cells. 
pFLAG-VP8 and pFLAG-CMV2 were used as positive and negative controls, respectively. The 
transfected COS-7 cell lysate was collected at 48 hpt, and analyzed by co-immunoprecipitation. 
VP8 and CK2 were detected by polyclonal anti-VP8 antibody and polyclonal anti-CK2α 
antibody followed by IRDye® 680RD goat anti-rabbit IgG. 
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Table 5.3 Peptides identified by liquid chromatography–mass spectrometry (LC-MS) in the CK2-
phosphorylated VP8. 
 
Note: “Prob.” indicates the highest probability score; and “Ident.” indicates the identification of 
events 
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5.5.5 Phosphorylation of VP8 contributes to BoHV-1 replication 
Based on the above results, a mutant VP8 (Mut-VP8), with all the critical 
phosphorylation sites for US3 (S
16
) and CK2 (T
65
, S
66
, S
79
, S
80
, S
82
, S
88
 and T
107
) substituted by 
alanines, was constructed and analyzed in in vitro kinase assays. The Mut-VP8 was not 
phosphorylated by either CK2 or US3, while these two kinases phosphorylated the WT-VP8 as 
was expected (Figure 5.5A).  
To study the impact of VP8 phosphorylation on virus replication, we analyzed the 
replication of a ul47 gene-deleted mutant (BoHV-1-ΔUL47), constructed previously (64), in WT-
VP8 and Mut-VP8 expressing cells. FBT cells were infected with BoHV-1-ΔUL47, and then 
transfected with pFLAG-WT-VP8, pFLAG-Mut-VP8 or pFLAG-YFP. At 36 hpi, the virus titer 
from the pFLAG-WT-VP8 transfected cells was higher than that from the pFLAG-Mut-VP8 
transfected cells, while the pFLAG-YFP transfected cells showed the lowest titer (Figure 5.5B). 
This indicated that BoHV-1-ΔUL47 replicated better in the WT-VP8 expressing cells than in the 
Mut-VP8 expressing cells. 
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Figure 5.5 WT-VP8 benefits virus replication more than Mut-VP8, which is not phosphorylated 
by CK2 and US3. 
(A) Confirmation of non-phosphorylated Mut-VP8 in the in vitro kinase assay. A Mut-VP8, 
which had all the critical phosphorylation sites for US3 (S
16
) and for CK2 (T
65
, S
66
, S
79
, S
80
, S
82
, 
S
88
 and T
107
) substituted by alanines, was constructed and analyzed in kinase assays with CK2 
and US3. (B) BHV1-ΔUL47 replication in WT-VP8 expressing cells and in Mut-VP8 expressing 
cells. FBT cells were infected with BHV1-ΔUL47 at a MOI of 0.3. At 4 hpi, cells were 
transfected with pFLAG-WT-VP8 or pFLAG-Mut-VP8. A control sample was transfected with 
pFLAG-YFP. Viruses were collected at 36 hpi, and titrated on MDBK cells. 
 66 
 
5.5.6 Phosphorylation alters the intracellular localization of VP8 and PML protein 
To determine whether phosphorylation of VP8 influences its subcellular localization, as 
has been found for other proteins, the localization of WT-VP8 and Mut-VP8 was examined by 
immunofluorescence in transfected COS-7 cells. WT-VP8 displayed nuclear localization (Figure 
5.6A), which was consistent with previous results (155). Furthermore, the transfected cells 
developed circular bodies in the nucleus with WT-VP8 being strongly labeled on these circular 
bodies. The size of these nuclear bodies extended in a time-dependent manner. At 12 h they were 
visible as small dots in the nucleus and at later time points they became larger (Figure 5.6A, 
upper panel). In contrast, the Mut-VP8 was evenly distributed throughout the nucleus, and was 
not accumulated to the nuclear bodies (Figure 5.6A, lower panel). Double-staining using anti-
nucleolin antibody and anti-VP8 antibody confirmed that these bodies were different from the 
nucleolus (data not shown). A similar pattern was observed in BoHV-1 infected lung tissue 
(Figure 5.6B). Some cells in the infected tissue developed circular areas not stained with either 
DAPI or anti-VP8 antibody. A certain amount of VP8 accumulated to the edge of the circular 
areas. 
To gain insight into the identity of these nuclear bodies, the transfected cells were stained 
with both anti-PML and anti-VP8 antibodies. While the PML bodies were evenly distributed as 
round dots or speckles in the nucleus of non-transfected cells, WT-VP8 altered the distribution of 
PML protein by recruiting it to the edge of the circles (Figure 5.7). As is indicated by white 
arrow heads, PML aggregated to the nuclear bodies, where WT-VP8 was concentrated. 
Eventually, a large cluster of PML protein was formed around the VP8 bodies. The formation of 
nuclear bodies and accumulation of VP8 might happen independently of PML; instead, the 
nuclear bodies might recruit PML protein through interactions between VP8 and PML protein or 
other PML body components. This is supported by the observation that not all VP8 nuclear 
bodies were associated with PML protein; especially at 6 hpt several PML bodies were distinct 
from the newly developed VP8 nuclear bodies. This observation suggests that the PML 
accumulation happened after the VP8 nuclear body development. Figure 5.8 demonstrates the 
PML protein in the Mut-VP8 transfected COS-7 cells. Mut-VP8 did not accumulate to the 
nuclear bodies, and PML had the same distribution in the transfected cells as in the control cells. 
No co-localization was detected between Mut-VP8 and PML surrounding the nuclear bodies. 
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Figure 5.6 The cellular localization of WT-VP8 and Mut-VP8.  
(A) Localization and different patterns of WT-VP8 and Mut-VP8 in the nucleus. WT-VP8 and 
Mut-VP8 were expressed in COS-7 cells. VP8 was detected with polyclonal anti-VP8 antibody 
and Alexa-488 conjugated goat anti-rabbit IgG. DNA was labeled with DAPI. The cells were 
observed with a Zeiss LSM410 confocal microscope. (B) Localization of VP8 in BoHV-1 
infected lung tissue slices. 220-250 μm lung tissue sections infected with 106 PFU of BoHV-1 
for 24 h. VP8 was detected with polyclonal anti-VP8 antibody and Alexa-488 conjugated goat 
anti-rabbit IgG. DNA was labeled with DAPI. The slides were observed with a Zeiss LSM410 
confocal microscope. 
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Figure 5.7 Promyelocytic leukemia (PML) protein accumulation to nuclear bodies and co-
localization with WT-VP8.  
(A) pFLAG-VP8 was transfected into COS-7 cells. FLAG-WT-VP8 was detected with 
monoclonal anti-FLAG antibody and Alexa-488-conjugated goat anti-mouse IgG, and PML with 
polyclonal anti-PML antibody and Alexa-633 conjugated goat anti-rabbit IgG. DNA was labeled 
with DAPI. The cells were observed with a Zeiss LSM410 confocal microscope. The white 
arrow head indicates that at 6 hpt PML protein is recruited to the edge of nuclear bodies, where 
WT-VP8 accumulates, and that at 24 hpt nuclear PML accumulates to the bodies resulting in 
protein clusters.  
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Figure 5.8 The distribution of PML protein is not affected by Mut-VP8.  
pFLAG-Mut-VP8 was transfected into COS-7 cells. FLAG-Mut-VP8 was detected with 
monoclonal anti-FLAG antibody and Alexa-488 conjugated goat anti-mouse IgG, and PML with 
polyclonal anti-PML antibody and Alexa-633 conjugated goat anti-rabbit IgG. DNA was labeled 
with DAPI. The cells were observed a Zeiss LSM410 confocal microscope. 
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5.6 Discussion 
VP8 is a known phosphoprotein and substrate for US3 and CK2 in an in vitro kinase 
assay (15). Based on this information, the objective of this study was to identify the specific 
residues of VP8 which are modified by the US3 and CK2 kinases, as well as a possible function 
of VP8 phosphorylation. This is the first evidence for a difference in phosphorylation status of 
VP8 in host cells and mature virus, and for phosphorylation being a critical modification for VP8 
to recruit PML protein. We confirmed phosphorylation of VP8 by US3 and CK2 both in vitro 
and in vivo, and specified the active phosphorylation sites though site-directed mutagenesis and 
LC-MS. Phosphorylated, but not non-phosphorylated, VP8 tended to accumulate PML protein, 
which plays a role as an anti-viral protein (352). 
Although VP8 contains four consensus sequences for US3, only mutation of S
16
 
prevented VP8 phosphorylation by US3 (Figure 5.2D), demonstrating that the S
16
 is an essential 
residue for US3. It is not the only phosphoreceptor on VP8 because a phosphopeptide containing 
S
32 
was identified by LC-MS (Table 5.2). However, this site plays no decisive role in the 
phosphorylation at other sites, since mutating S
32
 did not result in reduced protein 
phosphorylation (Figure 5.2D). Both S
16
 and S
32
 are potential modified residues by US3 and they 
are within the US3-dependent consensus motif, Rn-X-S/T-Y-Y (n ≥ 2; X is any residue; Y 
cannot not be aspartate, glutamate or proline) (15). The phosphorylation of S
16
 might complete 
the kinase recognition motif for the neighboring residue S
32
 to be phosphorylated, resulting in a 
sequential phosphorylation cascade. We propose that US3 phosphorylates VP8 on S
16
 and that 
this triggers additional phosphorylation on S
32
. This contention is based on a previously 
described model, called primary phosphorylation, which proposes that the introduction of a 
phosphoryl group to a favorable site causes changes in the overall protein confirmation so that an 
otherwise unfavorable site is active for subsequent phosphorylation (354). Many other sequential 
phosphorylation examples have been described. For instance, a study of hepatitis C virus showed 
that there is a sequential and ordered cascade of phosphorylation events on the NS5A protein 
(355), where phosphorylation at S
238
 would trigger phosphorylation at S
235
. Similarly, the 
regulatory phosphorylation of eukaryotic Elongation Factor 2 (eEF2) at S
595
 by CDK2 directly 
stimulates phosphorylation on T
56
 by eEF2 kinase (356). Reversely, phosphorylation of a 
primary site may down-regulate the further phosphorylation on other sites. For example, 
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extracellular signal-regulated protein kinase (ERK) phosphorylates mitogen-activated protein 
kinase kinase 1 (MEK1) on T
292
, and this in turn blocks additional S
298
 phosphorylation (357). 
Phosphorylation of VP8 by CK2 was confirmed by applying pure, active CK2 protein 
and VP8 to the in vitro kinase assay. TBCA, a relatively new CK2 inhibitor, with better 
specificity and less cellular toxicity than DMAT (2-Dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole) (213), inhibited the phosphorylation of VP8 in tissue culture. This is in 
agreement with our previous observation that DMAT (15) blocks phosphorylation of VP8. CK2 
is constitutively expressed and active in COS-7 cells so TBCA was used to inhibit the CK2 
activity. The reduction of VP8 phosphorylation in the TBCA-treated cells demonstrated that VP8 
is phosphorylated by CK2 in vivo. Although no evidence has been reported that HHV-1 VP13/14 
is phosphorylated by CK2, the phosphorylation on this tegument protein might be mediated by 
cellular kinases, including CK2. This is supported by the observation that VP13/14 is 
phosphorylated in cells infected with a HHV-1 US3-dead mutant; furthermore, two potential 
consensus motifs for CK2 on VP13/14 have been reported (15). It has also been found that in 
certain circumstances hUS3 shares a similar amino acid content with PKA (358) and Akt (359), 
suggesting that these kinases may play a role in VP13/14 phosphorylation. 
Generally, CK2 modifies multiple residues with in one substrate, and overall about 75% 
of the phosphorylated sequences match the CK2 motif, S/T-X-X-D/E (360). Within the VP8 
sequence ten threonines and nineteen serines match the motif. To identify the active sites for 
VP8, we started by analyzing shorter forms of VP8. VP8 fragments without the C-terminal 
residues 1-120 were found not to be phosphorylated by CK2 (Figure 5.4A), which has two 
possible reasons. The residues 1-120 maintain the protein structure for phosphorylation; 
alternatively, all the active sites are within this area. The fragments that encompass the residues 
1-120 were phosphorylated, but the 1-258 fragment was more strongly labeled than the shorter 
ones, indicating the existence of active sites outside residues 1-120 (Figure 5.4A).  There are five 
consensus sequences (Figure 5.4B) for CK2 within this area. Although the LC-MS did not detect 
any phosphopeptide that contains CM2, CM3, or CM4, these motifs appeared to be critical to 
maintain the catalytic domains without disrupting the formation of the kinase-substrate complex 
(Figure 5.4D). 
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Two phosphopeptides containing the CM5 were detected by the LC-MS (Table 5.3) 
suggesting T
107
 is a phosphoreceptor. However, it is not the only active site for CK2, since 
mutating this residue only reduced the phosphorylation to a certain level (Figure 5.3C). Four 
additional phosphorylated sites (S
137
, S
221
, S
240
 and S
679
) were detected by tryptic LC-MS (Table. 
3.3). Among these sites, the T
107
 had the most abundant phosphorylation event, 3-10 times higher 
than that of the other sites. This demonstrates that the T
107 
is the preferred phosphorylation site 
for CK2. Moreover, the S
221
, S
240
 and S
679 
tended to be phosphorylated only in high 
concentration (3.3 ng/μl) of CK2, while a low concentration (≤  3.3 pg/μl) of kinase only 
phosphorylated T
107
 and S
137
. 
The mutagenesis results allowed us to generate a mutant VP8 (Mut-VP8) that is not 
phosphorylated by US3 or CK2 (Figure 5.5A). This enabled an investigation of the function of 
VP8 phosphorylation. Although phosphorylation by CK2 altered the subcellular localization of 
SV40 T-antigen (361), phosphorylation of VP8 had no obvious impact on its nuclear import. 
Both phosphorylated and non-phosphorylated VP8 were localized in the nucleus. In addition, the 
CM5, which contains a CK2 phosphorylation site, did not alter the nuclear import function of the 
VP8-NLS (R
11
RPRR
15
), as fusion proteins NLS-GFP and NLS-CM5-GFP had similar 
distribution patterns in the transfected COS-7 cells (data not shown). These results suggest that 
the phosphorylation does not change the nuclear localization of VP8. In contrast, 
phosphorylation by US3 on HHV-1 VP13/14 is needed for the NLS-mediated nuclear 
localization of VP13/14. VP13/14 contains a phospho-site for US3 at S
77
, which is close to the 
NLS. Phosphorylation at S
77
 by HHV-1 US3 is essential for the nuclear localization of VP13/14, 
as mutating S
77
 to an A results in accumulation of this protein to the nuclear rim (142). 
The expression of VP8 generated DAPI-stain negative nuclear bodies in COS-7 cells and 
WT-VP8 accumulated around these bodies (Figure 5.6A). A similar pattern was found in certain 
cells of infected lung tissue (Figure 5.6B), indicating a potential role of these non-stained areas 
in the pathology and mechanism of virus-host interaction during BoHV-1 infection. 
Concomitantly, PML protein was gradually attracted to the edge of the nuclear bodies, resulting 
in co-localization with WT-VP8 (Figure 5.7). Others observed that PML bodies suppress virus 
replication in HHV-1 infection. To survive in spite of the suppression, HHV-1 uses a regulatory 
protein ICP0 to degrade the PML bodies. This is supported by the finding that PML bodies 
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perform stronger suppression against HHV-1 infection in absence of the ICP0 protein (305). 
With respect to BoHV-1 infection, it is possible that VP8 plays a role in counteracting the PML-
mediated cellular antiviral process. This is in agreement with our previous observation that 
BoHV-1 replication is dramatically reduced in the absence of VP8 (64). 
The co-localization of WT-VP8 and PML protein in transfected cells suggests that VP8 
might exert its effects on PML by remodeling PML bodies. This is in contrast with the results of 
another study on HCMV demonstrating that the formation of nuclear bodies and the recruitment 
of PML is enhanced by UL82 (237) through increasing the efficiency of UL35 nuclear body 
formation (236). However, other cellular proteins may be involved in the formation of VP8 
nuclear bodies and remodeling of PML. We investigated the impact of phosphorylation of VP8 
on its ability to recruit PML. A non-phosphorylated VP8 (Mut-VP8) did not attract PML protein, 
although circular areas unstained by either DAPI or anti-VP8 antibody were observed (Figure 
5.8). As a result, the phosphorylation is a critical modification for VP8 to accumulate to nuclear 
bodies, as well as in subsequent remodeling of PML. It is possible that phosphorylation of VP8 
may perform a potential role in protecting BoHV-1 from the PML-mediated antiviral defense. 
This contention is also supported by evidence that BoHV-1-ΔUL47 replicated better in WT-VP8 
transfected cells than in Mut-VP8 transfected cells. While deletion of VP8 reduces the virus titer 
by over 100-fold (64), this was partially amended by transiently expressing WT-VP8 and Mut-
VP8, confirming the importance of VP8 in BoHV-1 replication. The fact that WT-VP8 increased 
the titer more than Mut-VP8 suggested that the phosphorylation of VP8 contributes to the virus 
replication. 
The changing phosphorylation status of VP8 during the different stages of viral infection 
suggests a regulatory role for this modification. Phosphorylation of the incoming VP8 might be 
an immediate event in BoHV-1 infection. It has been found that phosphorylation of VP13/14, a 
homologue of VP8 in HHV-1, occurs between virion penetration of the cell and the onset of viral 
protein synthesis (346). Our results showed that VP8 was extensively phosphorylated in BoHV-1 
infected cells. CK2 likely phosphorylates VP8 after viral entry and during VP8 transport through 
the cell, as this kinase is ubiquitous throughout the cell, including the plasma membrane, 
cytoplasm and nucleus (199). The virion-associated VP8 might capture the cellular kinase, and 
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the subsequent phosphorylation may help VP8 release, as was found for HHV-1 in that VP13/14 
phosphorylation improves its dissociation from virions (346). 
After release, the virion-associated VP8 has been shown to move to the nucleus as early 
as 2 h after infection (25), and this transport is mediated by the NLS independent of 
phosphorylation. The viral kinase US3 is synthesized later and is localized in the nucleus, where 
it can associate with VP8 (15). This indicates that the phosphorylation by US3 may affect a 
nuclear function of VP8, but not the tegument dissociation stage. This hypothesis is supported by 
a previous finding in HHV-1 that deletion of the viral kinase UL13 had no effect on VP13/14 
release in an in vitro assay (346). 
 In summary, this study demonstrates that phosphorylation is a critical modification for 
VP8 accumulation to nuclear bodies and recruitment of PML, which is important for the cellular 
antiviral defense. This function of VP8 appears to depend on its phosphorylation status. At least 
two kinases target VP8. The phosphorylation by US3 is likely a cascade process, in which the 
activation of S
16
 triggers further phosphorylation at S
32
. CK2 phosphorylates VP8 on at least five 
active sites, among which T
107
 is the preferred residue. 
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CHAPTER 6 
 
6 LINKER BETWEEN CHAPTER 5 AND CHAPTER 7 
In chapter 5, we determined the amino acids in VP8 that are responsible for 
phosphorylation through CK2 and US3. By knowing the essential residues for VP8 
phosphorylation, we generated a mutant VP8 with the essential residues substituted with alanines. 
This mutant VP8 was validated in an in vitro kinase assay and in transiently transfected cells. It 
was not phosphorylated by CK2 and US3. The non-phosphorylated VP8 had a reduced capacity 
to rescue the production of BoHV-1-ΔUL47 in tissue culture in comparison to wild-type VP8, 
suggesting a beneficial role of VP8 phosphorylation in BoHV-1 replication. Additionally, VP8 
may benefit BoHV-1 replication by redistributing PML protein. 
In chapter 7, we tested the impact of VP8 phosphorylation in virus replication in the 
context of BoHV-1 infection. A recombinant BoHV-1 encompassing non-phosphorylated VP8 
was generated based on the findings in chapter 5. A comparison of the life cycles of the mutant 
and wild-type viruses revealed functions of VP8 phosphorylation during BoHV-1 infection. 
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CHAPTER 7 
 
7 PHOSPHORYLATION OF BOVINE HERPESVIRUS-1 VP8 PLAYS A ROLE IN 
VIRAL DNA ENCAPSIDATION AND IS ESSENTIAL FOR ITS CYTOPLASMIC 
LOCALIZATION AND OPTIMAL VIRION INCORPORATION 
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7.1 Abstract 
VP8 is a major tegument protein of bovine herpesvirus-1 (BoHV-1) and is essential for 
viral replication in cattle. This protein obtains phosphorylation after transcription through 
cellular casein kinase 2 (CK2) and a viral kinase US3. In this study, a virus containing a mutated 
VP8, which is not phosphorylated by CK2 and US3 (BoHV-1-YmVP8), was constructed by 
homologous recombination in mammalian cells. When BoHV-1-YmVP8-infected cells were 
observed by electron transmission microscopy, blocking phosphorylation of VP8 was found to 
impair viral DNA encapsidation, resulting in release of incomplete viral particles to the 
extracellular environment. Consequently, less infectious virus was produced by the mutant virus, 
when compared with wild-type (WT) virus. A comparison of mutant and WT-VP8 by confocal 
microscopy revealed that mutant VP8 is nuclear throughout infection, while WT-VP8 is nuclear 
early during infection and associated with the Golgi at later stages. This together with the 
observation that mutant VP8 is present in virions, albeit in lower amounts, suggests that the 
incorporation of VP8 may occur at two stages. The first takes place without the need for 
phosphorylation and before or during nuclear egress of capsids, whereas the second occurs in the 
Golgi apparatus and requires phosphorylation of VP8. The results indicate that phosphorylated 
VP8 plays a role in viral DNA encapsidation and in the secondary virion incorporation of VP8. 
To perform these functions, the cellular localization of VP8 is regulated through phosphorylation. 
 
7.2 Importance 
In this study phosphorylation of VP8 was shown to have a function in BoHV-1 
replication. A virus containing a mutated VP8 that is not phosphorylated by CK2 and US3 
(BoHV-1-YmVP8) produced lower amounts of infectious virions in comparison with wild-type 
(WT) virus. The maturation and egress of WT and mutant BoHV-1 was studied showing a 
process similar to that reported for other alphaherpesviruses. Interestingly, lack of 
phosphorylation of VP8 by CK2 and US3 resulted in reduced incorporation of viral DNA into 
capsids during mutant BoHV-1 infection, as well as lower numbers of extracellular virions. 
Furthermore, mutant VP8 remained nuclear throughout infection in contrast to WT VP8, which 
is nuclear at early stages and Golgi-associated late during infection. This correlates to lower 
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amounts of mutant VP8 in virions and suggests for the first time that VP8 may be assembled into 
the virions at two stages, the latter being dependent on phosphorylation. 
 
7.3 Introduction 
Bovine herpesvirus-1 (BoHV-1), a member of the alphaherpesviridae, causes infectious 
bovine rhinotracheitis (IBR) in cattle, as well as conjunctivitis, vulvovaginitis and 
balanoposthitis. The herpesvirus particle is composed of a capsid containing the double-stranded 
DNA genome, which is surrounded by a tegument layer and an envelope containing viral 
glycoproteins (32). During the herpesvirus life cycle, genome synthesis, capsid assembly, DNA 
incorporation (362) and primary tegumentation (363) occur in the nucleus of infected cells. 
Subsequently, nucleocapsids leave the nucleus by budding through the nuclear membrane via an 
envelopment-de-envelopment pathway (364). Capsids acquire tegument proteins, envelope 
proteins and glycoproteins in the cytoplasm, and finally egress via the cellular secretory pathway 
(147). During the maturation process, viral components are sequentially incorporated into viral 
particles in a strictly controlled manner. 
Tegument proteins have various functions, including regulation of transcription (344), 
kinase functions (142) and virus assembly (345). The BoHV-1 ul47 gene product (289), VP8, is 
a 97 kDa tegument protein, which is indispensable for viral replication in host animals (64). 
While VP8 is the most abundant viral protein (25), the mechanism of incorporation of VP8 into 
virions is unknown. The cellular localization of VP8 changes at different stages of infection, 
indicating various roles of this protein during the virus life cycle. Navigated by a N-terminal 
nuclear localization signal (NLS) (154, 155), virion-derived VP8 is targeted to the nucleus 
immediately upon BoHV-1 infection (25, 154). At late stages of infection, VP8 accumulates in 
the cytoplasm (25), but no cytoplasmic function has been identified for VP8. In transfected cells 
VP8 is mainly restricted to the nucleus, and the nuclear VP8 appears to remodel the 
promyelocytic leukaemia nuclear body (PML-NB) (290), which is a suppressor of human 
herpesvirus 1 (HHV-1) replication (305). VP8 also has the capacity to interact with intron-less 
mRNAs of BoHV-1 (159).  
In BoHV-1-infected cells VP8 is highly expressed and extensively phosphorylated. 
Phosphorylation is an important post-translational modification for VP8 to maintain PML-
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remodeling capacity; however, it does not directly affect the nuclear localization of VP8 (290). 
This is in contrast to other proteins where phosphorylation changes their cellular localization. For 
example, VP22 of HHV-1 has the capacity to perform nuclear-cytoplasmic shuttling during 
infection, and the non-phosphorylated form localizes to the cytoplasm while the phosphorylated 
form localizes to the nucleus (348, 349). VP8 is mainly phosphorylated by a viral protein, US3, 
and a cellular protein, casein kinase 2 (CK2), through distinct target residues (15, 290). By site-
specific mutagenesis of BoHV-1 VP8, serine 16 was identified to be essential for 
phosphorylation by US3, and seven residues (threonine 65, serine 66, serine 79, serine 80, serine 
82, serine 88 and threonine 107) were critical for phosphorylation by CK2 (290).  
Phosphorylation on BoHV-1 proteins has been reported to correlate with viral replication 
and protein incorporation. Blocking tyrosine phosphorylation of glycoprotein E (gE), an 
envelope protein, reduces viral replication (365). Removing tyrosine phosphorylation of VP22 
decreases the amount of VP22 incorporated into virions (71). However, how phosphorylation 
benefits viral replication and determines the protein incorporation is not clear. The presence of 
VP8 in the cytoplasm and the nucleus indicates that this protein has different functions 
corresponding to the cellular localization. These functions might be related to the extensive 
phosphorylation of VP8, mediated by serine/threonine kinases CK2 and US3. This is also 
supported by a previous result that US3 associates with nuclear VP8 but not with cytoplasmic 
VP8 (15). 
To study the role of VP8 phosphorylation in BoHV-1 replication, we constructed a 
recombinant BoHV-1, containing a mutant VP8 that is not phosphorylated by CK2 or US3. This 
mutant virus showed reduced DNA encapsidation and virus production. Furthermore, VP8 was 
found to be nuclear at early stages and Golgi-associated late during infection, while mutant VP8 
remained nuclear throughout infection, which indicates that the localization of VP8 to the Golgi 
requires phosphorylation. Furthermore, as mutant VP8 was incorporated into virions, but in 
lower amounts, this suggests that VP8 may be incorporated into virions at two stages during 
BoHV-1 infection. 
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7.4 Materials and Methods 
7.4.1 Cells and virus 
Madin Darby bovine kidney (MDBK) cells and primary fetal bovine testis (FBT) cells 
were cultured in Eagle’s Minimum Essential Medium (MEM, Gibco, Life Technologies, 
Burlington, ON, Canada) supplemented with 10% fetal bovine serum (FBS, Gibco). Production 
of all viral stocks was carried out in MDBK cells as previously described (25). Briefly, virus 
infections were accomplished by rocking 150 cm
2
 85-90% confluent cell monolayers with 
BoHV-1 in 10 ml MEM at 37°C, which was replaced after 1 h with 10 ml MEM supplemented 
with 2% FBS, followed by further incubation at 37°C. The virus titer was determined by plaque 
titration in 24-well plates overlayed with 8% low-melting agarose in MEM (25, 64). 
 
7.4.2 Antibodies 
Monoclonal antibodies specific for gB, gC, and gD (78), and polyclonal antibodies 
specific for VP8 (25), VP22 (118), VP5 (64) and US3 (118) were raised as described previously. 
Monoclonal anti-Golgi 58K protein antibody was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). IRDye® 680RD goat anti-rabbit IgG and IRDye® 800CW goat anti-mouse IgG were 
purchased from Li-Cor Biosciences (Lincoln, NE, USA). Alexa®488-conjugated goat anti-
mouse IgG and Alexa®633-conjugated goat anti-rabbit IgG were purchased from Life 
Technologies. 
 
7.4.3 Construction of recombinant viruses 
Recombinant viruses were constructed by homologous recombination between WT strain 
108 (9) viral DNA and recombinant PCR products within FBT cells. UL47 was mutated (mUL47) 
so as to remove all essential phosphorylation sites within VP8 by replacing serine 16, threonine 
65, serine 66, serine 79, serine 80, serine 82, serine 88 and threonine 107 with alanine (13). 
Briefly, plasmids with YFP (yellow fluorescent protein) fused in frame with both UL47 and 
mUL47 together with flanking regions of homology, were constructed and used to generate DNA 
fragments (Figure 7.1A). A DNA fragment encoding YFP was PCR-amplified from pEYFP-N1 
using primers 5’-CGAGCTCAAGCTTCGAATTCTGCAGTC-3’, and 5’-GAAAGATCTCGCTT 
GTACAGCTCG TCCATGCC-3’, cut with HindIII and BglII, and cloned into pFLAG-VP8 and 
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pFLAG-Mut-VP8 (290) similarly cut, giving pYFP-UL47 and pYFP-mUL47. The recognition 
sequences for restriction enzymes designed in primers are underlined. The 5’ homology region 
was amplified from BoHV-1 DNA by PCR using primers 5’-GAAGGTACCGCTGGCCTTTGC 
GCATATGTACG-3’, and 5’-GAAACCGGTGCG TCTA AGGGCGCCTAGAA-3’, and inserted 
into pYFP-UL47 and pYFP-mUL47 after digestion with KpnI and AgeI, resulting in pUL48-YFP-
UL47 and pUL48-YFP-mUL47. For transfection, DNA fragments were generated by PCR using 
the primers 5’-CGTGTTCGTTTCGCTGTACT ATGC-3’ and 5’-CAGTAAATCAGGGAGCCC 
ATTGAG-3’; these fragments contained about 950 bp of homologous DNA for recombination 
on either side of the YFP and mutagenized UL47. 
To introduce the YFP-mUL47 into the viral genome (Figure 7.1B), 2 μg of PCR fragment 
was co-transfected with 1 μg of wild-type BoHV-1(WT BoHV-1) genomic DNA into FBT cells 
with Lipofectamine and PLUS reagent (Life Technologies). YFP-positive plaques were plaque 
purified several times to eliminate contamination from wild-type virus. The resulting virus 
(BoHV-1-YmVP8) encompasses an YFP-tagged mutant VP8. The same procedure was 
performed to introduce the YFP-UL47 into the viral genome, resulted a virus (BoHV-1-YVP8) 
expressing YFP-tagged WT-VP8. 
To produce a revertant virus with wild-type (WT) UL47, homologous DNA fragments 
containing 921 bp of DNA upstream of the ul47 gene and 1,308 bp from the starting codon of the 
ul47 ORF were PCR-amplified from the WT BoHV-1 genome by using the primers 5’-
CGTGTTCGTTTCGCTGTACTATGC-3’ and 5’-CAGTAAATCAGGGAGCCCATTGAG-3’. 
Two μg of this DNA was co-transfected with 1 μg of genomic DNA of BoHV-1-YmVP8 into 
FBT cells as described above. YFP-negative plaques were plaque purified several times to 
eliminate contamination from mutant virus. In the revertant virus (BoHV-1-RVP8) genome, the 
WT ul47 ORF was repaired. 
The PCR, restriction digestions, and ligations were carried out with Q5® Hot Start High-
Fidelity DNA Polymerase (NEB, Ipswich, MA, USA), restriction enzymes (NEB) and T4 DNA 
ligase (NEB). The DNA sequencing was performed by the NRC-Plant Biotechnology Institute 
(Saskatoon, SK, Canada). 
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7.4.4 Immunoprecipitation 
MDBK cells were pretreated with phosphate-free Dulbecco’s modified Eagle’s medium 
(DMEM; Life Technologies) for 3 h prior to virus infection and subsequent incubation with 
[
32
P]-orthophosphate (Perkin Elmer, Woodbridge, ON, Canada). Cell lysates were pre-cleared 
with Protein G-Sepharose (GE Healthcare, Burnaby, BC, Canada), and then incubated with anti-
VP8 polyclonal antibody and Protein G-Sepharose overnight at 4°C. The Protein G-Sepharose 
was washed three times with wash buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) and boiled 
for 5 min with SDS-PAGE sample buffer. The samples were separated in SDS-PAGE gels. The 
gels were subsequently dried and exposed to Imaging Screen-K for visualization on a Molecular 
Imager FX (Bio-Rad, Mississauga, ON, Canada). ProtoBlue Safe (National Diagnostics, Atlanta, 
GA, USA) was used to stain gels. 
 
7.4.5 Western Blotting 
Whole-cell extracts were prepared by suspension of cell pellets in 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% 
NP-40, 1% deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail (Sigma-
Aldrich) and phosphatase inhibitor cocktail (EMD Millipore). The cell lysates, clarified by 
centrifugation at 13,000 × g for 10 min at 4°C, were boiled in SDS-PAGE sample buffer for 5 
min. After separation by SDS-PAGE the proteins were transferred to nitrocellulose membranes 
and incubated with the appropriate antibodies. The membranes were washed and incubated with 
IRDye 600RD/800CW-conjugated secondary antibodies at a 1:20,000 dilution and scanned with 
an Odyssey® CLx Infrared Imaging System (Li-Cor Biosciences). 
Densitometry was used to quantify the proteins in the SDS-PAGE gels and Western blots. 
Capsid protein VP5 was used to normalize the amount of input viruses. The Relative Quantity 
(RQ) of each protein was calculated by dividing the density of the viral protein of interest (Dint) 
by the density of VP5 (DVP5) in the same lane. The Relative Difference of the protein of interest 
(RD) was used to illustrate the changes in quantity of that protein between the recombinant 
viruses (sample) and wild-type virus (WT). These calculations are presented as the following 
equation:  
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7.4.6 Confocal microscopy 
MDBK cells, cultured on Permanox 2-well chamber slides (Thermo Fisher Scientific, 
Waltham, MA, USA), were infected with viruses or mock-infected. At indicated time points, the 
cells were washed three times with PBS (136.9 mM NaCl, 2.7 mM KCl, 7.0 mM Na3PO4, and 
0.9 mM Na3PO4, pH 7.4), and fixed with 4% paraformaldehyde for 20 min, followed by three 
washes with PBS. Subsequently, the cells were permeabilized with 0.1% Triton X-100 in PBS 
for 20 min, washed with PBS, and then incubated with 1% normal goat serum (Gibco) in PBS 
for 30 min at room temperature. The cells were incubated with primary antibodies at the 
appropriate dilutions for 2 h at room temperature, followed by washing with PBS and incubation 
with Alexa Fluor®-conjugated antibodies (Life Technologies) at a 1:500 dilution for 1 h at room 
temperature. Finally, slides were mounted with ProLong Gold Antifade Mountant with DAPI 
(Life Technologies) prior to examination with a Leica SP5 confocal microscope (Leica 
Microsystems CMS GmbH, Mannheim, Germany) equipped with external argon ion 
488/633/461 nm laser. 
 
7.4.7 Transmission electron microscopy 
MDBK cells in T75 flasks were infected with viruses at a MOI of 1. At 15 hpi, the cells 
were harvested with trypsin and washed in cold PBS. The cells were pelleted at 500 × g for 10 
min at 4°C. The cell pellets were fixed with 2.5% glutaraldehyde in PBS for 4 h and post-fixed 
with 1% osmium tetraoxide for 4 h. After washing with PBS for 30 min, the fixed samples were 
dehydrated in graded concentrated ethanol (50, 70, 90, and 100%) and polymerized with 
propylene oxide for 1 h. Subsequently, the pellets were embedded in Epon 812, followed by 
polymerization for 3 days at 60°C. Ultrathin sections with a thickness of 50-70 nm prepared by a 
Reichert-Jung Ultracut E Ultramicrotome (Reichert-Jung, Vienna, Austria) were mounted on 
200-mesh carbon-coated grids, and post-stained with 2% uranyl acetate for 10 min and 1% lead 
citrate for 40 min. After washing with water and air drying, the specimens were observed with a 
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Philips CM10 transmission electron microscope (Philips Electron Optics, Eindhoven, 
Netherlands). 
 
7.4.8 Virus purification 
MDBK cells cultured in T150 flasks were infected with BoHV-1, BoHV-1-YVP8 or 
BoHV-1-YmVP8 at a MOI of 1. The medium was harvested when over 90% of the cells showed 
cytopathic effect, and centrifuged at 3,000 × g for 30 min at 4°C to remove cell debris. The 
viruses were pelleted by centrifugation at 25,000 rpm for 2 h at 4°C in a Beckman Coulter SW 
32 Ti Rotor (Beckman Coulter Inc., Atlanta, GA, USA). The virus pellets were resuspended in a 
small volume of TNE buffer (50 mm Tris-HCl, pH 7.4, 100 mm NaCl, and 0.1 mm EDTA) 
overnight. The virus suspensions were loaded on top of a 10-60% potassium sodium tartrate 
gradient in TNE buffer, and centrifuged at 25,000 rpm for 2 h at 4°C in a Beckman Coulter SW 
41 Ti rotor. 
 
7.4.9 Statistical analysis 
Data were analyzed by using Microsoft Excel 2010. Standard deviation was calculated 
based on the entire population of each group, and shown as vertical error bars. Two-tailed t test 
was used to determine the statistical differences between two groups. Differences were 
considered statistically significant if 0.01< P ≤ 0.05, and statistically highly significant if P ≤ 
0.01. 
 
7.5 Results 
7.5.1 Construction of recombinant BoHV-1 viruses 
To study the impact of phosphorylation of VP8 during BoHV-1 infection, we constructed 
a virus expressing mutant VP8 (Mut-VP8) in which all essential phosphorylation sites for CK2 
and US3 were removed by point mutations. YFP N-terminally fused to VP8 and Mut-VP8 served 
as a selection marker. Integration of DNA was confirmed by PCR (Figure 7.1C) and DNA 
sequencing. The PCR fragments were sequenced and found to be identical to the WT sequence 
of UL47 in the case of YFP-UL47 and R-UL47 (revertant UL47), and to the mutated sequence in 
the case of YFP-mUL47. VP8 proteins from infected cell lysates were analyzed by Western 
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Blotting. YVP8 (YFP-VP8) and YmVP8 (YFP-mutant VP8) are about 27.5 kDa larger than WT-
VP8 and RVP8 (revertant VP8), which correlates to the apparent molecular mass of YFP (Figure 
7.1D). 
 
7.5.2 Blocking phosphorylation of VP8 impairs the production of BoHV-1 
The phosphorylation status of WT-VP8, YVP8, YmVP8, and RVP8 in infected cells was 
investigated by immunoprecipitation. [
32
P]-orthophosphate-labeled VP8 proteins were purified 
from infected MDBK cells, and equal amounts were loaded onto SDS-PAGE gels (Figure 7.2A). 
WT-VP8 was phosphorylated in the infected cells, and YVP8 had a similar phosphorylation level 
as WT-VP8. However, YmVP8 showed a highly significant reduction in phosphorylation. 
Phosphorylation was restored in RVP8 to a similar level as that of WT-VP8 and YVP8. 
Production of WT BoHV-1, BoHV-1-YVP8, BoHV-1-YmVP8, and BoHV-1-RVP8 was 
analyzed by titrating the viruses from the combined supernatants and cells (Figure 7.2B). The 
titer of BoHV-1-YmVP8 was significantly lower than that of WT BoHV-1. The titers were 
restored to WT levels by repairing VP8 in BoHV-1-RVP8, and the BoHV-1-YVP8 titer was 
equal to that of WT BoHV-1. To verify the intracellular and extracellular production of the 
mutant virus, viruses from the cells and supernatants were collected separately every 5 h (up to 
30 hpi) and subjected to one-step growth analysis (Figure 7.2C-F). The intracellular WT BoHV-
1 titer rapidly increased from 5 hpi (10
 
PFU/ml) to 15 hpi (10
5.4
 PFU/ml), indicating a major 
replication stage during this time period. Subsequently, a moderate increase in titer was observed 
from 15 hpi (10
5.4
 PFU/ml) to 25 hpi (10
6.0
 PFU/ml), followed by a slight decrease during the 
next 5 h (from 10
6.0
 to 10
5.8
 PFU/ml). Concomitantly, the extracellular virus titer increased 
substantially between 10 hpi (10
4.6
 PFU/ml) and 20 hpi (10
8.0
 PFU/ml) (Figure 7.2C). This 
suggests that major egress takes place from 10 to 20 hpi. BoHV-1-YVP8 had a similar growth 
pattern to WT BoHV-1 (Figure 7.2D). In contrast, the intracellular BoHV-1-YmVP8 titer 
increased constantly and slowly from 5 hpi (10
0.8
 PFU/ml) to 30 hpi (10
3.6
 PFU/ml), and the 
extracellular virus titer increased concurrently from 5 hpi (10
2.6
 PFU/ml) to 30 hpi (10
4.6
 PFU/ml) 
(Figure 7.2E). Repair of the phosphorylation residues on VP8 brought the virus growth curve to 
a similar pattern as observed with WT BoHV-1 (Figure 7.2F). 
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Figure 7.1 Schematic representations of DNA constructs and the genome of recombinant viruses.  
(A) Development of DNA fragments for homologous recombination. The locations of restriction 
sites are indicated on each construct. (B) The genomes of the recombinant viruses. The BoHV-1 
genome consists of a unique long (UL) region and a unique short (Us) region, bracketed by 
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inverted-repeat sequences (IR and TR). The ORFs of ul48, and ul47 are highlighted. (C) PCR 
analysis of the viral genomes. Purified genomic DNA of WT BoHV-1, BoHV-1-YVP8, BoHV-
1-YmVP8, and BoHV-1-RVP8 were used as PCR template. PCR products covering from about 1 
kbp upstream flanking sequence of ul47 to the MluI restriction site of the ul47 gene were 
amplified using primers 5’-CGTGTTCGTTTCGCTGTACTATGC-3’ and 5’-CAGTAAATCAG 
GGAGCCCATTGAG-3’. PCR products were separated in a 1% agarose gel with a DNA marker. 
(D) Western Blotting of VP8 proteins. MDBK cells were infected with WT BoHV-1, BoHV-1-
YVP8, BoHV-1-YmVP8, or BoHV-1-RVP8 at a MOI of 1 for 20 h. Whole protein extracts from 
cell lysates were analyzed by Western Blotting using polyclonal anti-VP8 antibody and IRDye 
600RD-conjugated secondary antibody. Molecular weight markers are shown in the left margin. 
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Figure 7.2 Phosphorylation status of VP8 and growth characteristics of viruses in MDBK cells. 
(A) Analysis of VP8 proteins by immunoprecipitation. MDBK cells were infected with WT 
BoHV-1, BoHV-1-YVP8, BoHV-1-YmVP8, and BoHV-1-RVP8 at a MOI of 1 and labeled with 
[
32
P]-orthophosphate. Cell lysates were collected at 20 hpi, and used for VP8 purification by 
incubation with anti-VP8 polyclonal antibody and Protein G Sepharose. The samples were 
separated by SDS-PAGE and exposed to Imaging Screen K (upper panel). The gels were stained 
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with ProtoBlue Safe to indicate the amount of protein loading (lower panel). The relative 
differences of each sample against WT-VP8 are shown as numbers on the top line. (B) Titration 
of viruses. MDBK cells were infected with viruses at a MOI of 1. The supernatant and cells were 
collected at 24 hpi. Viruses from infected cells and supernatants were quantified by plaque 
titration on MDBK cell monolayers. The data were analyzed with Two-tailed t test. The 
statistical significance of the difference between the values is shown as “*”, indicating 0.01< P ≤ 
0.05; and “**”, indicating P ≤ 0.01. (C-F) Single-step growth curves of viruses. MDBK cells 
were infected with viruses at a MOI of 1, and cell culture medium and cells were harvested 
separately at the indicated time points. The titer of infectious virus progeny in each sample was 
determined by plaque assay on MDBK cells. 
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7.5.3 Phosphorylation affects the incorporation and the cellular localization of VP8 during 
infection 
Deletion of VP8 impairs the incorporation of gB, gD, VP22, and especially gC, into 
BoHV-1 (64). To determine whether phosphorylation of VP8 plays a role in incorporation of 
major glycoproteins or tegument proteins, whole protein extracts from purified virions were 
analyzed by SDS-PAGE (Figure 7.3A) and Western Blotting (Figure 7.3B). After densitometry, 
the normalized values for the BoHV-1-YVP8 and BoHV-1-YmVP8 proteins were compared to 
the corresponding values for the WT virus. The overall profiles of the three viruses were similar, 
with the exception that the incorporation of YmVP8 was lower than that of WT-VP8 and YVP8, 
and that the molecular weight of YVP8 and YmVP8 was about 27.5 kDa higher (Figure 7.3A) 
than that of VP8. The packaging of VP8 into BoHV-1-YVP8 and BoHV-1-YmVP8 virions was 
reduced by 10% and 65%, respectively. There were no obvious changes in glycoprotein (gB, gC, 
and gD), and tegument protein (VP22 and US3) amounts when analyzed by Western Blotting. 
The value of gC from BoHV-1-YmVP8 was compared to that of BoHV-1-YVP8, because gC 
(91 kDa) was partially masked by VP8 (97 kDa) in the WT BoHV-1 lane. The densities of YVP8 
and YmVP8 were 21% and 70% lower than that of WT-VP8 (Figure 7.3B), respectively, 
indicating that the reduced packaging of VP8 may be due to a block in phosphorylation. 
The localization of VP8 in infected MDBK cells was observed by confocal microscopy 
(Figure 7.4A). WT-VP8 first appeared in the cytoplasm at 2 hpi. At 4 hpi, the majority of WT-
VP8 localized in the nucleus, and the level of nuclear VP8 slightly decreased during the 
following 4 h. In contrast, the cytoplasmic VP8 population increased slowly before 4 hpi, and 
increased relatively quickly from 6 to 8 hpi, and ultimately exceeded the nuclear population. A 
similar trend in YFP-VP8 distribution was found in BoHV-1-YVP8-infected cells (Figure 7.4B). 
In BoHV-1-YmVP8-infected cells, the non-phosphorylated Mut-VP8 first appeared in the 
cytoplasm at 2 hpi. Nuclear Mut-VP8 started to increase from 2 to 8 hpi, while the cytoplasmic 
level remained the same (Figure 7.4B). Similar results with respect to the distribution of VP8 
proteins were found in infected embryonic bovine tracheal (EBTr) cells (data not shown). To 
track the location of VP8 in the cytoplasm, infected cells were labeled with monoclonal anti-58k 
protein antibody, which is used as a marker of the Golgi apparatus (366). In WT BoHV-1 and 
BoHV-1-YVP8 infected cells, VP8 accumulated to the cytoplasm and localized to the Golgi 
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network, while YmVP8 did not localize to the cytoplasm or Golgi apparatus of BoHV-1-YmVP8 
infected cells (Figure 7.5). 
To examine whether Golgi-association of VP8 resulted from translocation of virus 
particles, capsid protein VP5 was labeled with polyclonal anti-VP5 antibody in infected MDBK 
cells. In WT BoHV-1 infected cells, the VP5 signal was mostly in the nucleus and did not 
associate with cytoplasmic VP8, indicating that the majority of cytoplasmic VP8 was not virus-
associated (Figure 7.6). The distribution of VP5 was not different between WT BoHV-1 and 
BoHV-1-YmVP8 infected cells. YmVP8 showed a punctate pattern, but VP5 did not, indicating 
that the speckled YmVP8 was not virus-associated. 
 
7.5.4 Phosphorylation of VP8 benefits the viral DNA content 
To further study the effects of VP8 phosphorylation, the BoHV-1 life cycle was studied 
by transmission electron microscopy. Figure 7.7 demonstrates the life cycle of WT BoHV-1 
from empty nucleocapsids to cytoplasmic enveloped particles. Capsid formation and DNA 
encapsidation took place in the nucleus (Figure 7.7A-B). The nuclear capsids exited from the 
nucleus to the cytoplasm by budding through the two leaflets of the nuclear membrane. First, 
these nucleocapsids were in intimate contact with the inner nuclear membrane, while the 
membrane bent inward to enclose the capsid (Figure 7.7B), resulting in a primary-enveloped 
virus in the perinuclear space (Figure 7.7C). These capsids were surrounded by a smooth 
envelope. Capsids were released from the perinuclear space by fusion of the primary envelope 
with the outer nuclear membrane (Figure 7.7D), so that the viral particles lost the primary 
envelope (Figure 7.7E) and became free naked capsids in the cytoplasm (Figure 7.7F). The 
cytoplasmic capsids migrated towards to the Golgi area (Figure 7.7G) and obtained the 
secondary envelope by being wrapped with Golgi membrane (Figure 7.7H-I). Viral capsids were 
surrounded by a thick layer of electron-dense material in the Golgi apparatus and the Golgi-
derived envelope was contained visible surface projections, when compared with the perinuclear 
envelope (Figure 7.7H-J). BoHV-1-YVP8 infected cells were also observed by transmission 
electron microscopy, and the virus exhibited the same maturation as WT virus (data not shown). 
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Figure 7.3 Influence of blocking VP8 phosphorylation on virion composition. 
(A) Solubilized proteins of purified extracellular virions of BoHV-1, BoHV-1-YVP8 and BoHV-
1-YmVP8 were analyzed by SDS-PAGE and the proteins were stained with ProtoBlue Safe. The 
densities of VP5 and VP8 were analyzed by densitometry. The percentages of YVP8 and 
YmVP8 in comparison to WT-VP8 are indicated below each sample. (B) Western Blotting of 
viral proteins. Solubilized proteins of purified extracellular WT BoHV-1, BoHV-1-YVP8 and 
BoHV-1-YmVP8 virions were analyzed by Western Blotting. The proteins were detected with 
polyclonal anti-VP5, VP22, VP8 and US3 antibodies, monoclonal anti-gB, gC, gD antibodies, 
followed by IRDye® 680RD goat anti-rabbit IgG and IRDye® 800CW goat anti-mouse IgG. 
Each tested protein was simultaneously run with VP5, shown in the top panel of each group. 
Blots were analyzed by densitometry. 
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Figure 7.4 Localization of VP8 proteins in infected MDBK cells.  
MDBK cell monolayers were infected with WT BoHV-1, BoHV-1-YVP8 or BoHV-1-YmVP8 at 
a MOI of 5, and processed for immunofluorescence staining every 2 h until 8 hpi. (A) VP8 was 
labeled with polyclonal anti-VP8 antibody and Alexa 488-conjugated antibody. DNA was 
labeled with DAPI. Arrow heads indicate nuclear VP8 and arrows indicate cytoplasmic VP8. (B) 
The cell images of each time point were analyzed with a biological image processing program, 
Fiji (367). The average green value within a selected area in a picture was calculated by the 
program. At each time point, the cytoplasm and the nucleus of ten cells were selected and 
analyzed. The mean values are shown in the figure. The data were analyzed with Two-tailed t 
test. The statistical significance of the difference between the values is shown as “*”, indicating 
0.01< P ≤ 0.05; and “**”, indicating P ≤ 0.01. 
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Figure 7.5 Co-localization of cytoplasmic VP8 with the Golgi-apparatus.  
MDBK cell monolayers were infected with WT BoHV-1, BoHV-1-YVP8 or BoHV-1-YmVP8 at 
a MOI of 0.001 until plaques were well-developed. WT-VP8 was labeled with monoclonal anti-
VP8 antibody and Alexa 488-conjugated antibody. The Golgi-apparatus was identified with 
polyclonal anti-58k protein antibody and Alexa 633-conjugated antibody. The DNA was labeled 
with DAPI. The cells were observed under a Leica SP5 confocal microscope. The selected areas 
were enlarged in the bottom panel.  
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Figure 7.6 Co-immunostaining of VP8 and VP5.  
MDBK cell monolayers were infected with WT BoHV-1, BoHV-1-YVP8 or BoHV-1-YmVP8 at 
a MOI of 0.001 until plaques were well-developed. WT-VP8 was labeled with monoclonal anti-
VP8 antibody and Alexa 488-conjugated antibody. VP5 was identified with polyclonal anti-VP5 
antibody and Alexa 633-conjugated antibody. DNA was labeled with DAPI. The cells were 
observed under a Leica SP5 confocal microscope. The selected areas were enlarged in the 
bottom panel. 
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Figure 7.7 Transmission electron microscopy of cells infected with WT BoHV-1.  
MDBK cells infected with WT BoHV-1 at a MOI of 1 were collected and processed at 15 hpi 
and observed with a Philips CM10 transmission electron microscope. The selected areas from the 
picture in the middle (Bar = 200 nm) were enlarged and displayed on the right and left sides (Bar 
= 100 nm). 
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When compared with WT BoHV-1 (Figure 7.8A) and BoHV-1-YVP8 (Figure 7.8B) 
nuclear capsids, which mostly contained DNA cores at 15 hpi, BoHV-1-YmVP8 infected cells 
had more empty nucleocapsids present in the nucleus (Figure 7.8C). Five views were captured in 
the nucleus of cells infected with WT BoHV-1, BoHV-1-YFP or BoHV-1-YmVP8. The numbers 
of capsids with and without DNA core were counted in each view. Over 80% of the WT BoHV-1 
and BoHV-1-YVP8 nucleocapsids had DNA incorporated, while less than 30% of the BoHV-1-
YmVP8 nucleocapsids had DNA cores (Figure 7.8D). These results suggest that phosphorylated 
VP8 might play a role in promoting production or encapsidation of viral DNA. 
 
7.5.5 Phosphorylation on VP8 does not affect virus particle release from the nucleus 
In BoHV-1-YmVP8 infected cells, both empty capsids (Figure 7.9A-D) and DNA-
containing capsids (Figure 7.9F-I) egressed from the nucleus through the envelopment-de-
envelopment pathway. Empty nucleocapsids migrated towards the inner nuclear membrane 
(Figure 7.9A), which subsequently enclosed the capsids, forming a primary envelope 
surrounding the empty capsids. The particles were presented as two-layer halos in the perinuclear 
space (Figure 7.9A, B). DNA-free capsids (Figure 7.9C, D) and DNA-containing capsids (Figure 
7.9E, H, I) were found in the cytoplasm. Figure 9H shows that DNA-containing capsids were 
captured by the Golgi structure in the cytoplasm for further maturation and eventual release out 
of the cells (Figure 7.9J). There was no apparent evidence for blockage of empty capsid egress 
from the nucleus in BoHV-1-YmVP8 infected cells. 
The amount of extracellular virus of WT BoHV-1, BoHV-1-YVP8 and BoHV-1-YmVP8 
is presented in Figure 7.10. In agreement with the viral growth characteristics (Figure 7.2B), 
BoHV-1-YmVP8 -infected cells were surrounded by apparently smaller amounts of extracellular 
virions when compared to cells infected with WT BoHV-1 or BoHV-1-YVP8 (Figure 7.10A).  
Five views of extracellular virus of WT BoHV-1, BoHV-1-YVP8 and BoHV-1-YmVP8 were 
captured and the numbers of mature virus particles were counted. The numbers of released WT 
BoHV-1 virions and BoHV-1-YVP8 virions were significantly higher than those of BoHV-1-
YmVP8 (Figure 7.10B). The ultrastructure of the three viruses did not have any obvious 
difference (data not shown). 
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Figure 7.8 Analysis of the impact of blocking phosphorylation of VP8 on viral DNA content. 
(A-C) MDBK cells infected with WT BoHV-1, BoHV-1-YVP8, or BoHV-1-YmVP8 at a MOI 
of 1 were collected and processed at 15 hpi and observed with a Philips CM10 transmission 
electron microscope. The location of nuclear capsids was marked with a “*”.  “Cyt” indicates 
cytoplasmic area, and “Nuc” indicates nuclear area. The selected area from each picture was 
enlarged and displayed in the left-bottom corner (Bar = 200 nm). (D) The numbers of capsids 
were counted from five views of the nuclear areas infected with WT BoHV-1, BoHV-1-YVP8, 
or BoHV-1-YmVP8. The data were analyzed with Two-tailed t test. The statistical significance 
of the difference between the values is shown as “**”, P ≤ 0.01. 
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Figure 7.9 Transmission electron microscopy of cells infected with BoHV-1-YmVP8. 
MDBK cells infected with BoHV-1-YmVP8 at a MOI of 1 were collected and processed at 15 
hpi and observed with a Philips CM10 transmission electron microscope. The selected areas 
from the picture in the middle (Bar = 200 nm) were enlarged and displayed on the right and left 
sides (Bar = 100 nm). “Cyt”, “Nuc”, and “Ext” indicate cytoplasmic area, nucleus area and 
extracellular area, respectively. 
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Figure 7.10 Analysis of extracellular viruses.  
(A) MDBK cells infected with WT BoHV-1, BoHV-1-YVP8, or BoHV-1-YmVP8 at a MOI of 1 
were collected and processed at 15 hpi, and observed with a Philips CM10 transmission electron 
microscope. The extracellular viral particles are displayed (Bar = 1 μm). (B) The numbers of 
viral particles were counted from five views of extracellular areas of each treatment. The data 
were analyzed with Two-tailed t test. The statistical significance of the difference between the 
values is shown as “*”, 0.01< P ≤ 0.05. 
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To further confirm the presence of empty virions in BoHV-1-YmVP8 infected cells, viral 
particles released to the cell culture medium were collected and separated in a sodium potassium 
tartrate density gradient (Figure 7.11). WT BoHV-1 and BoHV-1-YVP8 consisted of a single 
virus band located at 40%-50% of the density gradient, while BoHV-1-YmVP8 had two visible 
bands. The lower band had the same density as that in wild-type virus. These bands contained 
mature virions with DNA cores (Figure 7.11A, B and D). The upper band of BoHV-1-YmVP8 
contained incomplete virions without DNA cores or with partial genomes (Figure 7.11C), which 
thus had a lower density than the complete virions. The band with complete WT BoHV-1 virions 
was thicker and brighter than that of BoHV-1-YmVP8. These data are consistent with the results 
shown in Figure 7.2 and Figure 7.10 that demonstrated lower virus production by BoHV-1-
YmVP8. 
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Figure 7.11 Gradient sedimentation analysis and TEM observation of extracellular viruses. 
 Extracellular viral particles were loaded onto 10-60% potassium sodium tartrate gradients in 
TNE buffer, and sedimented by centrifugation at 25,000 rpm for 2 h at 4°C in a SW41 rotor. The 
virus bands were visualized by passing a light beam from the top through the tartrate gradient in 
a dark environment. “**” indicates a band containing complete viruses with higher density, and 
“*” indicates a band containing incomplete viruses with lower density. (A-D) The virus bands 
were aspired and observed by TEM. “>” indicates a virion without a DNA core, “>>” indicates a 
virion with an incomplete DNA core, and “>>>”indicates a virion with a complete DNA core 
(Bar = 200 nm). 
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7.6 Discussion 
To characterize the function of phosphorylation on VP8 and eventually the impact on the 
life cycle of BoHV-1, a recombinant BoHV-1 virus expressing mutant VP8 was constructed. The 
mutant VP8, which has been previously studied in vitro (290) outside the context of infection, is 
not phosphorylated by CK2 or US3 as amino acid residues at the essential sites for the kinases 
have been substituted with alanines. The results showed that blocking phosphorylation on VP8 
leads to reduced virus production (Figure 7.2B). Accordingly, a lower number of complete 
BoHV-1-YmVP8 virus particles was found adjacent to infected cells when compared to WT 
BoHV-1 (Figure 7.10). According to the results of the single-step growth curve, this reduction 
may have at least two reasons. Firstly, the replication of the VP8-mutant virus was impaired 
when compared to that of wild-type virus. From 5 to 15 hpi, intracellular BoHV-1-YmVP8 
virions increased 163 fold (from 10
0.8
 PFU/ml to 10
3.1
 PFU/ml), whereas intracellular WT 
BoHV-1 virus experienced a more rapid amplification, about 26,700 fold (from 10 PFU/ml to 
10
5.4
 PFU/ml). As a result, during this period the amount of extracellular BoHV-1-YmVP8 was 
lower in comparison to extracellular WT BoHV-1. Secondly, the mature mutant virus was less 
efficiently released from the host cells than the wild-type virus. From 10 to 25 hpi, extracellular 
WT virus showed a rapid increase of ~2,000 fold (from 10
4.6
 PFU/ml to 10
7.9
 PFU/ml), which 
was associated with a slower increase in intracellular virus. In contrast the extracellular mutant 
virus increased about 20-fold (from 10
3.4
 PFU/ml to 10
4.8
 PFU/ml) (Figure 7.2C, E). Repairing 
phosphorylation on VP8 (Figure 7.2A) restored the virus titer (Figure 7.2B) and growth property 
(Figure 7.2F), suggesting the attenuated virus growth in BoHV-1-YmVP8 was due to diminished 
phosphorylation on VP8. 
The ultrastructural study of virus-infected cells revealed a potential function of 
phosphorylated VP8 in BoHV-1 maturation. The maturation process of WT BoHV-1 from the 
nucleus to the cytoplasm is displayed in Figure 7.7. Capsid formation and DNA incorporation 
occurred in the nucleus. Nuclear capsids traveled through the nuclear membrane via an 
envelopment-de-envelopment process, and obtained most of the tegument and envelope in the 
cytoplasm. This maturation and egress model is in agreement with the one described previously 
for other herpesviruses, such as HHV-1 (133), human cytomegalovirus (HCMV) (368) and 
pseudorabies virus (PRV) (364). In the nucleus of BoHV-1-YmVP8-infected cells, most capsids 
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did not contain a DNA core, indicating that phosphorylated VP8 may promote viral DNA 
production or packaging into capsids; however, this is not an absolute requirement as a certain 
number of DNA-containing particles were found in the nucleus, cytoplasm and extracellular 
environment. Encapsidation of herpesvirus DNA involves cooperation of many viral proteins 
that cleave viral DNA and introduce the cleaved DNA into capsids (369). The ul25 gene product 
of HHV-1 encompasses a capsid-binding domain, through which the protein targets to capsids 
and propels DNA into the capsid (94). Viral structural proteins L1 and L2 of PRV are required 
for assembly of viral DNA into capsids (370). For BoHV-1, phosphorylated VP8 appeared to be 
a contributing factor for DNA replication or encapsidation. DNA incorporation was not critical 
for nuclear egress of capsids, and neither was phosphorylation of VP8, because empty capsids 
were present in the perinuclear space and cytoplasm. In BoHV-1-YmVP8-infected cells, empty 
capsids merged with the inner nuclear membrane and obtained a primary envelope similar to 
DNA-containing capsids. Ultimately, the DNA-free particles were released to the extracellular 
environment, resulting in an additional lower-density virus band in a potassium tartrate gradient 
(Figure 7.11). 
The inefficient incorporation of mutant VP8 into the virion indicates that optimal VP8 
packaging requires phosphorylation and that this may have an impact on virion maturation and 
release. This also suggests that VP8 may be incorporated at two stages, the first occurring in the 
nucleus and the second one taking place in the cytoplasm. The YmVP8 from the mutant virus 
was mainly localized to the nucleus during the infection (Figure 7.4), indicating that the virion-
associated YmVP8 was incorporated prior to or during nuclear egress, and that phosphorylation 
by CK2 and US3 is not required for the primary incorporation of VP8. This conclusion is also 
supported by data from a previous study using VP8-specific immunogold staining that showed 
accumulation of VP8 protein around the nuclear capsids as well as along the outer nuclear 
membrane (25). The addition of certain tegument components of herpesviruses to capsids prior 
to or during nuclear egress is referred to as primary tegumentation (371). In HHV-1, UL36, UL37, 
ICP0 and ICP4 have been identified as primary tegument proteins that are present on the capsids 
before they get to the cytoplasm (371). The ul31 and ul34 gene products of PRV are incorporated 
in the primary enveloped capsids and eventually dissociate from the capsids during the later 
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process (372). US3 of PRV is another primary tegument protein which, however, does not 
dissociate from the viral particle during de-envelopment (373). 
Both viral particles (Figure 7.7) and WT-VP8 protein (Figure 7.5) accumulated to the 
Golgi area during the late stages of infection indicating that the Golgi apparatus is a major site 
for VP8 incorporation. Previous evidence that immunogold particle-labeled VP8 localized to the 
Golgi area (25) also supports these results. The secondary incorporation of VP8 requires this 
protein to be phosphorylated by CK2 and/or US3, as without CK2- and/or US3-mediated 
phosphorylation it did not associate with the Golgi (Figure 7.5). It is less likely that the Golgi-
associated VP8 is the result of viral particle transport, as the cytoplasmic localization of VP8 was 
independent from VP5 protein, a major component of viral capsids (Figure 7.6). 
That VP8 localizes in the cytoplasm and associates with the Golgi only during infection, 
but remains mainly in the nucleus in VP8-transfected cells (290), suggests that VP8 needs the 
presence of other viral components for direction to the Golgi. Blocking phosphorylation on VP8 
inhibited the protein from targeting the Golgi, which likely resulted in disruption of the 
secondary incorporation of VP8, and ultimately reduced infectious virus production. In contrast, 
tegument protein VP13/14, a gene product of HHV-1 UL47 and a homologue of VP8, assembles 
mainly in the nucleus. The majority of VP13/14 localizes in the nucleus during all infection 
stages, and it forms punctate patterns in the late stages. The relative cytoplasmic intensity of 
VP13/14 is very low in comparison to the nuclear intensity, which may result from viral particle 
migration (374). 
In summary, this study demonstrates that blocking phosphorylation of VP8 may have a 
negative impact on viral DNA encapsidation and reduce the viral replication efficiency. 
Phosphorylation was found to be essential for the cytoplasmic incorporation of VP8 into virions, 
but not for primary packaging of VP8 in the nucleus. Ultimately, the impairment in cytoplasmic 
maturation of the virus reduced the efficiency of viral release. 
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CHAPTER 8 
 
8 LINKER BETWEEN CHAPTER 7 AND CHAPTER 9 
Nuclear-to-cytoplasmic shuttling of VP8 has been observed in several previous studies 
(25, 72, 154). In BoHV-1-infected cells, VP8 was initially localized in the nucleus and then 
appeared in the Golgi apparatus. Results in chapter 7 suggest that the cellular localization of VP8 
may be correlated to the protein function at different phases of BoHV-1 infection. 
Phosphorylated VP8 promoted the viral DNA encapsidation in the nucleus. Afterwards, VP8 
moved from the nucleus to the Golgi where VP8 was incorporated into BoHV-1 virus. The 
virion-contained VP8 may benefit the infection at a pre-immediate early stage. In the next 
chapter, we describe a phosphorylation-based regulatory mechanism that controls the nuclear 
export of VP8 in BoHV-1 infected cells. We investigated the impact of US3 and CK2 in VP8 
translocation, respectively. The results suggested that the US3-mediated phosphorylation 
activates the nuclear export of VP8, but that CK2 does not affect the nuclear localization of VP8. 
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9.1 Abstract 
Bovine herpesvirus-1 (BoHV-1) infects bovine species to cause respiratory infections, 
genital disorders and abortions. VP8 is the most abundant tegument protein of BoHV-1 and is 
critical for virus replication in cattle. In this study the cellular translocation of VP8 was found to 
be regulated by a phosphorylation-based mechanism during BoHV-1 infection. Early during 
infection VP8 was translocated to the nucleus. Subsequently, presumably after completion of its 
role in the nucleus, VP8 localized to the cytoplasm and accumulated to the Golgi apparatus. 
During the VP8 translocation process, phosphorylation by the viral kinase US3 played a critical 
role in mediating the nuclear export of VP8. When US3 was deleted, or the essential US3-
phosphorylation site in VP8 was mutated, VP8 remained in the nucleus. Examination of the 
amino acid sequence of VP8 supported a potential role of US3-mediated phosphorylation in 
regulating the nuclear localization signals (NLSs) and nuclear export signals (NESs) of VP8. The 
US3-mediated phosphorylation sites (S
16
 and S
32
) are close to the NLSs (P
11
RPRR
15
 and 
R
48
PRVRRPRP
54
), supporting the contention that the NLSs might be disguised and deactivated 
by phosphorylation at these two residues. However, the nuclear export signals (NESs) are not 
close to the US3-targeted motifs and their functions appeared to be not abolished by the 
phosphorylation, such that they were capable of translocating VP8 into the cytoplasm. The 
cytoplasmic VP8 migrated to the cis-Golgi apparatus, but not to the trans-Golgi network (TGN), 
suggesting that VP8 is in the Golgi to be incorporated into the virions. 
 
9.2 Importance 
NLSs and NESs are important elements directing VP8 to the desired locations in the 
virus-infected cell. In this study a critical regulator was found that switches the nuclear and 
cytoplasmic localization of VP8 in BoHV-1 infected cells. BoHV-1 used viral kinase US3 to 
regulate the activity of the NLSs in VP8. Once US3 was expressed, phosphorylated VP8 
egressed from the nucleus and subsequently accumulated in the cis-Golgi apparatus, presumably 
to be incorporated into virions. In addition, we propose that the Golgi localization of VP8 is 
stimulated by other viral factors. 
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9.3 Introduction 
Bovine herpesvirus-1 (BoHV-1) is a member of the alphaherpesviridae, and 
predominantly infects cattle. It causes infectious bovine rhinotracheitis, pustular vulvovaginitis 
and balanoposthitis (28). This virus may also cause abortions in host animals during pregnancy 
(47). BoHV-1 contains a double-stranded DNA genome of 135 kilo base pairs (kbp) enclosed in 
a capsid shell which is about 125 nm in diameter (69). Outside the capsid is a tegument protein 
layer surrounded by a lipid envelope and glycoproteins (64). VP8 is the major component of the 
tegument layer and is essential for BoHV-1 to infect host animals (25). It is a late protein 
expressed by the ul47 gene, which is conserved in the alphaherpesviridae (289). In human 
herpesvirus 1 (HHV-1) the ul47 gene expresses a non-essential tegument protein, named 
VP13/14 (14). 
VP8 is phosphorylated by the viral unique short protein 3 (US3) and the cellular casein 
kinase 2 (CK2) in BoHV-1-infected cells (15). Phosphorylation of VP8 is removed when the 
protein is incorporated into mature virions, indicating that the major role of phosphorylation 
might be regulating cellular functions of VP8 (290). US3 phosphorylates VP8 at residues S
16
 and 
S
32 
(290), and phosphorylation at S
16
 is essential for the subsequent phosphorylation at S
32 
(290). 
CK2 has multiple targets on VP8 with different preferences. Seven residues (T
65
, S
66
, S
79
, S
80
, 
S
82
, S
88
, and T
107
) localized in the N-terminus of VP8 are critical for phosphorylation through 
CK2, T
107 
being most frequently phosphorylated (290). 
The localization of VP8 with in a cell changes with the progression of BoHV-1 infection 
(25). Early during infection, VP8 is accumulated in the nucleus. Subsequently, VP8 accumulates 
in the Golgi apparatus in the cytoplasm at later stages of infection (375). Two arginine-rich 
nuclear localization signals (NLSs), P
11
RPRR
15
 and R
48
PRVRRPRP
54
, contribute to the nuclear 
localization of VP8 (72, 154). At least two nuclear export signals (NESs) have been described in 
VP8. One of them depends on the chromosomal maintenance 1 (CRM1)-signal pathway and the 
other one is CRM1-independent (156). It has been suggested that they are not the only NESs in 
VP8 because mutating both NESs does not completely block VP8 translocation from one nucleus 
to another within the same cell generated by interspecies heterokaryons (155, 156). In the BoHV-
1 replication cycle the NLSs and NESs of VP8 might be regulated by a viral strategy to precisely 
navigate VP8 to a desired subcellular location. 
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Phosphorylation-regulated cellular localization of proteins has been reported for many 
proteins including eukaryotic and viral proteins. One example is that phosphorylation controls 
the cellular recycling of eIF6, a protein essential for separation of the 60S subunit from the 40S 
subunit, and trafficking from the cytoplasm to the nucleus (376). When phosphorylated through 
casein kinase 1 (CK1), eIF6 is translocated from the nucleus to the cytoplasm together with the 
60S subunit (376). The cytoplasmic eIF6 is then dephosphorylated through calcineurin (376) and 
subsequently recycled to the nucleus (377). Phosphorylation also controls the sub-cellular 
localization of VP13/14 in HHV-1 (289). The nuclear localization of VP13/14 is mediated 
through a NLS and is regulated by US3 of HHV-1. US3-phosphorylated VP13/14 localizes in the 
nucleoplasm and in the nuclear membrane of HHV-1-infected cells. However, without 
phosphorylation, VP13/14 is predominantly in the nuclear membrane. This translocation of 
VP13/14 is correlated to stromal keratitis caused by HHV-1 in mice (142). VP8 of BoHV-1 has 
been described as a nuclear-cytoplasmic shuttling protein, leading to the hypothesis that cellular 
localization of VP8 might be regulated by US3- and/or CK2-mediated phosphorylation. 
 
9.4 Materials and methods 
9.4.1 Viruses and cell lines 
Madin-Darby bovine kidney (MDBK) cells, human hepatoma (Huh-7) cells, African 
green monkey fibroblast-like (COS-7) cells, embryonic bovine tracheal (EBTr) cells, fetal 
bovine testis (FBT) cells, and Henrietta Lacks’ immortal (Hela) cells were cultured in Eagle’s 
minimum essential medium (MEM) (Gibco/Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10 mM of N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES, 
Gibco), 1% non-essential amino acids (Gibco), and 10% fetal bovine serum (FBS, Gibco). 
US3-deleted virus (ΔUS3-BoHV-1) and US3-revertant virus (RUS3-BoHV-1) were 
generated from the Cooper strain (24). A virus expressing YFP-VP8, BoHV-1-YVP8, was made 
from the 108 strain (25). Production of all viral stocks was carried out in MDBK cells as 
previously described (290). Briefly, virus infections were accomplished by incubating 85-90% 
confluent cell monolayers in 150 cm
2
 flacks with 10 ml diluted virus at 37°C, which was 
replaced with 15 ml of MEM with 2% FBS at 1 hpi. Viruses were collected when cytopathic 
effect was well developed. The virus titers were determined by plaque titration on MDBK cells 
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in 24-well plates overlaid with 8% UltraPure low-melting-point agarose (Invitrogen/Thermo 
Fisher Scientific) in MEM. 
 
9.4.2 Generation of US3-deleted BoHV-1 (ΔUS3-BoHV-1) and US3-revertant BoHV-1 
(RUS3-BoHV-1) 
The viral genome of ΔUS3-BoHV-1 in a bacterial artificial chromosome (BAC) system 
was developed through homologous recombinations in E. coli DH10B cells (24) (Donovan et al. 
manuscript in preparation) between a plasmid pCooper BAC and a recombinant DNA fragment 
that contains a kanamycin resistance cassette flanking an upstream region and a downstream 
region of the us3 gene. The homologous recombination system also contains a pML300 plasmid 
that carries the lambda-red recombinant genes driven by a recombinase-sensitive promotor. 
Recombination in DH10B cells was stimulated with rhamnose and clones containing pΔUS3-
BoHV-1 BAC were selected with proper antibiotics. 
To generate a US3-revertant BoHV-1 (RUS3-BoHV-1) the en passant mutagenesis 
strategy, a two-step marker-less red recombination system, was adopted. A linear transgene 
fragment was used for the recombination with pΔUS3-BoHV-1 BAC. This transgene fragment 
encompassed a central cassette containing an I-SceI recognition site and a zeocin selective 
marker. The centre cassette was flanked by the front half of the us3 gene, which was deleted in 
ΔUS3-BoHV-1, and the rear half of the us3 gene. These flanking regions contained 300 bp of 
identical sequences for the second-step recombination. On each distant end of the transgene 
fragment, it contained the upstream and downstream regions of the us3 gene for the first-step 
recombination. The first-step recombination system took place in DH10B cells harboring 
pΔUS3-BoHV-1 BAC, the transgene fragment, and pML300. The second-step recombination 
was performed in the E.coli strain GS1783, expressing an inducible I-SceI enzyme and lambda-
red enzymes. By stimulating the expression of I-SceI enzyme followed by activating the lambda-
red recombination, the I-SceI site and the zeocin selective marker were removed, resulting in 
BAC clones containing pRUS3-BoHV-1. Viruses were rescued by transfecting pΔUS3-BoHV-1 
and pRUS3-BoHV-1 into fetal bovine testis (FBT) cells, respectively. 
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9.4.3 Antibodies and plasmids 
The antibodies used were monoclonal antibodies specific for VP8 (1G4 2G2) (25), FLAG 
(Sigma-Aldrich), and formimidoyltransferase cyclodeaminase (FTCD) (Sigma-Aldrich), and 
polyclonal antibodies specific for VP8 (25), US3 (118), golgin subfamily B member 1 
(GOLGB1) (Sigma-Aldrich), and trans-Golgi network integral membrane protein 2 (TGOLN2) 
(Thermo Fisher Scientific). Alexa 488-conjugated goat anti-mouse IgG and Alexa 633-
conjugated goat anti-rabbit IgG (Thermo Fisher Scientific) were used for immunofluorescent 
staining. IRDye® 680RD goat anti-rabbit IgG and IRDye® 800CW goat anti-mouse IgG (Li-Cor 
Biosciences, Lincoln, NE, USA) were used for Western Blotting. 
Plasmids pFLAG-VP8 and pUS3-HA were previously generated by amplification from 
the cDNA of the BoHV-1 108 strain (15). Plasmids pFLAG-VP8-S16A and pFLAG-VP8-M65-
017 were modified from pFLAG-VP8 by site-directed mutagenesis (290). 
 
9.4.4 Immunofluorescent staining and quantification 
Tissue cultures were prepared in permanox chamber slides (Thermo Fisher Scientific). 
After washing with phosphate-buffered saline (PBS) (136.9 mM NaCl, 2.7 mM KCl, 7.0 mM 
Na3PO4, and 0.9 mM Na3PO4, pH 7.4) the cultures were fixed with 4% paraformaldehyde for 20 
min and again washed with PBS. The fixed cells were permeabilized with 0.1% Triton X-100 in 
PBS for 30 min, washed with PBS, and blocked with 1% normal goat serum (Gibco) for 30 min. 
To identify the proteins of interest, the cells were incubated with primary antibodies for 2 h, and 
then with secondary antibodies for 1 h. Cells were washed three times with PBS following each 
antibody incubation. All incubations and washes were performed at room temperature. To stain 
the nucleus the slides were incubated with DAPI (4,6-diamidino-2-phenylindole, 0.5 µg/ml) for 
10 min at 37⁰C. To identify lipids, cells were stained with Nile red (10 μg/mL). To identify 
trans-Golgi, cells were treated with brefeldin A (BFA, 5 μg/ml, Biolegend, San Diego, CA, USA) 
or DMSO (0.1%). Finally, the slides were mounted with ProLong Gold Antifade Mountant 
(Thermo Fisher Scientific) prior to examination with a Leica SP5 confocal microscope (Leica 
Microsystems CMS GmbH, Mannheim, Hesse, Germany). 
Three-color images were generated by sequential scanning using 488 nm, 633 nm, and 
461 nm lasers. A computer program Leica Application Suite X (Leica Microsystems CMS 
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GmbH) was used to process the images and to calculate the relative quantification of fluorescent 
intensities according to the manufacturer’s manual. After making selections of the nuclear and 
cytoplasmic areas, the mean intensity of each channel within the defined area was quantified by 
the software, shown as procedure defined unit (PDU). The generated data were used for 
statistical analysis. 
 
9.4.5 Western Blotting 
Cell pellets were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1% deoxycholate, 0.1% SDS) supplemented with 
protease inhibitor cocktail (Sigma-Aldrich). The cell lysates were clarified by centrifugation at 
13,000 × g for 10 min at 4°C. The clarified lysates were boiled in SDS-PAGE sample buffer for 
5 min. Proteins were separated by using SDS-PAGE. After separation, they were transferred to 
nitrocellulose membranes and incubated with primary antibodies. The membranes were then 
washed and incubated with IRDye® 600RD/800CW-conjugated secondary antibodies (Li-Cor 
Biosciences, Lincoln, NE, USA). The resulting membranes were scanned with an Odyssey® 
CLx Infrared Imaging System (Li-Cor Biosciences). 
 
9.4.6 Transmission electron microscopy 
MDBK cells were infected with viruses at a MOI of 1. At 15 hpi, the cells were harvested 
with trypsin and washed in cold PBS. The procedure for transmission electron microscopy has 
been previously described (375). Briefly, after centrifugation at 500 ×g for 10 min at 4°C, cells 
were fixed with 2.5% glutaraldehyde and then with 1% osmium tetraoxide. The fixed samples 
were dehydrated with graded concentrated ethanol and polymerized with propylene oxide. After 
dehydration, the pellets were embed using Epon 812. Ultrathin sections of 50-70 nm in thickness 
were prepared by a Reichert-Jung Ultracut E Ultramicrotome (Reichert-Jung, Vienna, Austria) 
and were mounted on 200-mesh carbon-coated grids. The sections were post-stained with 2% 
uranyl acetate and 1% lead citrate. The specimens were observed with a Philips CM10 
transmission electron microscope (Philips Electron Optics, Eindhoven, North-Brabant, 
Netherlands). 
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9.4.7 Statistical analysis 
Data were analyzed with Microsoft Excel 2010. Standard deviations were calculated 
based on the entire population of each group and are shown as error bars. A two-tailed student's 
t-Test with two-sample unequal variances was used to determine the statistical differences 
between two independent populations. If 0.01< P values ≤0.05 differences between two 
populations were considered statistically significant; if P values ≤0.01 differences were 
considered statistically highly significant. 
 
9.5 Results 
9.5.1 Nuclear VP8 is transported to the cytoplasm during the late phase of infection 
VP8 has been found to accumulate in the Golgi apparatus in BoHV-1 infected cells late 
during infection (375). This raised the question whether the previously synthesized nuclear VP8 
or the newly synthesized cytoplasmic VP8 was accumulated in the Golgi. To determine the 
source of Golgi-localized VP8, wild-type VP8 with two different tags (FLAG-VP8 and YFP-
VP8) was expressed in EBTr cells, a bovine cell line that is susceptible to BoHV-1 infection and 
to transient transfection. FLAG-VP8 was first expressed by transient transfection. After 24 h, the 
transfected cells were mock-infected or infected with BoHV-1-YVP8 to express YFP-VP8. 
Transiently expressed FLAG-VP8 localized in the nucleus of mock-infected cells, which did not 
express YFP-VP8, from 28 hpt to 43 hpt (Figure 9.1). In comparison, when the transfected cells 
were infected with BoHV-1-YVP8, YFP-VP8 appeared in the nucleus and colocalized with 
FLAG-VP8 at 4 hpi (Figure 9.1). At 11 hpi YFP-VP8 appeared in the nuclear periphery of the 
cytoplasm, while nuclear YFP-VP8 was reduced. At 19 hpi most of the YFP-VP8 accumulated in 
the perinuclear region of the cytoplasm, while nuclear YFP-VP8 was greatly reduced. Within the 
time frame of infection, transfected FLAG-VP8 was translocated from the nucleus to the 
cytoplasm in a fashion identical to that of YFP-VP8, providing evidenc that nuclear VP8 is 
transported to the Golgi during the infection.  
In transfected EBTr cells, nuclear VP8 accumulated around ring-shaped sub-nuclear 
structures (Figure 9.1). These VP8-induced sub-nuclear rings also appeared in VP8-transfected 
COS-7 cells. To identify these sub-nuclear structures, VP8-transfected COS-7 cells were stained 
with Nile red (Figure 9.2), a compound that is commonly used for the detection of intracellular 
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neutral lipids (378, 379). The interior of the round structures was stained with Nile red, 
indicating they were nuclear lipid droplets (LDs). The LDs appeared at 7 hpt with FLAG-VP8, 
and they gradually grew into larger nuclear LDs at 24 hpt. However, the non-transfected COS-7 
cells did not have LDs. Huh-7 cells that naturally contain LDs (380) were used to indicate the 
efficacy of lipid-staining by Nile red. Numerous LDs of different sizes were observed in the 
cytoplasm of Huh-7 cells. These results indicate that the expression of VP8 caused the nuclear 
LD formation in transfected cells, and VP8 accumulated around the LDs, forming ring-shaped 
structures. 
 
9.5.2 US3 is critical for the cytoplasmic translocation of VP8 during the late stage of BoHV-1 
infection 
To examine the impact of US3 on the cellular localization of VP8, MDBK cells, bovine 
cells that are susceptible to BoHV-1 infection, were infected with wild-type BoHV-1 (Cooper 
and 108), ΔUS3-BoHV-1 (Cooper), and RUS3-BoHV-1 (Cooper). The localization of VP8 was 
observed at 4 and 8 hpi. At 4 hpi VP8 and US3 appeared in the nuclei of cells infected with wild-
type viruses and revertant virus. ΔUS3-BoHV-1 infected cells expressed VP8 but not US3, and 
VP8 was also in the nucleus (Figure 9.3A). There was no noticeable difference between the four 
viruses in the nuclear localization of VP8 early during infection. In wild-type virus-infected cells 
VP8 was translocated to the cytoplasm at 8 hpi, leaving US3 in the nucleus. The two strains of 
wild-type viruses and the revertant virus showed comparable patterns of VP8 localization, and 
the expression of US3 was increased in these cells. However, in ΔUS3-BoHV-1-infected cells 
the majority of VP8 was in the nucleus with punctate appearance, and US3 was not detected 
(Figure 9.3B). VP8 and US3 were not observed in mock-infected cells (Figure 9.3C). The protein 
expression by the four viruses was confirmed by Western Blotting, showing that US3 was 
expressed by all viruses except ΔUS3-BoHV-1, and that VP8 was expressed by all viruses. US3 
of the Cooper strain migrated slightly faster than US3 of the 108 strain (Figure 9.3D). These 
results implicate that US3 activates the nuclear export of VP8 in infected cells at a later stage of 
infection. 
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Figure 9.1 Translocation of VP8 from the nucleus to the cytoplasm in BoHV-1-YVP8-infected 
cells.  
EBTr cells transfected with pFLAG-VP8 were cultured for 24 h before infection. The FLAG-
VP8-expressing cells were then mock-infected or infected with BoHV-1-YVP8 at a MOI of 5. 
Cells were fixed at indicated time points for immunofluorescent staining. FLAG-VP8 was 
detected with monoclonal anti-FLAG antibody followed by Alexa 633-conjugated secondary 
antibody. YFP-VP8 was tracked through the YFP label. The cell nucleus was shown by DAPI 
staining. 
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Figure 9.2 Accumulation of VP8 around nuclear lipid droplets (LDs) in transfected cells.  
COS-7 cells were transfected with pFLAG-VP8 and fixed at 7 and 24 hpt. Control groups 
included the non-transfected COS-7 and Huh-7 cells. VP8 was detected with VP8 specific 
monoclonal antibody followed by Alexa 488-conjugated secondary antibody. Cells were stained 
with Nile red and DAPI. 
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Figure 9.3 Cytoplasmic localization of VP8 at a late stage of BoHV-1 infection requires US3. 
(A-C) MDBK cells were infected with indicated viruses at a MOI of 5 or mock-infected. Cells 
were processed for immunofluorescent staining at 4 and 8 hpi. VP8 was detected with 
monoclonal anti-VP8 antibody followed by Alexa 488-conjugated secondary antibody. US3 was 
identified with polyclonal anti-US3 antibody followed by Alexa 633-conjugated secondary 
antibody. The cell nucleus was indicated by DAPI staining. (D) Virus-infected MDBK cell 
lysates were analysed by Western Blotting. VP8 and US3 were detected with mouse anti-VP8 
and rabbit anti-US3 antibodies, respectively. 
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9.5.3  Phosphorylation by US3 activates the nuclear export of VP8 
Since US3 was required for the cytoplasmic transport of VP8, it was possible that the 
kinase activity of US3 regulates translocation of VP8. To confirm this, the impact of US3 on the 
cellular translocation of wild-type VP8 and a mutated VP8 (VP8-S16A) was compared in 
transfected cells (Figure 9.4). Previously we reported that US3-mediated phosphorylation in 
VP8-S16A is abolished by substituting the essential residue S
16
 with an A (290). In the absence 
of US3, wild-type VP8 and VP8-S16A were localized in the nucleus (Figure 9.4A, panel 1 and 
3). When US3 was expressed, wild-type VP8 was distributed throughout the cell, whereas VP8-
S16A was localized in the nucleus (Figure 9.4A panels 2 and 4), demonstrating that 
phosphorylation by US3 is critical for the nuclear export of VP8. 
The relative quantities of cytoplasmic and nuclear VP8 were measured based on the 
intensity of green fluorescence pixels within the confocal microscopy pictures of above cells. 
Wild-type VP8 in the cytoplasm was significantly increased in US3-expressing cells when 
compared with cells without US3 (Figure 9.4B). When the phosphorylation site of VP8 was 
mutated, US3 was not capable of increasing the quantity of cytoplasmic VP8 (Figure 9.4B). 
These results implicated a critical role of phosphorylation by US3 in the transport of VP8 to the 
cytoplasm.  
In US3 and wild-type VP8 co-transfected cells, VP8 was dispersed in the cytoplasm 
(Figure 9.4A), which was different from the juxtanuclear aggregation of VP8 shown at the late 
phase of BoHV-1 infection (Figure 9.3B). This observation suggests that the Golgi-accumulation 
of VP8 is due to a second transport following nuclear export of VP8, and not dependent on US3-
mediated phosphorylation. The cytoplasmic VP8 might require an unidentified viral protein or 
stimulus to target the Golgi. 
To demonstrate that the nuclear export of VP8 might be enhanced with increasing 
amounts of US3, FLAG-VP8 was first transfected into EBTr cells and US3-HA was 
subsequently transfected at different time points into the cells expressing FLAG-VP8. At 0 hpt, 
before transfection with US3-HA, the average readout at the 633 nm channel was 6.9 PDU, thus 
this level was considered as the baseline for US3 expression. The fluorescent pixels below this 
baseline were considered as background signals. The results show that from 0 hpt to 15 hpt with 
pUS3-HA, the intensity of nuclear US3 increased to about 130 PDU. With the increase of US3, 
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cytoplasmic VP8 gradually increased from 20 DPU to 120 DPU, while the intensity of nuclear 
VP8 did not significantly change (Figure 9.5), confirming that US3 activated cytoplasmic 
transport of VP8. 
 
9.5.4 NLSs and US3 phosphorylation sites of VP8 are adjacent and conserved 
In the amino acid sequences of VP8 from strains 108 and Cooper, NLSs (155, 156) and 
US3-phosphorylated residues (290) were closely localized in the extreme N-terminus of VP8 
(Figure 9.6). NLS1 was immediately followed by a phosphorylated residue S
16
. In between of 
NLS1 and NLS2 is the second phosphorylation site at S
32
. Together with the results that 
phosphorylation by US3 activated cytoplasmic localization of VP8 (Figure 9.4 and 9.5), this 
suggests that US3-mediated phosphorylation might interfere with the activity of the NLSs. 
Moreover, multi-way protein alignment showed that the two US3 phosphorylation residues and 
NLS2 were conserved among two strains of BoHV-1 viruses. NLS1 was partially conserved with 
two-amino-acid variation in the Cooper strain comparing with the strain 108. This indicates that 
phosphorylation-regulated activity of the NLS might be conserved among these strains. 
 
9.5.5 Phosphorylation by CK2 does not alter the nuclear localization of VP8 
In addition to US3, VP8 is also phosphorylated by CK2 (290). To determine whether 
phosphorylation by CK2 regulates the nuclear localization of VP8, the cellular localization of 
VP8-M65-107, which was not phosphorylated by CK2 (290), was compared with that of wild-
type VP8 in EBTr cells (Figure 9.7). Previously, VP8-M65-107 was modified from wild-type 
VP8 by introducing site-directed mutations at critical residues (T
65
, S
66
, S
79
, S
80
, S
82
, S
88
, and 
T
107
) for CK2-mediated phosphorylation (290). Wild-type VP8 and VP8-M65-107 localized in 
the nucleus of transfected cells (Figure 9.7), implicating that blocking CK2-mediated 
phosphorylation did not change the nuclear localization of VP8. 
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Figure 9.4 US3-mediated phosphorylation promotes the cytoplasmic localization of VP8.  
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(A) EBTr cells were transfected with different (combinations of) plasmids. Cells in panel 1 were 
transfected with pFLAG-VP8. Cells in panel 2 were co-transfected with pFLAG-VP8 and pUS3-
HA. Cells in panel 3 were transfected with pFLAG-VP8-S16A. Cells in panel 4 were co-
transfected with pFLAG-VP8-S16A and pUS3-HA. VP8 was identified with monoclonal anti-
VP8 antibody followed by Alexa 488-conjugated secondary antibody, and US3 was identified 
with polyclonal anti-US3 antibody followed by Alexa 633-conjugated secondary antibody. (B) 
Relative quantification of the cytoplasmic and the nuclear VP8. Software Leica Application 
Suite X (version 3.0.2) was used to analyze confocal pictures. The intensity of VP8 was 
represented as the fluorescence pixels at a wavelength of 488 nm. The mean values of PDU are 
shown in the bar graphs. Error bars represent the standard deviations. The statistical significance 
is shown as follows: **, P≤ 0.01. 
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Figure 9.5 The amount of cytoplasmic FLAG-VP8 increases with the expression level of US3-HA.  
(A) The intensities of cytoplasmic and nuclear VP8. EBTr cells were transfected with pFLAG-
VP8 and incubated for 12 h. This allowed VP8 to be expressed and localized to the nucleus. 
Subsequently, cells were transfected with pUS3-HA at 12 hpi, 17 hpi, or 22 hpi after transfection 
with pFLAG-VP8. All samples were fixed at 27 h for immunofluorescent staining, and the cell 
images were analyzed with software Leica Application Suite X for protein quantification. 
Intensity of fluorescence pixels at wavelength of 488 nm was captured to indicate the quantity of 
VP8. The mean values of PDU are shown in the bar graphs. Error bars represent the standard 
deviations (B) The intensity of US3 in the nucleus. Intensity of fluorescence pixels at a 
wavelength of 633 nm was captured to indicate the quantity of US3. The statistical significance 
is shown as follows: *, 0.01 < P ≤ 0.05; **, P ≤ 0.01. 
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Figure 9.6 Nuclear localization signals (NLSs) and US3-phosphorylated residues in partial 
sequences of VP8.  
Protein sequences of VP8 from strains 108 and Cooper were obtained from a protein bank, 
UniProKB (http://www.uniprot.org/). NLS1 and NLS2 are underlined. US3-phosphorylated 
residues are labeled with “*”. Multi-way protein alignment was performed using a program, 
Clone Manager (381). Gray color indicates conserved regions and white color indicates 
mutations or deletions. 
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Figure 9.7 Phosphorylation through CK2 does not change the nuclear localization of VP8.  
EBTr cells transfected with pFLAG-VP8 or pFLAG-VP8-M65-107 were fixed for 
immunofluorescent staining. VP8 proteins were labeled with polyclonal anti-VP8 antibody 
followed by Alexa 488-conjugated secondary antibody. The cell nucleus was stained with DAPI. 
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9.5.6 Nuclear export of VP8 is sensitive to leptomycin B (LMB) 
To determine whether the nuclear export of VP8 during BoHV-1 infection is dependent 
on CRM1, a CRM1-specific inhibitor, leptomycin B (LMB), was used to treat BoHV-1 infected 
MDBK cells. Wild-type BoHV-1 infected cells were cultured with or without LMB (Figure 9.8). 
At 4 hpi VP8 was in the nucleus, while at 6 hpi the distribution of VP8 was different between the 
two treatments. VP8 formed perinuclear aggregates in the cell cytoplasm without LMB. In 
contrast, in LMB-treated cells VP8 remained in the nucleus and did not accumulate in the 
cytoplasm. When cells were cultured till 8 hpi without LMB the majority of the cells showed 
cytoplasmic accumulation of VP8, whereas cells with LMB displayed occasional cytoplasmic 
accumulation of VP8. These results showed that the nuclear export of VP8 was delayed by the 
CRM1-specific inhibitor, but not completely inhibited. 
 
9.5.7 VP8 is co-localized with cis-Golgi cisternae proteins 
The location of the Golgi cisternae was determined with antibodies specific for with two 
Golgi proteins, FTCD and GOLGB1. FTCD has been found to associate with the Golgi 
membranes of the cis- and medial-cisternae (382-384), and is involved in the conversion of L-
histidine to L-glutamate (384, 385). GOLGB1 is a transmembrane Golgi protein (386) that 
mainly associates to the Golgi apparatus (387) with preference to the cis-Golgi (388). In mock-
infected MDBK cells, FTCD and GOLBG1 showed almost identical localization in the Golgi 
area (Figure 9.9, top panel). This was consistent with previous findings that both proteins were in 
the cis-cisternae and the stacks of the Golgi (382-384, 387, 388). Thus, GOLGB1 was used as a 
marker protein to indicate the cis-Golgi and the Golgi stacks in BoHV-1 infected MDBK cells 
(Figure 9.9, lower panels). At 6 h 40 min post infection, VP8 appeared in the cytoplasm but most 
VP8 was localized in areas different from GOLGB1. At 7 h 20 min post infection, the majority 
of VP8 was co-localized with GOLGB1 in the cytoplasm. The co-localization of VP8 and 
GOLGB1 persisted till 8 h of infection. 
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Figure 9.8 The nuclear export of VP8 is sensitive to leptomycin B (LMB). MDBK cells were 
infected with BoHV-1. 
Culture medium supplemented with or without LMB (20 nM) was applied to cells at 1 hpi. 
Medium with or without LMB was renewed every 2 h. Cells were fixed at 4, 6, and 8 hpi, and 
stained with monoclonal anti-VP8 antibody followed by Alexa 488-conjugated secondary 
antibody. The cell nuclei were indicated by DAPI staining. 
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Figure 9.9 Co-localization of VP8 and a cis-Golgi protein. 
MDBK cells mock-infected or infected with wild-type BoHV-1 (108 strain) were fixed for 
immunofluorescent staining. Mock-infected cells shown in the top panel were identified with 
mouse anti-FTCD and rabbit anti-GOLGB1 antibodies. BoHV-1-infected cells in the lower three 
panels were identified with mouse anti-VP8 and rabbit anti-GOLGB1 antibodies. Secondary 
antibodies were Alexa 488-conjugated goat anti-mouse IgG and Alexa 633-conjugated goat anti-
rabbit IgG. The cell nucleus was stained with DAPI. The cells were observed under a confocal 
microscope. Selected areas of the pictures in the first row were zoomed in and shown on the right 
side. 
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During BoHV-1 infection, the Golgi apparatus went through obvious morphological 
changes. The cis-Golgi and the Golgi stacks illustrated with GOLGB1 were reshaped as capsule-
like structures. VP8 gradually accumulated towards these structures. However, in mock-infected 
cells, the Golgi structures labeled with FTCD and GOLGB1 were multilayer sheets closely 
adjacent to the cell nucleus (Figure 9.9). 
 
9.5.8 VP8 is not in the trans-Golgi network 
To determine whether VP8 was associated with the trans-Golgi network (TGN), BFA 
was used to distinguish the TGN from the cis- and medial-Golgi. It is known that BFA causes 
redistribution of membranes and proteins of the Golgi cisternae, while the TGN responds 
differently to this compound (389-391). To confirm this effect, FTCD and GOLGB1 were used 
to demonstrate the Golgi cisternae, including the cis-Golgi network. TGOLN2, a protein that 
associates with the TGN to participate in the transport between the TGN and the cell surface 
(392), was used to indicate the TGN. The experiment was performed in Hela cells, a commonly 
used human cell line, because the antibody against TGOLN2 is of human origin and does not 
cross interact with bovine lines. In non-treated Hela cells, FTCD and TGOLN2 formed clear 
juxtanuclear aggregates (Figure 9.10). In BFA-treated cells, FTCD was scattered at 2 h of 
treatment, whereas TGOLN2 aggregations were reshaped but not dispersed. With BFA the 
TGOLN2 aggregates persisted till 8 h post treatment. Moreover, in cells that were co-stained 
with antibodies against FTCD and GOLGB1, the two cis-Golgi proteins were scattered by BFA 
at 2 h, confirming that the cis- and medial-Golgi but not the TGN was redistributed by BFA. 
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Figure 9.10 Brefeldin A (BFA) disperses the cis-Golgi proteins but not the trans-Golgi network 
(TGN) protein. 
Hela cells were treated with BFA or DMSO. The BFA was renewed every 2 h. Cis-Golgi 
proteins FTCD and GOLGB1 were detected with mouse anti-FTCD and rabbit anti-GOLGB1 
antibodies. TGN protein TGOLN2 was detected with rabbit anti-TGOLN2 antibody. Alexa 488-
conjugated goat anti-mouse IgG and Alexa 633-conjugated goat anti-rabbit IgG were used as 
secondary antibodies. The cellular DNA was stained with DAPI. 
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BoHV-1-infected cells were treated with BFA to determine its impact on VP8 
distribution. MDBK cells were infected with BoHV-1 followed by BFA treatment at 1 hpi. In the 
presence of BFA, nuclear VP8 appeared at 4 hpi. From 4 to 8 hpi the infected cells contained 
increasing amounts of cytoplasmic and nuclear VP8 with diffused distribution (Figure 9.11A). In 
the DMSO-treated cells, cytoplasmic VP8 gradually accumulated in the juxtanuclear areas from 
6 to 8 hpi. The cytoplasmic distribution of VP8 in DMSO-treated cells was profoundly different 
from that of VP8 in BFA-treated cells. A comparable impact of BFA on the Golgi-localization of 
VP8 was observed in EBTr cells (data not shown). To observe the dispersal of Golgi-localized 
VP8, MDBK cells infected with BoHV-1-YVP8 were treated with BFA at 7 hpi when VP8 
accumulated in the Golgi apparatus. The cells were observed with life-cell imaging confocal 
microscopy at 7 hpi for 30 min. Five minutes after BFA was applied, the amount of Golgi-
localized YFP-VP8 started to decrease. The cytoplasmic VP8 aggregates were dispersed within 
30 min of BFA treatment. 
 
9.5.9 BoHV-1 virions are wrapped with electron-dense material within vesicles near the Golgi 
stacks 
The Golgi apparatus of BoHV-1-infected MDBK cells were observed with transmission 
electron microscopy. At 15 hpi, numerous viral capsids were accumulated near the Golgi stacks 
(Figure 9.12A, B). Many were enclosed within vesicles. The capsids inside the vesicles were 
coated with a thick electron-dense layer, but the capsids outside the vesicles did not have this 
layer. Figure 9.12C shows that the membrane of a virus-containing vesicle was connected to the 
membrane of the Golgi cisternae, indicating that the Golgi apparatus might develop these 
vesicles to envelop virus. This is in agreement with the observations in Figure 9.9 that the Golgi 
was enlarged in BoHV-1 infected cells. 
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Figure 9.11 The Golgi accumulation of VP8 is sensitive to brefeldin A (BFA).  
(A) MDBK cells infected with BoHV-1 were treated with BFA or DMSO at 1 hpi. Cells were 
fixed and stained with monoclonal anti-VP8 antibody followed by Alexa 488-conjugated 
secondary antibody. The cell nuclei were stained with DAPI. (B) MDBK cells infected with 
BoHV-1-YVP8 were treated with BFA at 7 hpi. The imaging of life cells showing YFP-VP8 was 
performed from 7 hpi for 30 min.  
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Figure 9.12 Transmission electron microscopy of BoHV-1-infected cells. 
(A, B) BoHV-1 viral particles are located near the Golgi apparatus. (C) A viral particle is 
enveloped by membrane extended from the Golgi apparatus.  MDBK cells infected with BoHV-1 
(108 strain) at a MOI of 1 were harvested at 15 hpi, and observed with a Philips CM10 
transmission electron microscope (Bar = 200 nm). Solid black arrow heads indicate the Golgi 
stacks; Solid black arrows indicate capsids wrapped with electron-dense materials and 
membranes. Hollow arrows indicate unwrapped capsids. 
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9.6 Discussion 
In this study US3-mediated phosphorylation was found to activate the nuclear export of 
VP8 during BoHV-1 infection, suggesting that the modification status of VP8 is altered when it 
moves from the nucleus to the cytoplasm and, ultimately, from the Golgi into the mature virus. 
VP8 contains two functional NLSs on the extreme N-terminus (72) leading the protein to 
translocate into the nucleus early during infection. The cellular kinase CK2 is universally 
expressed in almost every subcellular structure; therefore, it might be available to phosphorylate 
VP8 inside or outside of the nucleus. However, the nuclear localization of VP8 did not require 
and was not affected by CK2-mediated phosphorylation (Figure 9.7). This implicates that early 
during infection, VP8 is effectively transported into the nucleus to promote early events of virus 
replication, for instance viral DNA encapsidation (375), and to redistribute ND10 (290). To 
perform these nuclear functions VP8 requires phosphorylation (375). Additionally, the nuclear 
VP8 appears to cause abnormal lipid metabolism in cells. Nuclear LDs were formed in VP8-
transfected EBTr cells and COS-7 cells (Figures 9.1 and 7.2). This ability was unique to VP8 
because nuclear LDs were not found in US3-transfected and YFP-transfected cells (data not 
shown). This indicates VP8 may alter the lipid metabolism of host cells to supply lipid for viral 
replication. Such peculiar lipid accumulation has been reported in human herpesvirus-8 (HHV-8) 
-infected cells during the lytic phase of infection (393). HHV-8 infection increases the cellular 
triglycerides that are stored in the cytoplasmic LDs. This has been suggested to be related to the 
abnormal viral requirements for lipids (393). During BoHV-1 infection, VP8 may change the 
cellular lipid metabolism. 
Nuclear VP8 is transported to the cytoplasm at later stages of infection (Figure 9.1). The 
results of Figures 9.3 and 7.4 implicate that US3-mediated phosphorylation activates the nuclear 
export of VP8, as the majority of VP8 was in the nucleus of transfected cells if US3 was not 
expressed. Cytoplasmic VP8 gradually increased with the progression of US3 expression. 
However, the intensity of nuclear VP8 did not decrease with the increase of cytoplasmic VP8 
(Figures 9.4B and 9.5). The reason might be that VP8 was constantly synthesized and imported 
into the nuclei of transfected cells. 
During BoHV-1 infection, a regulatory system might exist to balance the activities of 
NLSs and NESs at the right time. Early during infection, VP8 is transported into the nucleus 
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suggesting that the NLSs are active and possibly are more efficient than the NESs. To move to 
and remain in the cytoplasm later during infection, VP8 would need to have inactive NLSs or 
NESs that are more effective than the NLSs. Since US3-mediated phosphorylation is essential 
for the cytoplasmic localization of VP8, US3 appears to be involved in regulating the balance 
between NLSs and NESs. Evidence supporting this is found in the amino acid sequence of VP8. 
US3-phosphorylated residues (S
16
 and S
32
) and the NLSs (P
11
RPRR
15
, and R
48
PRVRRPRP
54
) are 
closely located in the same region of VP8 (Figure 9.6). Thus, the NLSs might be active to guide 
VP8 into the nucleus when VP8 is not phosphorylated by US3 at early times of infection. When 
the nuclear VP8 is phosphorylated by US3 the addition of phosphoryl groups on S
16
 and S
32
 may 
mask the binding activity of the NLSs, resulting in VP8 leaving the nucleus. In addition to 
inactivation of the NLSs, the nuclear export of VP8 also requires functional NESs. The NESs of 
VP8 might be constantly active and not impaired by US3-mediated phosphorylation. This would 
be in agreement with previous findings that VP8 within a transfected cell nucleus is transported 
to the non-transfected nucleus in an interspecies cell fusion assay (155, 156). When US3 is 
expressed in a cell, the NLSs are inactivated and the function of the NESs possibly will become 
predominant, leading to the nuclear export of VP8. The possibility remains that, in properly 
folded VP8, NESs could be affected or activated by US3-mediated phosphorylation. Because of 
the lack of a tertiary structure of VP8 it is difficult to have direct evidence. However, previous 
research has found that VP8 is exported from one nucleus and enters another in a fused cell in 
the absence of US3 (155), indicating the activity of VP8 NESs may not require US3. In addition, 
VP8 with NLSs deletion localizes in the cytoplasm (144, 155), supporting that inactivating NLSs 
by deleting the motifs or by masking the sequence through phosphorylation may result in VP8 
localizing in the cytoplasm.  
There are variations in the sequences of VP8 amongst different strains (Figure 9.6) and 
the electrophoretic mobility of US3 of the Cooper strain was higher than that of the 108 strain 
(Figure 9.3D). However, because the US3 target sites and NLS motifs in VP8 are conserved, this 
US3-regulated cellular localization of VP8 is likely to be conserved among the tested strains of 
BoHV-1. Consistently, the patterns of nuclear-cytoplasmic translocation of VP8 were identical in 
strains 108 and Cooper (Figure 9.3A and B). 
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When VP8 finishes its tasks in the nucleus, it is transported into the cytoplasm (Figure 
9.1). This might be a recycling process of VP8 from the nucleus to the cytoplasm so as to 
effectively use the protein and/or allow virion incorporation. The types of NESs in VP8 have 
been explored in several studies. A leucine-rich peptide L
485
SAYLTLFVAL
495
 (NES1) of VP8 is 
a classic CRM1-dependent signal, the activity of which is sensitive to LMB (144, 155, 156). 
Another NES that is CRM1-independent exists in the region between residue 95 and 123 (NES2) 
(156). LMB treatment delayed nuclear export of this protein during BoHV-1 infection (Figure 
9.8), which might be due to inhibition of NES1 by LMB. However, LMB did not completely 
block the cytoplasmic localization of VP8, which is consistent with the characteristic of NES2. 
During the late phase of infection, both NESs might be functional to ensure the nuclear export of 
VP8. 
After leaving the nucleus, VP8 continues to the Golgi apparatus. The results from Figure 
9.9 demonstrate that the cytoplasmic VP8 gradually migrated towards the Golgi and co-localized 
with cis-Golgi protein. Although the nuclear export of VP8 required US3-mediated 
phosphorylation, the subsequent Golgi-localization is not directly related to US3 (Figure 9.4). 
VP8 needs further modifications by or interactions with other viral factors in the cytoplasm to 
accumulate in the Golgi. 
The Golgi apparatus is an important site for cytoplasmic maturation of herpesviruses. 
This organelle is composed of several continuous compartments, including cis-Golgi network 
(CGN), cis-, medial-, trans-cisternae, and TGN (394). They play different, yet related, roles in 
protein sorting, modification, transport, and secretion (395, 396). Therefore, determining the 
localization of VP8 in the Golgi compartments will reveal a potential function of the Golgi-
localized VP8. We demonstrated co-localization of VP8 and cis-Golgi marker protein, proving 
that VP8 might be translocated to the cis-Golgi. We next tested whether VP8 was also localized 
in the TGN. BFA is a fungal antibiotic that causes rapid and dramatic disorganization of the 
cisternal Golgi in mammalian cells by redistributing the membrane and enzymes from the Golgi 
cisternae to the endoplasmic reticulum (ER) (389, 391). However, the response of TGN to BFA 
is dissimilar to that of the Golgi cisternae (391). This was confirmed in Hela cells in which the 
TGN protein TGOLN2 aggregated the juxtanuclear space when cultured with BFA, whereas the 
cis-Golgi protein FTCD was dispersed (Figure 9.10). BFA blocked the Golgi-localization of VP8 
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(Figure 9.11A) and disrupted the Golgi-localized VP8 (Figure 9.11B). A similar result was found 
in the cis-Golgi protein FTCD, but not in the TGN protein TGOLN2, indicating VP8 may be 
associated with the cisternal Golgi rather than the TGN. 
Herpesvirus particles obtain their envelopes and are delivered towards the cell membrane 
through the TGN (397, 398). It is unlikely that VP8 is involved in the process of envelopment or 
viral egress. The major purpose of VP8 targeting to the Golgi apparatus might be packaging into 
virus to be released into newly infected cells to initiate the next viral life cycle. The electron 
microscopy results showed that many vesicles were formed near the Golgi stacks and some 
vesicle membrane was connected with Golgi stacks. Viral capsids were wrapped with electron-
dense materials within these vesicles, possibly to obtain a tegument layer. Similarly, in the 
immunofluorescently stained cells the Golgi cisternae became small cystic structures containing 
VP8 during BoHV-1 infection (Figure 9.9). These findings support the hypothesis that VP8 is 
incorporated into BoHV-1 particles in these Golgi vesicles. 
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CHAPTER 10 
 
10 GENERAL CONCLUSIONS AND DISCUSSION 
10.1 General conclusions 
Early during infection of BoHV-1, VP8 localizes in the cell nucleus and is 
phosphorylated by a cellular kinase CK2. CK2 phosphorylates VP8 at multiple residues, 
including T
65
, S
66
, S
79
, S
80
, S
82
, S
88
, T
107
, S
137
, S
221
, S
240
, and S
679
. The N-terminal residues (T
65
, 
S
66
, S
79
, S
80
, S
82
, S
88
, T
107
) are essential for VP8 phosphorylation mediated by CK2. This 
phosphorylation does not change the cellular localization of VP8. CK2-phosphorylated VP8 
redistributes PML foci in VP8-transfected cells, suggesting a role of VP8 in PML-related 
antiviral defences. Moreover, CK2-phosphorylated VP8 promotes viral DNA encapsidation in 
BoHV-1-infected cell nucleus. However, blocking phosphorylation of VP8 does not abolish the 
egress of BoHV-1. BoHV-1-YmVP8 virions with and without DNA cores are released into 
extracellular environment. Before or during the nuclear egress of BoHV-1, the virus incorporates 
a small amount of VP8.  
At late stages of BoHV-1 infection, nuclear VP8 is phosphorylated by US3 at two 
residues, S
16
 and S
32
. Phosphorylation at S
16
 is essential for the subsequent phosphorylation at 
S
32
. When nuclear VP8 is phosphorylated by US3, it is exported into the cytoplasm. 
Phosphorylation at S
16
 and S
32
 may inhibit the activity of NLSs, and thus affect the cellular 
localization of VP8. In the cytoplasm VP8 may be modified by or interact with other viral factors 
to accumulate in the cis-Golgi, but not in the TGN. VP8 is then abundantly incorporated into the 
virus in the Golgi apparatus. When the mature virus is released into the extracellular 
environment, VP8 that is incorporated on the virus is not phosphorylated, suggesting that a de-
phosphorylation process takes place during and/or after the incorporation of VP8 into BoHV-1 
virus. In addition, VP8 causes lipid accumulation in the nucleus of VP8-transfected cells, 
forming nuclear LDs, indicating that VP8 may alter cellular lipid metabolisms to supply lipid for 
viral replication. 
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10.2 General discussion 
VP8 is in a phosphorylated form in BoHV-1-infected cells but not in BoHV-1 virions, 
implicating that phosphorylation regulates the functions of VP8 in infected cells and that a 
mechanism for dephosphorylating VP8 is needed. Having confirmed that VP8 is phosphorylated 
through a viral kinase US3 and a cellular kinase CK2 during BoHV-1 infection, we identified the 
critical residues for phosphorylation in VP8, aiming to block phosphorylation of VP8 and to 
identify the functional significance of this modification. 
US3 and CK2 phosphorylate VP8 by recognizing distinct motifs (15). VP8 has two 
functional consensus sequences for US3 (R
14
RSGT
18
 and R
30
RSLL
34
). Phosphorylation at S
16
, 
the primary target residue, is essential for the subsequent phosphorylation at S
32
. Phosphorylation 
of VP8 mediated by CK2 is more complicated than by US3. CK2 phosphorylates multiple 
residues of VP8. A cluster of N-terminal motifs for CK2 is critical for phosphorylation at other 
sites in VP8. This suggests that CK2 may phosphorylate VP8 in a sequential manner. CK2 
initially phosphorylates VP8 in the N-terminal region, and subsequently in the middle and the C-
terminal regions. CK2 has different preferences towards the target residues, T
107
 being the most 
frequently phosphorylated site. Coordinated phosphorylation of multiple residues in a single 
protein is described in other kinases. For instance, phosphorylation of phospholamban (PLB) at 
S
16
 by PKA is obligatory to phosphorylation at T
17
 by calmodulin-dependent kinase 2 (CAMK2) 
(399). The conformational changes caused by primary phosphorylation are required for 
activating the subsequent phosphorylation (400). Such phosphorylation pattern might also apply 
to US3- and CK2-mediated phosphorylation in VP8. 
VP8 is in the cell nucleus early during infection with BoHV-1. VP8 does not need to be 
phosphorylated to translocate into the nucleus. However, it requires phosphorylation to perform 
certain nuclear functions. Phosphorylated VP8 promotes the viral genome to be incorporated into 
capsids in the nucleus. When cells are infected with a mutant virus expressing non-
phosphorylated VP8, viral DNA encapsidation is less efficient in comparison with wild-type 
virus. Although the non-phosphorylated VP8 also localizes in the nucleus, it has a reduced 
capacity to promote the packaging of the viral genome. A model for genome encapsidation has 
been suggested for HHV-1, which requires cleavage of the concatemeric replicated viral genome 
prior to incorporation into capsids (87, 88), and stabilization of the DNA-contained capsids to 
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retain the viral genome (7). Although the actual mechanism of cleaving the genome concatemer 
has yet to be described, some viral proteins has been found to play roles in this process. The 
alkaline nuclease UL12 might be one of the enzymes that cleave the viral DNA concatemer, 
because an in vitro study has found that UL12 digests HHV-1 DNA replication intermediates into 
heterogeneous fragments in size from 10 to 50 kb (87). UL12 specifically targets the cleavage 
sites through recognizing special DNA structural modifications instead of particular sequences 
(87). Deleting UL12 severely reduces the virus production of HHV-1(401). UL12.5 is a capsid-
associated nuclease translated from an internal start codon of the ul12 gene (88). UL12.5 may 
contribute to processing the viral genomes by its nuclease activity when they are incorporated 
into capsids (88). Although the actual role of UL12.5 has yet to be identified, it cannot substitute 
the biochemical functions of UL12, and vice versa (88). The cleaved viral DNA is inserted 
through a portal into a capsid shell (89). This insertion process requires collaboration between 
several viral proteins (6, 7, 90, 91) and recognition of two unique signal elements in the viral 
genome (85, 86). In order to retain the incorporated DNA, capsids are further stabilized by viral 
proteins UL17 and UL25 (7). It is possible that BoHV-1 uses a DNA encapsidation strategy 
similar to HHV-1 because some HHV-1 proteins are conserved in other alphaherpesviruses. For 
example, UL12 has the similar nuclease activity in HHV-1 and HHV-5 (87). Capsid portal 
protein UL6 and DNA stabilizing protein UL25 are conserved between HHV-1 and BoHV-1 (68). 
More proteins contributing to DNA encapsidation are yet to be identified. The finding that VP8 
is required for the optimal incorporation of the BoHV-1 genome suggests that the protein may 
play a role in the DNA encapsidation. 
Nuclear localization of VP8 does not require the protein to be phosphorylated by CK2 or 
US3, and is not blocked by CK2-dependent phosphorylation, providing VP8 the opportunity to 
efficiently enter the cell nucleus. Nuclear VP8 modulates cellular factors presumably to create a 
suitable environment for BoHV-1 infection. Transfected VP8 disturbs the balance of cellular 
lipid metabolism, causing lipid to accumulate in the cell nucleus. It is known that infection with 
herpesvirus, such as HHV-5 and HHV-8, causes disorders of the cellular lipid metabolism (402, 
403), (393, 404). The cellular cholesterol is significantly increased in HHV-5-infected cells when 
compared to mock-infected cells (402). Given the fact that virus delivery (405) and envelopment 
(402) are all dependent on cellular lipids, there is a high demand for lipid in productively 
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infected cells. VP8 causes lipid accumulation in host cells, presumably to supply lipid for viral 
production. When VP8 is accumulated in the nucleus of a transfected cell, LDs are gradually 
developed in the nucleus. VP8 intensely coats to the surface of the LDs forming bright ring-like 
structures. The development of nuclear LDs is not restricted by abolishing phosphorylation of 
VP8 indicating that the regulation of the lipid metabolism does not require phosphorylation. 
 Another cellular factor affected by VP8 is PML foci. PML of ND10s forms punctuated 
nuclear foci in a non-mitotic cell (250). The normal distributing pattern of PML is interrupted by 
phosphorylated VP8 in transiently transfected cells. Punctate PML foci are replaced with larger 
PML aggregates on the surface of LDs, where VP8 is accumulated. When BoHV-1 enters host 
cells, the virus releases many tegument proteins that are important for initiating viral replication. 
VP8 is dissociated from incoming viruses and has the potential to redistribute PML. Although 
VP8 does not directly degrade PML, it might interrupt the anti-viral function of PML by 
redistributing it. According to studies on adenovirus 5, viral protein E4ORF3 causes PML and 
SP100 foci to form strips that are separated from viral DNA replication compartments in order 
for the viral DNA to effectively replicate (406-408). This suggests that the antiviral function of 
ND10 can be affected by redistributing the protein components of ND10. In the initial stages of 
BoHV-1 infection, the incoming viral DNA might be restricted by ND10 in the nucleus, in a 
pattern similar to that of other alphaherpesviruses (306). Before degradation of SUMOylated 
PML by ICP0 synthesized at the immediate early stage (298), incoming VP8 might repress the 
antiviral activity of PML by redistributing PML. Evidence that the virus uses tegument proteins 
to interfere with ND10 antiviral functions has been described for HHV-5 infection. Tegument 
protein pp71 disrupts the ATRX-DAXX complex in ND10 to increase the expression of 
immediately early proteins (242, 329). This process is facilitated by another tegument protein 
UL35 which redistributes ND10 (235, 236). Implicated by the fact that the pattern of PML 
redistributed by VP8 is similar to the pattern of ND10 formed by UL35 (236), VP8 might 
perform a comparable function as UL35 to interrupt ND10 at the initial stage of BoHV-1 
infection. 
At late stages of BoHV-1 infection, VP8 is transported from the nucleus to the cytoplasm 
(25, 154). Phosphorylation by US3 is necessary and sufficient to activate the nuclear export of 
VP8. When VP8 is co-expressed with US3 it appears in the cytoplasm; whilst when US3 is 
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deleted in BoHV-1 the nuclear VP8 is not transported in to the cytoplasm of cells infected with 
this virus. The nuclear export of VP8 is also abolished by mutating the essential residue (S
16
) for 
US3-mediated phosphorylation, confirming that the nuclear export of VP8 requires the protein to 
be phosphorylated by US3. 
The US3-regulated localization of VP8 is explained by the adjacent locations of US3-
target residues and NLSs in the extreme N-terminus of VP8. Phosphorylation at S
16
 and S
32
 may 
inactivate the nearby NLSs by occupying the space for protein binding. When the NLSs are 
masked by the nearby phosphoryl groups, the effect of NESs might be revealed, and VP8 is 
consequently exported from the nucleus into the cytoplasm. It is less likely that NES is activated 
by US3 for at least two reasons. First, US3 motifs are not close to any of the identified NESs, 
and the NESs are independent of each other (155, 156). Second, NESs might be active when 
US3 is absent. Previous research on NESs in VP8 has been performed in transiently transfected 
cells that do not have US3 (155, 156). The results have shown that VP8 is able to be exported 
from one cell nucleus and subsequently enter into another cell nucleus (155, 156). 
Protein phosphorylation not only inactivates the nuclear localization of a substrate. In 
some situations, phosphorylation works in an opposite way. For instance, in HHV-1 infection, 
US3 promotes the nuclear localization of VP13/14 by phosphorylating the protein (143). 
VP13/14 contains a NLS and thus it predominantly localizes in the nuclei of HHV-1-infected 
cells. US3-phosphorylated VP13/14 is mainly localized in the nucleoplasm, while the non-
phosphorylated VP13/14 is mostly accumulated at the nuclear membrane (142). The reason 
might be that the NLS of VP13/14 is enhanced by phosphorylation at a nearby residue mediated 
through US3 (142). 
US3 may not contribute to the nuclear function of VP8 because US3-phosphorylated VP8 
is exported to the cytoplasm and is unavailable to regulate nuclear events. However, CK2 might 
play a key role in regulating the nuclear activities of VP8 since CK2 phosphorylation does not 
disturb the nuclear localization of VP8. As a universally distributed cellular kinase CK2 is 
available to phosphorylate VP8 without changing its cellular localization as soon as VP8 enters 
or is synthesized in a cell. 
In the cytoplasm VP8 is accumulated in the Golgi apparatus. The Golgi accumulation of 
VP8 is not directly regulated by US3, supported by the findings that VP8 is not in the Golgi of 
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cells co-expressing US3 and VP8. However, it only takes place in the context of BoHV-1 
infection, suggesting that a virus-related modification or protein interaction is required for 
cytoplasmic VP8 to target the Golgi apparatus. VP8 is mainly in the cis-Golgi and does not 
spread to the TGN. Given the fact that the TGN is resistant and the cis-Golgi is sensitive to a 
Golgi-redistributing drug, BFA (391), the response of Golgi-localized VP8 to BFA would reflect 
the localization of VP8 in the Golgi compartments. Golgi-localized VP8 was quickly dispersed 
by BFA, which is a common reaction of cis-Golgi proteins (391). VP8 is less likely to participate 
in viral envelopment and transport that mainly take places in the TGN. Instead, VP8 uses the cis-
Golgi as the major site to be incorporated into progeny virus. When cytoplasmic translocation of 
VP8 is blocked by mutating phosphorylation sites VP8 is not able to localize to the Golgi, thus 
virus-incorporated VP8 is considerably reduced. The small amount of virus-associated VP8 
implies that the incorporation of VP8 may also take place before or during the viral capsids 
egress from the nucleus. Packaging large amounts of VP8 into virions may have significance in 
remodeling PML during the next round of infection. 
Overall, this research demonstrated that, in the life cycle of BoHV-1, VP8 performs 
several major functions that are correlated with its subcellular localization and are regulated by 
phosphorylation (Figure 10.1). During a productive infection of BoHV-1, a large amount of VP8 
is synthesized in infected cells. The de novo synthesized VP8 enters the cell nucleus and is 
phosphorylated by CK2 during this time. In the nucleus, CK2-phosphorylated VP8 is involved in 
the incorporation of the viral genome into the capsids. The nuclear VP8 also alters the cellular 
lipid metabolism. Presumably when the majority of DNA encapsidation is completed, the nuclear 
VP8 is phosphorylated by US3, which subsequently triggers the nuclear-to-cytoplasmic transport 
of VP8. In the cytoplasm, with a thus far unidentified virus-induced modification or protein 
interaction, VP8 is accumulated into the cis-Golgi apparatus, where it is packaged into the viral 
particles that are also localized in the Golgi. There might be a de-phosphorylation process for 
VP8 because the virion VP8 is not phosphorylated. After incorporation into the progeny virus, 
VP8 leaves the host cell inside the virions when released from the cell. The virion VP8 will 
become incoming VP8 during subsequent infection, and has the potential to redistribute PML.  
During viral infection, phosphorylation regulates biological functions of viral proteins 
through different dynamic patterns, and leads to diverse biological outcomes. Immediate protein 
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63 (IE63) of HHV-3 is predominantly localized in the nucleus during productive infection, and is 
in the cytoplasm during latency (409). The nuclear and cytoplasmic localization of IE63 is 
related to the balance between CDK1-dependent phosphorylation and CK1/CK2-dependent 
phosphorylation (409, 410). Blocking CK1/CK2-mediated phosphorylation induces more IE63 to 
localize in the cytoplasm (409, 411). However, abolishing CDK1-mediated phosphorylation 
increases the nuclear localization of IE63 (410). IE63 negatively regulates viral DNA replication 
during HHV-3 infection and it has been known that the contribution of IE63 to HHV-3 
pathogenesis is dependent on the differentiated human cell types (412, 413). It might partially 
because the enzyme systems are different between those cell types. For example, IE63 is 
phosphorylated by CDK1, a universally expressed kinase, at T
222
 and S
224 
(410). The same 
residues are also phosphorylated by CDK5, a kinase that is only active in neural cells (410). 
Consequently, phosphorylation of IE63, contributed by different kinases in two types of cells, 
may lead to dissimilar biological impacts. Phosphorylation is important for many other 
herpesvirus proteins to regulate protein activity, including VP13/14 of HHV-1 which uses 
phosphorylation to regulate nuclear localization (142), UL12 of HHV-1 which requires 
phosphorylation to obtain nuclease activity (414), and ORF57 of HHV-8 which needs 
phosphorylation to interact with heterogeneous nuclear ribonucleoprotein K (hnRNP K), a 
cellular protein involved in gene expression (415). 
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Figure 10.1 Summary of the translocation of VP8 during the infection of BoHV-1.  
The nucleus, cytoplasm and Golgi apparatus of a host cell are illustrated. Gray arrows indicate 
the translocation directions of VP8. BoHV-1 virion enters the host cell and releases VP8 which is 
the incoming VP8. During the infection, VP8 is de novo synthesized and is translocated into the 
nucleus. When VP8 comes across the cellular kinase CK2 it becomes phosphorylated. The 
nuclear localization, and possibly the CK2-dependent phosphorylation, also happens to the 
incoming VP8. In the nucleus, VP8 is capable of redistributing PML, changing the cellular lipid 
metabolism, and promoting the viral DNA encapsidation. When nuclear VP8 is phosphorylated 
by a viral kinase US3 the nuclear-to-cytoplasmic translocation of VP8 is activated. In the 
cytoplasm, VP8 is accumulated in the cis-Golgi, where it is packaged into the progeny virus of 
BoHV-1. These viruses, with VP8 incorporated, are released into the extracellular environment 
when they are mature.  
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10.3 Future directions 
In the nucleus of BoHV-1-infected cells, VP8 promotes viral DNA to incorporate into 
capsids, and it requires VP8 to be phosphorylated. Newly synthesized viral DNA and capsids 
require further processing prior to encapsidation (87, 88, 90). Disrupting any of the processing 
steps will reduce the efficacy of DNA encapsidation. Omitting VP8 phosphorylation increases 
empty nuclear capsids and reduces virus titer, indicating an important role of phosphorylated 
VP8 in viral DNA encapsidation. VP8 is possibly involved in cleaving the genome concatemer 
by promoting the activity of viral nucleases, or in modifying the viral capsids by interacting with 
capsids proteins. In future research, the impact of VP8 in the cleavage of viral DNA concatemer 
will be determined by observing the impact of VP8 on the efficacy of BoHV-1 nuclease. To 
identify the impact of VP8 in BoHV-1 capsids maturation, A, B, and C capsids will be analyzed 
with and without the presence of VP8.  
CK2-phosphorylated VP8 redistributes PML foci in VP8-transfected cells. PML protein 
gradually accumulates to the surface of nuclear LD that is coated with VP8. However, non-
phosphorylated VP8 does not cause such accumulation of PML protein. Several herpesvirus 
tegument proteins play important roles in disrupting or redistributing ND10 proteins. For 
example, in HHV-4-infected cells, ATRX-DAXX complex is disrupted by BNRF-1 (241). Pp71 
of HHV-5 degrades DAXX (104). UL35 of HHV-5 redistributes ND10 foci, containing PML, 
SP100, DAXX, and ATRX, in transfected cells, and enhances the activity of pp71 to degrade 
DAXX (104, 237). The unique PML pattern in VP8-transfected cells is similar to that in UL35-
transfected cells (235, 236). This supports the possibility that BoHV-1 VP8 contributes to 
disrupting ND10 components. Thus, future research may firstly focus on identifying the impact 
of VP8 in ND10 foci-contained proteins. PML could be directly redistributed by VP8, or be 
indirectly reorganized by another ND10 protein which directly contacts with VP8. Secondly, 
since VP8 is abundantly released into BoHV-1-infected cells at pre-immediate early phase, it is 
likely that incoming VP8 is involved in counteracting ND10. Identifying whether incoming VP8 
molecules target ND10 foci will provide evidence for the role of incoming VP8 in neutralizing 
ND10-dependent anti-viral defences.  
At late stage of BoHV-1 infection when VP8 is phosphorylated by US3, VP8 is 
translocated from the nucleus to the cytoplasm. Because US3-dependent phosphorylation 
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residues are near the NLSs of VP8, the activity of NLSs might be interfered with by 
phosphorylation. A tertiary structure of VP8 is needed to confirm this mechanism in the future. 
Moreover, US3 does not directly transport VP8 through the nuclear membrane, because US3 
remains in the nucleus when VP8 is exported to the cytoplasm. This indicates that US3-
phosphorylated VP8 may be subsequently involved in NES-dependent protein-protein 
interactions to transport through the nuclear membrane. Besides of the two known NESs of VP8, 
more NES has been suggested to exist in the protein (144, 155, 156). Future research might focus 
on identifying functional NESs of VP8 and NES-dependent signal pathways.  
After exporting from the nucleus, VP8 is transported into the cis-Golgi apparatus in the 
cytoplasm of BoHV-1-infected cells. However, VP8 is scattered in the cytoplasm in VP8 and 
US3-cotransfected cells, indicating that other viral factors are involved in translocating 
cytoplasmic VP8 into the Golgi. Future study will identify the viral factors that mediate the 
Golgi-localization of VP8. A protein localizes to the Golgi apparatus either through Golgi 
localization signals (416) or though interacting with another Golgi-localized proteins (382). Thus, 
after identification of the viral factor that mediates the Golgi-localization of VP8, research will 
be set out to answer whether a Golgi localization signal of VP8 is activated by the factor or VP8 
is transported to the Golgi by interacting with the factor.  
A mutant BoHV-1 expressing non-phosphorylated VP8 has a reduced titer in comparison 
with wild-type virus, because VP8 needs US3- and CK2-mediated phosphorylation to change 
cellular localization and to perform proper functions. A previous finding shows that VP8-deleted 
virus does not replicate in cattle, and thus it is not suitable to be an attenuated vaccine candidate 
(64). As non-phosphorylated VP8 only omits phosphorylation-related functions, the mutant virus 
replicates better than ΔUL47-BoHV-1 in tissue culture. This indicates that the replication 
capacity is partially restored in the mutant virus by expressing non-phosphorylated VP8. In 
future research, the replication capacity and the virulence of this mutant BoHV-1 will be tested 
in host animals. The virulence and replication capacity can be controlled by restoring some of the 
mutated phosphorylation residues in VP8 according to the needs of animal research. The mutant 
BoHV-1 will potentially contribute to vaccine development against BoHV-1 infection. 
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